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Abstract 
In the last decade personal genomics has been available to the public by 
direct-to-consumer marketing and sales. Different tests are available 
including single nucleotide polymorphism (SNP) genotyping. SNP 
genotyping measures variation in nucleotides at specific points in 
deoxyribose nucleic acid (DNA) and can be analysed for information about 
ancestry, physical traits, risk of susceptibility to common complex diseases, 
genetic disorder carrier status and drug metabolism. SNPs have been 
analysed in human populations to associate variation with particular traits 
and common complex diseases, though the association data for disease 
risk is known to be unreliable. Some claim that direct-to-consumer genetic 
testing embodies a positive shift from medical hegemony to a market-
oriented system while others are apprehensive about the lack of 
involvement of medical professionals and purchasers’ lack of 
understanding of probabilistic genetic information. These different views 
represent the dispute over SNP genotyping sold directly to the public that 
this study focuses on. 
 
My thesis explores this emerging technology using the Social Construction 
of Technology to investigate the experiences of a group of early adopters of 
the technology in the UK. I contrast their experiences with those of a group 
of UK genetic clinicians and examine participants’ respective 
understandings of SNP genotyping and its possible implications for the 
NHS. 
 
Whilst the data largely mirror the extant literature, they give an insight into 
the importance of social factors in influencing decision-making in relation to 
adopting or rejecting new technology. I discuss the data’s common themes 
of knowledge of genomics, the importance of social networks in 
understanding and engaging with new technologies, and personal versus 
collective medicine that characterise both groups’ experiences. To 
conclude I explore these themes in relation to the concept of biosociality. 
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Chapter 1 : Introduction 
 
This thesis examines Direct-to-Consumer Genetic Testing (DTCGT) in the 
United Kingdom (UK) context from the perspective of genetics clinicians 
and users of this technology. Its purpose is to examine the way these two 
groups of actors are shaping personal genomics in this country through 
their discourse and the impact of their engagement with it on the UK’s 
collective national healthcare provision. I commence this written 
presentation of the project with a story about an encounter I had during my 
time as a doctoral student. I have decided to share this story as it 
represents a watershed moment in my thinking about the sociology of 
science and a salutary illustration of the basis for the disputes that are at 
the core of this study. 
 
The German geneticists 
I began to really appreciate first-hand the importance of ‘the social’ in 
science during a state-funded workshop on Genetic Transparency which I 
attended in 2013 during the course of the PhD study. This week-long 
workshop was held at Lübeck University for Europe-wide doctoral and post-
doctoral researchers and focused on the ethical and social implications of 
human genomics and genetic medicine. Different guest experts attended 
each day and presented their work alongside that of the participants, with 
discussion following each presentation and at the end of each day. The 
week culminated in the development of a book proposal for a volume on 
Genetic Transparency to be written in the year following the workshop with 
contributions from all the participants and experts (Dreyer et al, 
forthcoming). 
 
My presentation was scheduled for the first day of the workshop at which 
the guest ‘experts’ were two German geneticists who presented their work 
on genomic sequencing at the beginning of the day. In addition a clinical 
geneticist specialising in cardiac genetics was in attendance as one of the 
facilitators of the workshop. It is notable that my presentation was only the 
second of the workshop participants’, the first being given by a German 
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physician and doctoral student who is researching DTCGT from a clinical 
medical perspective, making mine the first non-positivist presentation of the 
workshop. I presented my early findings from the users’ data in this project 
and discussed these in the context of expertise, arguing that users appear 
to have at least interactional expertise in personal genomics, based on 
Collins’s and Evans’s work on expertise (Collins and Evans 2007).  
 
If the convenors of the workshop hoped for lively debate, my presentation 
gave it a flying start. In the group discussion following my presentation 
there was heated debate between the geneticists and workshop 
participants about the nature of genetic science and the validity of my work. 
After the session, the three geneticists physically prevented me from 
leaving the room for the break and continued to offer their criticisms of my 
work despite my peers’ robust defence of it in the earlier discussion. Rather 
than commenting on what I was proposing, they protested that my work 
was scientifically flawed. Why had I interviewed only 16 people? Had I not 
done a power calculation? How could I judge expertise when I was not an 
expert (i.e. a geneticist)? It was a good thing that they were not examining 
my PhD thesis, as it would fail because I clearly had no idea what I was 
doing or how to be scientific. The geneticists seemed to imply that I was no 
expert, either by credentials or experience, and thus was acting as an 
impostor. 
 
I am used to my research topic prompting discussion; usually it is about 
people’s initial reactions to the idea of DTCGT, as they have rarely 
encountered the concept before. On this occasion a knowledgeable 
audience were reacting even more strongly and this was striking. The 
concept of expertise seemed to be at the core of the group’s individual 
reactions to my suggestion that early adopters of DTCGT in the UK have 
similar levels of expertise in personal genomics as genetics clinicians, 
though it is likely to be of a different nature. The well-rehearsed debates 
about DTCGT seemed to be represented in the room. The scientists 
represented sceptical and paternalistic views about DTCGT, suggesting 
that it was nonsense and should not be accessible by the public while most 
workshop participants voiced support for a more objective view of the 
actors involved and challenged the geneticists’ categorical, authoritative 
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rhetoric, both in relation to DTCGT and their criticisms of my work in 
particular.  
 
The German story is interesting because it illustrates professionals’ 
vigorous anger in response to this technology. I wondered why they 
seemed so livid, what was the cause of their visceral response? Reflecting 
on the incident subsequently I thought that their response could indicate 
tribal behaviour, particularly when their professional norms and status were 
subject to challenge, both in terms of disciplinary and ethnic differences. It 
showed that being culturally bounded within their positivist worldview, the 
scientists involved had little understanding of qualitative research, let alone 
the sociology of science and technology.  
 
I was in a similar place at the beginning of this study: aligned to healthcare 
professionals, disapproving of public engagement with genetic technologies, 
which I rationalised with bioethical concerns. That is, I had an asymmetrical 
or partial perspective. This incident (which endowed me with a certain 
notoriety among my colleagues at the workshop) served to show me that 
my views had altered in that I could stand apart from these scientists and 
still appreciate their views having held similar ones myself until recently 
(albeit not in relation to qualitative research). Most importantly, I could 
appreciate the cultural and social basis for their views rather than interpret 
them as a personal attack. However, I was caught off-guard and felt 
physically intimidated at the time. I was disappointed that I had not been 
able to persuade them that there was an alternative perspective of 
genomics (particularly given the premise of the workshop). In hindsight I 
realise my sociological naivety contributed to this situation and I would 
certainly take a different approach to such a situation now.  
 
This experience proved a watershed in my learning during the course of 
this project. It demonstrated to me the powerful influences that social 
factors have on identities, boundaries, knowledge and beliefs. In adhering 
to their positivist view that science constitutes privileged, objective 
knowledge, the German geneticists unintentionally demonstrated the 
reverse that is that their views are partial and subjective. It emphasised the 
importance of acknowledging the wider social contexts of different actors’ 
constructions of their experiences or values and their influence on 
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developments in science and technology, including my own, as I hope this 
thesis will show. 
 
The problem of DTCGT 
DTCGT has evolved over the last decade, both as a result of the 
completion of the sequencing of the human genome and the genome-wide 
association studies (GWAS) that ensued and as an extension to the direct-
to-consumer marketing of drugs in the United States of America (USA) 
which started in the 1980s (Gollust et al 2002). Initially offering metabolic 
and nutritional advice based on the analysis of a few specific nucleotides in 
an individual’s deoxyribose nucleic acid (DNA), dramatic improvements in 
technology and reduction in costs mean that DTCGT now has a much 
wider capability and is more widely available, being mainly traded via the 
Internet. The DTCGT market offers numerous types of test including the 
more familiar monogenic tests to predict risk of genetic diseases such as 
familial breast cancer or Huntington’s disease (HD), tests offering health 
improvement information (often linked to marketing of health improvement 
products), tests for physiological responses to drugs (pharmacogenomics) 
and tests for susceptibility to common complex diseases such as type 2 
diabetes mellitus, osteoarthritis or hypertension (Borry et al 2010). The 
focus for this research project is the testing that claims to establish 
susceptibility to common complex diseases, which is usually sold in the 
context of a genome-wide scan of hundreds of thousands of single 
nucleotide polymorphisms (SNPs), also known as SNP genotyping1. These 
tests simultaneously analyse the variation in single nucleotides at 
thousands of points across a whole genome (genetic material of an 
organism) to provide information about various aspects of genomic data 
including ancestry, physical traits, genetic disease, carrier status, 
pharmacogenomics and common complex disease risk (Leachman et al 
2011). 
 
As the phrase suggests, DTCGT refers to genetic testing sold directly to the 
public without the involvement of healthcare professionals. Tropes of 
                                                
1 Unless explicitly stated to the contrary, I use the term DTCGT in this thesis to 
refer to tests that involve SNP genotyping rather than alternative kinds of genetic 
testing. 
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personalisation are fundamental in order to appeal to the market and 
companies selling DTCGT emphasise the advantages of accessing 
information for making personalised health and lifestyle decisions in an 
autonomous, confidential manner. They do so by linking personalisation to 
genetics using deterministic language (Arribas-Ayllon et al 2011a). By 
appealing to the ‘personal’ in personal genomics in an overt way, DTCGT 
companies emphasise the appeal of individual autonomy, promising to 
empower the individual with information about their genome. Moreover this 
model of accessing health information is promoted as providing 
convenience and privacy, being accessed directly by the purchaser from 
any convenient Internet connection (Borry et al 2010).  
 
The vision of autonomy and empowerment created by DTCGT companies 
has deliberately raised expectations, as is often the case with emerging 
biotechnologies (Hedgecoe and Martin 2003). These expectations have 
been reinforced by the lobby for the democratising benefits of personal 
genomics in terms of its availability to the public and the empowerment 
associated with accessing one’s own genetic information rather than having 
access restricted by paternalistic healthcare professionals (HGC 2003, 
McGowan and Fishman 2008, Juengst et al 2012). However, this aspect of 
genetic testing is controversial because there are forceful counterclaims 
related both to the science that SNP genotyping is based on and to the 
problems associated with genetic information being available without the 
conventional associated genetic counselling.  
 
The SNP genotyping employed in DTCGT is controversial because the 
data from GWAS that provide the basis for calculation of the meaning of 
variance have low validity and reliability, having been studied only in 
discrete populations. Whilst the raw data yielded is thought to be highly 
accurate, the choice of SNPs for analysis varies between companies, and 
the interpretation of the results is much more uncertain being based on 
GWAS studies whose populations may vary physiologically from the 
individual whose genome is being compared (Kraft and Hunter 2009, 
Leachman et al 2011). Additionally, DTCGT is widely reported as having 
poor clinical utility because the SNP variance is only one minor factor that 
contributes to the aetiologies of common complex diseases; epigenetics 
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and environmental factors provide a much greater influence on the risk of 
disease (Janssens et al 2008, Ng et al 2009, Leachman et al 2011). 
 
In addition to concerns about the validity of SNP genotyping, there are 
concerns about the public’s ability to appreciate the nature of the 
information a SNP genotype provides or to interpret the information 
provided by DTCGT without the help of genetic counsellors. Results for 
health-related aspects of the test are expressed as relative risks, which it is 
argued are difficult for the public to understand because they tend to 
individualise risk (Lloyd 2001, Paling 2003, Collins et al 2011). Given the 
companies’ promissory rhetoric and the lack of conventional counselling, 
fears have been expressed that people may overwhelm healthcare facilities 
to obtain professional help with interpreting their genome scan results. 
Without it they may on the one hand suffer needless anxiety or family 
disruption and possibly seek drastic intervention to avoid disease. On the 
other hand they may adopt a complacent approach to their health in the 
light of test results based on information of poor clinical utility (Wolfberg 
2006, ACMG 2008).  
 
Concerns about the public’s understanding of genetic information accessed 
via companies whose rhetorical style is seen as genetically deterministic 
aligns with suggestions that genetic determinism increases in association 
with new medical technologies in molecular biology. The companies’ focus 
on the importance of genetic information corresponds to the potential for 
geneticisation in that it supports the genetic basis for identity and individual 
problems (Rapp 2000). In addition their appeals to individual responsibility 
for heath and disease prevention using genetic information supports Kelly’s 
assertion that geneticisation accompanies the upsurge of individual 
surveillance and responsibility for health (Kelly 2007). Apprehensions about 
the potential rise of genetic determinism are linked to the historical legacy 
of the eugenics movement and have no doubt directly influenced the 
conservative nature of conventional clinical genetics with its emphasis on 
confidentiality, informed consent and non-directive counselling (Fox Keller 
1992, Hogarth et al 2008). This powerful moral interpretation, whilst risking 
being judged as paternalistic, informs the negative expectations of DTCGT 
that are circulated and are in contrast to the positive ones centred on 
empowerment and autonomy. It underpins healthcare professionals’ and 
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particularly genetics clinicians’ views about access to health-related genetic 
information, despite DTCGT’s companies’ assertions that their tests are not 
‘health’ tests, a claim made ostensibly to avoid regulatory constraints 
(Vorhaus 2010a). However, many have argued that the public will perceive 
them as such; some studies’ findings support this view (McGuire et al 2009, 
Mavroidopoulou et al 2015). 
 
This dispute has the potential to undermine the public’s confidence in the 
healthcare establishment because DTCGT users’ expectations of 
personalised genomics may be in conflict with current healthcare provision. 
This is particularly true in the UK where the principal provision of by the 
National Health Service (NHS) is free at the point of access and there is 
less financial onus on individuals to take responsibility for their health care. 
While the public may be increasingly autonomous in seeking information 
from DTCGT, they may also continue to expect conventional healthcare 
support for test interpretation and subsequent intervention. Difficulties 
achieving this either due to ignorance of genomics on healthcare 
professionals’ part or a lack of capacity in healthcare service provision, 
could adversely affect both the public and healthcare providers in terms of 
expectations and patient-clinician relationships (McGuire and Burke 2008). 
The importance of keeping the public’s trust and engaging users, DTCGT 
companies and healthcare professionals in developing new relationships 
within a more democratic approach to health care are suggested as a more 
realistic way forward as the genomic era progresses (McGowan and 
Fishman 2008, Patch et al 2009, HGC 2010).  
 
Personalised medicine 
Having outlined the problem of DTCGT that has resulted in this study of 
DTCGT in the UK context, it is important to clarify how I use the phrase 
“personalised medicine” through the thesis. The phrase is important in 
relation to DTCGT because since the completion of the Human Genome 
Project (HGP) the rhetoric of personalisation has been used to link 
expectations about genomics to advances in medicine, scientific research 
and commercialisation of healthcare for the public (Arribas-Ayllon et al 
2011a). Richard Tutton has demonstrated how the concept of the personal 
in medicine significantly pre-dates the HGP, appearing as a common theme 
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in patient-clinician relationships for decades. However the rhetorical 
emphasis on personalisation was adopted by journalists and then more 
widely used in response to developments in genomics (Tutton and Jamie 
2013). There are two predominant aspects to personalised medicine both 
of which refer to customisation; the first aspect relates to the development 
of drug treatments tailored to particular genotypes, whether the individual’s 
or the genome of their cancer cells. The second relates to the capacity for 
individuals to be empowered by their genomic knowledge and to make 
healthier decisions about their life-styles (Tutton 2014). DTCGT companies 
that include pharmacogenomics testing use both these aspects to market 
their products to the public. But they capitalise on the latter, appealing to 
individual responsibility for health and the importance of empowering 
genomic information in decision-making. The narratives about personalised 
medicine are significantly more complex than this brief outline suggests and 
I shall discuss this further in relation to the study’s findings and conclusions 
later in the thesis. However, for now I use the phrase personalised 
medicine to refer to both the aspects of customisation outlined above, as 
this is the rhetorical position of the DTCGT users and 23andMe, the 
company they purchased their health-related SNP genotyping from. 
 
The project 
The debates surrounding DTCGT demonstrate the current lack of stability 
of this technology. This instability and the lack of empirical work on DTCGT 
in the UK context provided the impetus for me to undertake this research 
project. Initially, my interest in personal genomics was informed by my 
experiences of nursing people with colorectal and breast cancer. I 
wondered if the public would be tempted to use this technology to try to 
ascertain their (and their family’s) risk of developing cancer. Patients I 
encountered were concerned for family members, as is commonly 
experienced in clinical genetics counselling (Chadwick 1999). However, 
these people also appeared to misinterpret the aim of national screening 
programmes with their emphasis on risk prediction rather than treatment or 
prevention, as David Armstrong has explored (Armstrong 1995, Armstrong 
and Eborall 2012). In my experience people appeared to assume either that 
screening offered protection or, alternatively, that it would not provide any 
useful approach to their family’s personal risk management, being a 
  
 
9 
population-based initiative rather than a personal one. Thus, I wondered, 
would SNP genotyping for disease risk provide them with an alternative 
route to trying to manage their risk of cancer?  
 
On the basis of my early interest in DTCGT, I developed a research 
proposal to investigate the uptake and experiences of users of DTCGT 
internationally, based on the bioethical principles of autonomy and trust. I 
was unsuccessful in gaining funding for the project on that basis. Prior links 
with Cardiff University then proved fortuitous in presenting the opportunity 
to investigate DTCGT from a sociological perspective; a somewhat different 
approach to researching the topic resulted and is presented in this thesis. 
As my account of my experiences in Lübeck demonstrates this opportunity 
has profoundly influenced my thinking about science and genomics. 
Delanty’s suggestion that emerging genetic technologies make it 
implausible to separate science from society is resonant as it reinforces the 
argument for pursuing a sociological approach to studying this contentious 
topic and the actors who influence the debates about it (Delanty 2002). 
Accordingly it seems appropriate to use Pinch and Bijker’s social 
construction of technology (SCOT) as the framework for the study. My 
decision to do so assumes MacKenzie and Wajcman’s understanding of 
the meaning of technology. They suggest that technology encompasses 
knowledge or understanding about technology as well as the artefact itself, 
and that that knowledge is socially influenced by individuals, groups and 
contexts, and by extension, their discourse about the technology 
(MacKenzie and Wajcman 1999). DTCGT provides information that is open 
to interpretative flexibility and which is thus shaped by actors in relation to 
its quality, utility and validity. These actors’ understandings provide an 
additional dimension to technology along with the artefact and the 
information it provides. This aligns with the assertion that genetic testing is 
not simply a laboratory procedure but also a “social practice” (Arribas-
Ayllon et al 2011b:3) or socio-technology.  
 
Throughout this thesis I refer to actors shaping DTCGT technology on the 
basis that discourse is part of how technology is used and that technology 
encompasses more than the artefact itself. In doing so I am able to 
conceive this research as a study that investigates how DTCGT is socially 
constructed and shaped by groups closely associated with it in the UK 
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context. This has enabled a wider, more objective and arguably more 
interesting, investigation of personal genomics and the actors involved with 
it. Rather than examining DTCGT from the perspective of its impact on the 
public and their relationships with healthcare professionals, I am instead 
able to provide a broader examination of the various ways in which the two 
principal groups of actors engaged with DTCGT in the UK talk about and, 
thus, shape the discourse, knowledge and thus the technology of personal 
genomics. These two principal groups are the members of the public who 
buy DTCGT2 and the genetics clinicians3  who may be called upon to 
counsel them.  
 
Research question, aims and objectives 
So, the research question that this study addresses is  
“What are UK users’ and genetics clinicians’ experiences of DTCGT?” 
 
The study aims to establish users’ and genetics clinicians’ contributions as 
relevant social groups to shaping personal genomic technology in the wider 
social context of the NHS in the UK. More specifically it examines users’ 
motivations for engaging with DTCGT and both users’ and genetics 
clinicians’ expectations of DTCGT and how these are influenced. Users’ 
and clinicians’ views about direct access to personal genomic information 
are explored and how users make sense of complex risk information is 
ascertained. The nature and scope of genetics clinicians’ involvement with 
users of DTCGT and the implications for the NHS are examined. Finally, 
the implications of the study’s findings for personal genomics technology in 
the UK context and their influence on the possibilities for stabilisation of this 
technology are explored. 
 
To complete this introduction I will go on to outline the thesis chapters. 
                                                
2 The people who bought DTCGT and participated in the study can be described as 
early adopters of the technology, being similar to those described by McGowan et 
al (2010). Detail about recruitment of these participants is given in Chapter Three. 
However it is important to note here that the approach taken to recruitment has 
inadvertently resulted in participants who are activists with outspoken views about 
DTCGT and that this will have affected the data collected.  
3 Whilst General Practitioners are the public’s first point of contact for healthcare 
expertise, genetics clinicians are the most likely HCPs in the NHS to be 
knowledgeable about and consulted to interpret DTCGT. They were thus likely to 
make a more direct contribution to the debates about personal genomics at the 
time this study started. 
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The thesis structure 
In order to set the scene for the project in more depth, Chapter Two 
outlines the procedure by which SNP genotyping is achieved and how 
consumers can purchase a test. This description is situated in a history of 
DTCGT through which I examine the conditions of possibility that have 
enabled its reification. Consideration is given to the three principal areas of 
influence, namely the technological, ideological and moral influences that 
contributed to the development of personal genomics services being sold 
directly to the public. The chapter is completed with an examination of 
regulatory influences on personal genomics and of how, until recently, the 
vacuum provided by the lack of regulatory oversight facilitated the 
development of DTCGT. 
 
With this important context in place, Chapter Three proposes the study 
design. Using a review of the sociological research into genetic testing, I 
situate this study in the canon of Science and Technology Studies (STS) 
generally and genetic testing research more specifically. This exploration of 
other researchers’ work extends the context for my research from Chapter 
Two’s background, by providing sociological insights into genetic testing. It 
simultaneously provides a platform from which to justify my theoretical 
approach, using the SCOT framework and the tools that have guided my 
thinking and decision making in relation to the data collection and analysis. 
Methodologically I demonstrate how the use of interviews is an established 
approach in sociological research into genetic testing and is particularly 
apposite for studying genetic testing communicated in the online 
environment. Having outlined the theoretical and methodological 
approaches to the study, the latter part of Chapter Three presents detail 
about the study design, including approvals gained, information about the 
participants, how interviews were conducted and the approaches to the 
data analysis. 
 
Chapters Four, Five and Six explore each of the three overarching themes 
from the data. In Chapter Four the concept of socialising DNA is the focus. 
Participants’ beliefs and ideals about genomic information and the influence 
of networks and expectations are examined. The uncertain new technical 
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world of SNP genotyping is informed and facilitated by the expectations of 
the technology that its enactors have presented in an attempt to stabilise it. 
The effects of these expectations and the censorious ones circulated in 
professional genetics networks are examined for their effects on the 
participants developing understandings of the technology and their 
discourse about it. In addition, I explore the concept of responsibility for 
health or patients’ welfare, which provides a moral standpoint which the 
participants support in their networks and construct their views of DTCGT.  
 
The theme in Chapter Five is personalising DNA, one which aligns closely 
to Novas’s and Rose’s concept of the “somatic individual”, whose imagining 
and embodiment of DNA results in an altered individual (Novas and Rose 
2000:487). Here, the participants’ perceptions of DNA in the context of SNP 
genotyping are explored in relation both to its influence on their individual 
identities and embodiment of its information (in both groups) and to the 
clinicians’ work to align their expectations with their counselling practice. In 
contrast to Chapter Four, this chapter explores the individual, internal and 
personal aspects of participants’ expressed ideas about DNA in the context 
of SNP genotyping. 
 
Chapter Six considers the tensions between users and clinicians in their 
respective support for personal or collective medicine. Responsibility is a 
feature on which this tension turns and I explore how users and clinicians 
are diametrically opposed in their interpretation of the relevance of 
genomics to the NHS. Common ground is found in their consideration of 
pharmacogenomics, but this represents only little glimmer of hope for 
resolution of the dispute that personal genomics presents to these two 
groups of actors. 
 
The final chapter brings the findings of the study together and draws 
conclusions from the three main themes in the data in relation to 
biosociality. This discussion leads to suggestions for possible future work in 
this area, either in genome sequencing or in theory development in the 
areas of citizenship in the context of people’s engagement with genomics. 
 
Having presented an introduction to the thesis, I will go on to explore the 
historical background to DTCGT in Chapter Two. This is important for 
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understanding the context in which early adopters of the technology and 
genetics clinicians have come to occupy different positions in the debate 
about personal genomics. 
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Chapter 2 : The history of direct-to-consumer 
genetic testing 
 
Genetic testing has long been the subject of sociological research generally 
and science and technology studies specifically. This century’s 
developments in genomics have enabled commodification of genetic 
information in the shape of DTCGT, which provides additional scope for 
study of the implications and effects of this development on individuals, 
groups and organizations with any interest in its capability. In order to 
provide the context for this study, this chapter will examine the history and 
development of DTCGT to see how the stage has been set for users’ and 
clinicians’ involvement. In addition, the on-going influence of historical 
events on technologies’ evolution supports my decision to adopt this 
approach (MacKenzie and Wajcman 1999). I have decided to do this by 
examining the conditions that prepared the ground for DTCGTs emergence, 
examining the scientific, social, economic and political factors involved. 
This wider social context is important for my subsequent examination of 
how users and clinicians are shaping the technology, as Klein and 
Kleinman (2002) suggest. First I will examine the conditions of possibility 
that were in place in order that DTCGT could evolve, then I will go on to 
explore the regulatory landscape and the main events that feature in it.  
 
Conditions of possibility for DTCGT 
Three factors contributed to the emergence and existence of DTCGT as it 
is currently provided. These can be broadly grouped into the technological, 
the ideological and the ethical (or moral order).  
1) Technologically, the developments in genetics early this century in 
the HGP and subsequent GWAS and the increasingly available access to 
information technology and the Internet have been key to making DTCGT 
possible to provide and to access.  
2) The ideological aspect concerns the shift to neoliberalism, 
specifically health consumerism, which is changing public expectations in 
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relation to information and healthcare provision. The role of companies and 
consumers in shaping DTCGT is crucial to setting the scene for how UK 
users and genetic clinicians are shaping DTCGT. 
3) The problematisation of acquiring genetic information continues to 
provoke debate about associated ethical issues and society’s response to 
these, its moral order. However, DTCGT’s unclear ontological status has 
added fuel to these discussions that is unmatched by consistent regulatory 
decision-making or the ability to apply such regulation effectively. Thus, a 
regulatory vacuum has resulted, facilitating the developments of DTCGT 
companies’ activity. The actors involved in the debates about regulating 
DTCGT will contribute to the role of society and culture more broadly in 
influencing DTCGT as this section will show (Bijker 2010). 
 
I will now go on to examine each of these areas in more detail, starting with 
technology in order to set the context for DTCGT and how it is undertaken. 
 
Technology 
The three principal technological factors that influenced the early 
emergence of DTCGT were all becoming part of wider social 
consciousness during the last decade of the twentieth century. These were 
the Internet, the HGP and GWAS. In order to provide background for this 
study of DTCGT, I will first outline what types of information DTCGT 
provides and the process of purchasing, testing and receiving results. Then 
I will discuss the developments and influence of the Internet, the HGP and 
GWAS on the emergence of DTCGT. 
 
DTCGT – the procedure 
DTCGT companies sell genetic tests for various purposes. Types of testing 
include whole genome or exome sequencing, where the sequence of 
nucleotides along the length of the individual’s genome (entire DNA) or 
exome (DNA that codes for functional proteins) is elicited. Tests can also 
identify paternity, single-gene mutations, or carriers of single gene 
disorders. Genotyping compares markers in an individual’s DNA with 
another individual’s markers or a reference sequence and contrasts them in 
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order to calculate probabilities of the person having particular traits or 
developing common complex diseases (Sander 2000). SNP genotyping 
includes testing for  
§ ancestry 
§ inherited characteristics such as tongue rolling or ear-lobe shape 
§ metabolic responses to certain drugs and nutrients 
§ exercise physiology for training and nutrition planning 
§ susceptibility estimates for common diseases with complex causes 
including cardiovascular disease, various cancers and Type 2 
Diabetes Mellitus 
§ pre-symptomatic, predictive carrier or diagnostic tests for certain 
single gene mutations causing diseases such as cystic fibrosis or 
breast cancer due to BRCA gene mutations 
(Chapman 2010) 
DTCGT is simple to purchase. Having accessed a DTCGT company 
website and paid a fee online, the customer sends their sample of saliva in 
a tube, a buccal swab or a blood spot from a capillary sample on porous 
paper to the company’s laboratory. The procedure for analysing samples 
involves extracting DNA from the sample and copying (amplifying) it several 
times. It is then spliced into sections by enzymes and each section is 
tagged with a fluorescent marker. The tagged sections are introduced to a 
glass slide chip on which are millions of small sections of DNA known as 
probes. Each of these is complementary to one of the SNPs being tested 
for. When introduced to the chip, the customer’s spliced DNA sections will 
pair with the probes on the chip where the nucleotide sequences are 
complementary. Pairing results in activation of the marker indicating which 
SNPs the customer’s DNA contains (etc Group 2008). In due course the 
customer receives notification of results, mostly via a secure personal 
webpage on the company’s website. Depending on the company and the 
service purchased, a qualified doctor may or may not be involved and there 
may be an option to receive counselling. Some companies notify users 
regularly about updates to the results as more SNPs are identified by 
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GWAS and the customer’s DNA is compared against these (McBride et al 
2010)4. 
The phrase “new genetics” is frequently used in relation to genomics in 
general and DTCGT in particular. This is without its meaning having been 
clearly defined, but its deterministic value is related to the shift in genetics 
from analysis of chromosomes and isolation of single genes to the 
molecular level of genetics from which the HGP and GWAS have 
developed (Conrad and Gabe 1999). These will be discussed after I have 
considered the information technology developments that have supported 
the emergence of DTCGT. 
 
The Internet 
From 1991, the worldwide web made access to centrally stored information 
available to anyone with access to the Internet. The Internet provides 
interlinked computer networks that enable access to electronic 
communications media. Using the Internet and browser software, 
documents and ‘spaces’ can be navigated via the worldwide web. Web 2.0 
was developed following incremental technological developments and this 
facilitates interaction and user-generated content to be displayed, 
contributing to the development of online social networking and commercial 
activity. As hardware costs fell from the end of the 20th century, people 
have been increasingly able to use the Internet for personal, commercial 
and professional communication, information storage and access and trade 
(Ward 2006, O’Reilly 2009). More recently, access to the worldwide web 
and social networks has been significantly aided by the development of a 
range of wireless hand-held devices. These developments have enabled 
almost ubiquitous access to the Internet and social networks and, in the 
information age, play a key role in democratization and personalisation, 
particularly in relation to Web 2.0. Its personalised mode of access and 
interaction has made the Internet the perfect vehicle for DTCGT (Foster 
and Sharp 2008, Arribas-Ayllon et al 2011b).  
                                                
4 SNP genotyping differs from DNA sequencing in that it analyses single nucleotides at 
various points across the individual’s entire genome, rather than analysing all the 
consecutive nucleotides in a gene, or the whole genome. 
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The Human Genome Project and GWAS: 
Most influential on the capability of DTCGT was the project to sequence the 
human genome. Begun in 1990, the project was undertaken by the 
International Human Genome Consortium at university laboratories in six 
countries with parallel work being done by Celera Genomics, a biochemical 
technology company founded by Craig Venter (Wright et al 2011a). 
Completion of a functional map of the human genome was completed 
earlier than anticipated in 2003 (IHGSC 2004).  
 
Genetic sequencing was facilitated by biotechnological developments; the 
first was the invention of the polymerase chain reaction (PCR) in 1983. This 
process uses temperature changes and the enzyme taq polymerase to first 
break up DNA into a single strand and then create copies of that DNA 
sequence from single nucleotides labelled with molecules to enable their 
identification and sequencing of the strands of DNA. The development of 
DNA microarrays followed, which utilize specific sequences of DNA as 
probes. When mixed with a solution containing spliced sections of DNA, 
these probes bind to complementary sections of DNA, capturing them for 
subsequent sequencing. These two developments laid a foundation for 
further developments, including next-generation sequencing, which enabled 
genetic sequencing on an increasingly massive and cheaper scale (Wright 
et al 2011a). 
 
GWAS were made possible by mapping the human genome and the 
biotechnology advances in sequencing apparatus; their aim is to draw 
correlations between human genotype variations and diseases by 
genotyping DNA from large numbers of donors to human biobanks. 
Genotypes of people with or without the diseases of interest are analysed 
and compared for nucleotide variations that can be linked to the diseases 
(Kaye et al 2009). The genotypes of SNPs for an increasingly large number 
of conditions and traits are being established through GWAS. These data 
provide the template information against which DTCGT companies 
compare customers’ genotypes and calculate disease risk for complex 
multi-factorial diseases (Edleman and Eng 2009, McBride et al 2010).  
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DTCGT companies have deliberately used deterministic language in their 
marketing material, as shown in Figure 2.1. However, related to the 
difficulties of ‘personalising’ relative risk estimates from a study population, 
there are a number of issues associated with SNP analyses for common 
complex disease risk evaluation relating to the tests’ utility and validity. A 
genetic test is said to have analytic validity when it accurately detects the 
genetic anomaly being tested for; clinical validity relates to how well the 
genetic anomaly indicates presence of disease; clinical utility indicates the 
ability of the test to provide information about diagnosis and treatment that 
is of use to the affected individual (Holtzman 1999). DTCGT is widely 
reported as having low clinical validity and utility in comparison with 
predictive genetic testing for single gene defects (Kuehn 2008, Van 
Ommen and Cornel 2008, Caulfield et al 2009, Edelman and Eng 2009, 
Kraft and Hunter 2009, Patch et al 2009, Annes et al 2011, Evans et al 
2011).  
 
 
Figure 2:1Genetic Predisposition DNA Testing  
(International Biosciences 2015) 
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The analytical validity of some companies’ SNP analyses has been 
questioned. Janssens et al (2008) reported on the lack of sufficient 
evidence for SNPs being useful for disease risk information. Ng et al and a 
Government Accountability Office (GAO) report both showed that 
comparison of test results on the same DNA yielded different results for 
disease risk estimates from some of the larger DTCGT companies (Ng et al, 
Kutz 2010). Another study by population geneticists demonstrated that the 
algorithms used by the personal genomics companies 23andMe, 
deCODEme and Navigenics resulted in substantially different risk 
predictions due to the use of different SNPs to analyse for the same 
conditions, different risk calculation formulae and different reference 
population risks to factor into the calculations by each of the companies 
(Kalf et al 2013). This bears out Martin Richards’ experience of getting 
different results in his auto-ethnographic study (Richards 2010). 
Underpinning these institutional variations in reference data used to 
ascertain customers’ SNP variants is the problem of the quality of the 
human reference genome. The original sequence was neither accurate nor 
contiguously assembled and has resulted in a less than optimal baseline 
sequence (Mardis 2010)5. Moreover, SNP analysis ignores other genetic 
factors that may affect an individual’s propensity to develop disease such 
as epigenetic effects and copy number variants (CNVs) both of which alter 
the DNA and its expression (phenotype). SNPs are thought to contribute no 
more than about 10% to the overall risk of disease; environmental factors 
are a much more powerful influence on an individual’s disease risk (Ng et al 
2009). 
 
These difficulties highlight one of the principal debates related to the 
technological aspect of DTCGT. Using terminology associated with 
genetics, DTCGT companies imply the deterministic nature of their 
products. Petersen and Bunton while analysing the uncertain meaning of 
the phrase “new genetics” suggest that the implications of new molecular 
genetic knowledge align with a Foucauldian concept of “bio-power”. This 
new knowledge increases the level of control over the human biological life 
cycle, influencing life from conception to death (Petersen and Bunton 2002). 
                                                
5 The human reference genome is being improved with ongoing sequencing work 
by the Genome Resource Consortium (Wellcome Trust Sanger Institute 2014) 
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But the obvious alignment of bio-power with DCTGT companies’ discourse 
in marketing genotype analysis is undermined by the stochastic and 
contingent nature of the results of SNP genotyping. 
 
I would argue that the problematic nature of DTCGT is well known among 
geneticists, bioinformaticians and related scientists, the “core set” as 
described by Collins and Evans in their polemical paper on expertise in 
science studies (Collins and Evans 2002:242). But other stakeholders in 
the wider DTCGT community view the capability of DTCGT with less 
uncertainty whether negatively or positively. On the one hand the majority 
of healthcare professionals are used to operating within a cause-effect-
treatment model and understand Mendelian genetic patterns of inheritance. 
They are less used to the muddier waters of genomic SNP analysis as 
contributing partial information to risk assessments for complex diseases 
and thus tend to simply dismiss it as either useless or misleading (Heschka 
et al 2008, Boddington 2009, Ormond 2009). On the other hand, DTCGT 
companies appear to have traded on the likelihood that their customers will 
have limited understanding of what their genotyping test is really capable of 
telling them (Patch et al 2008, Kaye 2008). Users are thus thought to be 
convinced of the certainty and determinism of the information DTCGT 
offers in relation to disease risk. It is likely, however, that early adopters 
may well approach DTCGT with less certainty of its capability than was 
originally thought, as early research found (McGowan et al 2010) and as 
explored by Harvard psychologist Steven Pinker in his New York Times 
article about his own experiences of genomic testing (Pinker 2009). 
 
Pinker neatly undermines the deterministic nature of personal genomics in 
several ways. He outlines the subjective way DTCGT company scientists 
choose GWAS data for associations between SNPs and phenotypes, the 
absurdity of testing for some of the traits included when obvious 
phenotypes either indicate the same information or contradict it – in his 
case his genotype for male-pattern-baldness that is not phenotypically 
evident, and the difficulties of translating relative risk data. The advice to 
consume healthily and exercise more applies as the intervention for almost 
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all his results but, as he notes, he did not need to pay for SNP genotyping 
to know that (Pinker 2009). 
 
However, Pinker also writes about individual curiosity, the entertaining 
aspects of personal genomics and the democratic argument for freedom of 
access to personal information rather than paternalistic regulation, which he 
and others support (Pinker 2009, Vorhaus and MacArthur 2010). This 
emerging democracy is key to the ideological conditions for DTCGT, which 
I will discuss next. 
 
Ideology 
Neoliberalism and healthcare consumerism 
Since the latter half of the 20th century Western governments have led the 
development of neoliberal approaches to national leadership and 
globalisation. Often attributed to Margaret Thatcher and Ronald Reagan, 
recent approaches to neoliberalism are characterised by the central role of 
the state in ensuring an emphasis on privatisation, deregulation, free trade 
and competition both within and across state borders (Davies 2014). The 
resultant emphasis on capitalism has influenced healthcare provision (to 
varying extents in different countries) and provided opportunities for choice 
and individualised consumerism of healthcare services, notably in North 
America where DTCGT first developed and is largely based. It also results 
in the inequity characteristically associated with neoliberalism, in this case 
in access to health care and opportunities for responsible behaviour. 
However, devolvement of responsibility for health care to individuals places 
responsibility for health, health promotion and disease risk management on 
citizens some of whom have become autonomous consumers of healthcare 
services (Arribas-Ayllon et al 2011b).  
 
US citizens in particular, have become increasingly autonomous healthcare 
consumers with growing expectations of their entitlements to healthcare 
provision (Robinson 2005). These expectations and their effects on 
consumption patterns have contributed to the development of new markets 
for new health technologies and services (Green 1991). Consumer 
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expectations are in turn influenced by numerous companies marketing 
health-related products directly to consumers, using all available media. For 
example, since the early 1980s pharmaceutical companies have advertised 
prescription medicines to the public in the USA using consumer choice as a 
tool to influence prescribing decisions (Gollust et al 2002). This has had the 
added effect of engaging the public with their health and with prescribed 
pharmaceuticals for treatments of common illnesses. Whilst prescribing 
remains the preserve of healthcare professionals, advertising to the public 
has not only positively influenced pharmaceutical companies’ income but 
also contributed to engaging the public in their health and prescribed 
pharmaceutical treatments for illness (Huang 2000).  
 
The situation is slightly different in the UK with NHS healthcare provided by 
compulsory subscription. Whilst medicines sold directly over-the-counter 
are advertised direct-to-consumer (DTC), DTC advertising does not 
influence drug prescribing per se because it is illegal to advertise 
Prescription-only-Medicines to the public in the UK and the EU (Ventola 
2011). Prescribing by NHS employees is restricted to generic (non-
patented) versions wherever possible and the National Institute for Health 
and Care Excellence (NICE) is directly involved in influencing the 
availability of many prescription drugs for cost-effectiveness (NICE 2012). 
However, the public are increasingly encouraged to manage individual risks 
to their health by participating in nationally advertised health promotion 
schemes related to diet and exercise and disease screening programmes 
such as those for hypercholesterolaemia, hypertension and breast or 
colorectal cancer (NHS 2011). 
 
The increasing democratisation of health care has influenced individuals’ 
relationships with healthcare providers and the traditionally paternalistic 
and authoritative nature of healthcare professionals. In the UK, this was 
influenced significantly by the last conservative government of the 20th 
century; in an attempt to reduce costs and improve management in the 
NHS they published the “Patient’s Charter” (DoH 1991a) and their white 
paper “The Health of the Nation” (DoH 1991b). These strategic documents, 
whose principles have been built on by successive governments, served to 
  
 
24 
facilitate a shift in thinking about health care from illness to health and a 
shift of power from healthcare professionals towards individual citizens by 
giving them rights, choice and simultaneously, responsibility for maintaining 
their health (Klein 2010). Consequently, both citizens and healthcare 
professionals have autonomy for their practice in relation to managing 
health; citizens for promoting their own health and managing risks to it, 
clinicians for providing resources for health promotion, screening and 
intervention. Whilst the aims of both groups superficially appear to be 
congruent in this respect, this dynamic shift challenges traditional medical 
hegemony and the public’s increasing autonomy may be in conflict with the 
current, resource-strapped NHS. This challenge could affect both the public 
and healthcare professionals in terms of their differing expectations 
impacting on the patient-clinician relationship, which has previously been 
based on trust. I will examine this issue further in the later section on Moral 
Order. 
 
More autonomy in relation to consumption of health care requires individual 
responsibility and knowledge of health and disease in order that citizens 
effectively manage their health and the potential risks to it. The media 
largely fulfil this need providing a conduit for information between scientists 
or healthcare providers and the public. There is a plethora of information in 
the media about health and illness and about scientific and technical 
advances in relation to them, specifically in genetics and genomics, with 
almost daily publications. However, the media’s reductionist, over-simplified 
interpretations often significantly undermine scientific objectivity. This is 
exemplified in a short piece on the British Broadcasting Corporation’s 
(BBC) Internet site entitled “Scientists crack the human code”; in just 750 
words it refers to the HGP, the basic biology of DNA, key people involved in 
the project including Craig Venter and John Sulston, and the 
announcement jointly by US and UK leaders at that time, Bill Clinton and 
Tony Blair (BBC 2000). Assumptions are made that it is on the basis of this 
style of information dissemination that the public’s self-education in current 
science and health care is based, in particular their knowledge of genomics 
and its relationship to health screening. 
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At the beginning of the 21st century the stage was set for DTCGT by the 
interplay of various factors. The public was primed to manage their 
individual health and risks to it and had increasing expectations of 
developments in genetics as promised by the media and companies 
marketing their products directly to the public. The emergence and 
commercial activity of these companies were able to exert considerable 
(albeit varying) influence on DTCGT technology owing to their organisation 
and investment as Williams and Edge note (1996). An examination of the 
companies involved in marketing DTCGT follows. 
 
Myriad Genetics 
One of the first companies to engage with the DTCGT market was Myriad 
Genetics. Myriad Genetics is a diagnostic biotechnology company, founded 
in 1991 by scientists researching genetics of breast and ovarian cancer. As 
part of an international research collaboration, Myriad developed predictive 
genetic tests for the BRCA1 and 2 genes, in addition to other malignant 
disease genetic markers. The company took the unprecedented step of 
applying for patents for BRCA1 and 2 mutation testing and exerted its rights 
to a monopoly on testing and for mutations and drug susceptibility in these 
genes in the USA; the patents were reduced in Europe (Conley et al 2011). 
Myriad began marketing these tests directly to consumers and their doctors 
at the turn of the century and launched advertising campaigns in some 
states in the USA in 2002 and 2007 (Caplan 2007).  
 
Fig 2.2 shows an example of a Myriad advertisement from the 2007 
campaign, which uses powerful language to persuade younger women of 
many backgrounds to arm themselves with knowledge about their genetics 
to avoid breast and ovarian cancer. Their abbreviation of the slogan ‘Be 
Ready Against Cancer - BRAC’ is almost identical to the abbreviation 
BRCA, the name for the breast cancer genes. Myriad’s campaign simplifies 
the information on risks of developing breast or ovarian cancer omitting to 
say that most breast cancers are not hereditary (and thus that testing is not 
relevant for most women). All breast cancer causes are conflated with 
being hereditary and linked to the BRCA genes, implying that most women 
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will be affected but that testing will empower and possibly even protect 
them - “Cancer doesn’t have to be inevitable”. 
 
 
Figure 2:2 Myriad Genetics Advertisement  
(Caplan 2007) 
 
The launch of their BRCA test marketing strategy in 2007 was described by 
the company as a public health education exercise. However, their 
simplistic, commercial approach was characterized by a lack of detailed 
information about testing, its outcomes or disadvantages. The clinical utility 
and validity of tests was not referred to and thus the implication of false 
positive or negative testing was not addressed. Neither did they refer to the 
possibilities for subsequent expensive and potentially inappropriate testing 
and mutilating treatment for women and their families who might be 
affected. In addition the problems associated with false reassurance and 
complacency following a negative result are ignored (Matloff and Caplan 
2008); the company’s current website covers none of these aspects. 
 
Hull and Prasad cleverly compare this marketing approach with the central 
theme of the play ‘Wit’ in which the central character learns to interpret 
healthcare professionals’ rhetorical devices as providing false hope rather 
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than truth. Hull and Prasad criticize Myriad’s early emotionally orientated 
marketing strategy for their distortion of what tests can offer and potentially 
harming future customers by implying certainty from testing. They illustrate 
the advertisement’s lack of information in relation to the specificity and 
sensitivity of the tests, or suggestions to seek medical advice prior to 
testing (Hull and Prasad 2001).  
 
After a long-running legal wrangle with the US Supreme Court, Myriad 
Genetics lost its rights to hold patents of DNA but its almost exclusive 
provision of BRCA testing in the USA appears to have continued regardless 
(Wagner 2013). This and the widespread criticism of the company’s 
marketing strategy do not seem to have undermined the company’s trading, 
although their business is largely US focused, 86% of their revenue being 
from BRCA testing in the USA (Conley et al 2011). Arguably, their high 
media profile could be seen to equate to free advertising.  
 
Sciona 
At the same time, a UK company made a relatively brief and ultimately 
unsuccessful foray into DTCGT. Sciona, then based in the UK, sold tests 
for nutrigenomics. DNA was analysed for SNPs in up to nine genes thought 
to be linked to metabolism and customers were offered nutritional and 
lifestyle advice on the basis of the results. The company’s activities raised 
concerns about the questionable use of hype and hope in their marketing 
strategy, particularly because of the lack of evidence for the utility of the 
tests. In addition, the advice being given to purchasers was similar to any 
health improvement advice, namely to eat more fresh fruit and vegetables, 
consume less saturated fats and alcohol and take more exercise (Editorial 
NG 2002, Meek 2002, Vineis and Christiani 2004).  
 
Further factors came to light about Sciona that were of specific relevance in 
the UK. The tests were being sold on the high street in the Body Shop 
chain of stores (see Figure 2.3). This was embarrassing on two counts. 
First, the Body Shop uses its ethical approach to business as a marketing 
strategy and the ethical debate provoked by DTCGT being sold on the high 
street did not sit comfortably with that company policy. Second, the UK 
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government had invested in the company on the basis of its innovation, 
possibly informed by Tony Blair’s earlier publicity with Bill Clinton on the 
completion of the first draft of the human genome sequence in 2000 
(Newton 2001). This was provocative to scientists, including Professor Wolf 
of Dundee University, Dr Bingham from Cambridge University and Paolo 
Vineis from Turin University, none of whom felt the validity or utility of the 
tests were meaningful. Finding that public investment had been awarded to 
a company who were using other scientists’ early genomic data raised 
concerns about the different standards required for research in public 
versus private companies (Meek 2002, Vineis and Christiani 2004).  
 
 
Figure 2:3 Sciona Company webpage with news of Body Shop partnership  
(Wayback Machine 2013) 
 
GeneWatchUK, a not-for-profit group monitoring genetic technologies for 
the public interest, raised objections to the test and its availability to the 
unsuspecting public in Body Shop stores. GeneWatchUK’s concerns 
related to misleading marketing, meaningless test results, poor evidence 
base and lack of regulation similar to that which would apply to genetic 
tests used in clinical genetics in the NHS (GeneWatchUK 2002, 
GeneWatchUK 2004). Sciona’s marketing in high street stores was short 
lived. Despite having been approached by Sciona, several other well-
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known companies including Boots the Chemist, John Lewis and Marks and 
Spencer decided not to sell the kits and the Body Shop chain removed 
them from its shelves within months of first stocking them. Sciona 
subsequently re-located to Colorado in the US, though they continued to 
market to the UK on the Internet, but the company ceased trading in 2009 
(GeneWatchUK n.d, Chapman 2010). 
 
Leading DTCGT companies 2007-2013 
From the plethora of publications and weblog entries, 2006-2013 saw an 
increase of activity in relation to DTCGT, as the market initially blossomed 
and then began to shrink again as the global economic crisis unfolded. In 
2007 the principal companies selling health-related tests started their DTC 
business, namely deCODE genetics, 23andMe and Navigenics, as well as 
Knome, which offers whole genome sequencing (Lenzer and Brownlee 
2008). In their rhetorical move of appealing to the “personal” in personal 
genomics in an overt way, both with some company names such as 
23andMe, deCODEme and Knome (my emphasis) and with marketing 
strategies that highlight empowerment, convenience, privacy and autonomy, 
the DTCGT market asserts the desirability of the neoliberal, autonomous 
self who Petersen had earlier proposed as a self-assessing, caring and 
improving individual (Petersen 1996). Personalisation is linked to 
consumerism in the promises companies make to empower the individual 
with information about their genome and their health to prevent disease and 
improve quality of life (Kaye 2008, McGowan and Fishman 2008, Nordgren 
and Juengst 2009, Arribas-Ayllon et al 2011b). The Erosion, Technology 
and Concentration Group (etc Group, a civil society organization 
addressing socioeconomic and ecological issues surrounding new 
technologies) also highlight the personal emphasis that companies make, 
but neatly contrast this with the impersonal nature of the GWAS data that 
DTCGT analyses are generated from (etc Group 2008).  
 
These DTCGT companies’ products played to the democratising autonomy 
of neoliberal citizenship by being available to anyone (with sufficient 
disposable income and an Internet connection), without the gate-keeping 
and appointment systems of conventional healthcare providers 
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informing health insurers (Foster and Sharp 2008, Gurwitz and Bregman-
Eschet 2009). Associated advantages include learning about genomics, 
genetics and disease with a view to gaining knowledge for risk 
management and improving one’s health and lifestyle (Matloff and Caplan 
2008, McGowan and Fishman 2008). This section will consider the main 
companies’ contributions to the personal genomics evolution between 2007 
and 2013. 
 
deCODE genetics was established in Iceland in 1996 by Harvard 
neuroscientist and geneticist Kari Steffanson with the intention of 
researching genomics and pharmacology to benefit patients. deCODE 
initially secured funding from the pharmaceutical industry company Roche 
to use Iceland’s unique genetic database for pharmacogenomics research 
and development. deCODE floated on the stock market in 2000 and 
developed commercial DTCGT later that decade with deCODEme, using its 
databases to research genes and pharmacogenomics for various 
conditions, including Alzheimer’s disease. Failing to keep pace 
commercially with its research success, the company was brought down by 
the Icelandic financial crisis. Following a bankruptcy declaration in 2009, 
the company re-launched but still failed to convert its research success into 
revenue, despite its uncompetitive DTCGT6 (Vorhaus 2010a). In October 
2012 deCODE was taken over by US biotechnology company, Amgen, who 
saw deCODE’s databases as crucial to their pharmacogenomics research 
and development programme. Amgen/deCODE genetics withdrew its DTC 
genotyping test deCODEme to new customers in January 2013. The 
shifting fortunes of deCODE and this takeover serve to exemplify concerns 
voiced about data protection in relation to genetic samples and information. 
Whilst people’s DNA samples remain in Iceland for now, at the time of the 
takeover there was disquiet in Reykjavik about a US company having 
control of Icelandic (and other customers’) genetic samples and their data 
protection is only as good as the current legislation (Herper 2012, Vorhaus 
2012).  
 
                                                
6 deCODE sold the most expensive and least comprehensive SNP genotyping test 
on the DTC market. 
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Navigenics, launched in 2007, offered personalised genomics in its Health 
Compass product, but the company took the more cautious approach to its 
services by requiring a physician to order the test for a patient and by 
offering a genetic counselling service to patients. This tempered approach 
to the DTCGT market was presumably adopted to increase sales and pre-
empt possible future regulatory constraints, but may also have been 
associated with one of its founders, physician Professor Agus. With its 
more moderate approach to DTCGT, Navigenics notably partnered with the 
Scripps Translational Research Institute and the Mayo Clinic for studies 
into the effects of genetic disease risk estimates on personal genomics 
users. Findings from both studies indicated that effects on users’ anxiety 
were minimal and likely to abate over time (Bloss et al 2011, James et al 
2011). Attracted by Navigenics’s highly accurate sequencing technology in 
its Clinical Laboratory Improvement Amendments (CLIA) certified 
laboratories, Life Technologies Corporation, a global biotechnology 
company, acquired the business in August 2012, following which 
Navigenics’s personal genomics product was no longer sold (Vorhaus 
2012). Here too the issue of data protection and confidentiality is of concern, 
potentially to both Navigenics’s customers and clinicians. Former 
customers accessing the Navigenics website are reassured that their data 
are accessible for three years but that their sample will be destroyed, as will 
their data, after August 2015. Physicians are similarly informed that patients’ 
data will be available for three years but will then be destroyed and that, in 
line with the consent gained from patients prior to testing (including a 
consent form in addition to direction to Terms and Conditions), their data 
will not be sold on to third parties and will only be used for the purposes 
they consented to (Navigenics 2013). 
 
23andMe was launched in 2007 in California by biotechnologists Linda 
Avey, Paul Cusenza and Anne Wojcicki, with financial backing from 
Wojcicki’s husband Sergey Brin’s company, Google. Significant changes to 
their product and marketing strategies followed a Cease and Desist order 
from the Food and Drugs Administration (FDA) in 2013, which I shall 
address later in this section. However, from their launch in 2007, the 
company’s unique selling point in DTCGT was their focus on research and 
the social aspects of genomics for personalised ancestry and health testing. 
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Using the tropes of personalisation and empowerment common to DTCGT 
marketing, 23andMe engages customers in the 23andMe community with 
blogs, discussion boards and forums on their website. Here users can 
share and discuss information, experiences and questions with others, 
capitalising on the potential for social networking that these Internet sites 
enable. Prior to 2013, 23andMe’s commitment to research was 
foregrounded with invitations to customers to be part of research that will 
“benefit us all” in the future (see Figure 2.4), simultaneously appealing to 
the personal as well as an altruistic sense of contribution. Users were 
invited to engage in “citizen science” by voting to prioritise the company’s 
research projects and by submitting their genomic data and online surveys 
for phenotypic information to be used in genomic and pharmacogenomics 
research. Awarded Time magazine’s Invention of the Year in 2008 for 
making its product accessible and affordable, 23andMe have led the 
market in DTCGT with arguably the most competitively priced, cost-
effective product available.  
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Figure 2:4 “23andWe”: 23andMe's research community webpage to 
November 2013  
(23andMe 2013) 
 
23andMe promotes its self-professed “democratic” approach to personal 
genomics and research by using social networking and has engaged user 
participation (users’ votes) to influence the research it engages in. However, 
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its relationship with its user community was significantly dented in 2012 
with the company’s announcement of their award for a patent for 
sequencing SNPs associated with Parkinson’s disease (PD). The 
commercialisation of customers’ free SNP data to develop a patent with the 
intention of improving the company’s income by enforcing its application 
seemed contradictory to the company’s repeatedly voiced philosophy of 
genomic democracy (although users had agreed this as per the Terms and 
Conditions small print). In addition, it is not clear if the 23andWe community 
voted PD to the top of the company’s research agenda or if the fact that 
Sergey Brin’s family have mutations linked to PD was a more significant 
influence. The Michael J Fox Foundation, a research organization set up by 
the Hollywood actor who developed young-onset PD at 30, is now 
partnered with 23andMe, using its customers’ genomic and survey data to 
contribute to PD research (23andMe 2012a). 
 
Having lowered the price of their test kit, from $999 at their launch in 2007 
to just $99 in 2012 (23andMe 2012b), 23andMe launched a USA television 
advertising campaign in the late summer of 2013. The aim was to increase 
their customer numbers from 400,000 to a million but unfortunately this goal 
was undermined when the FDA issued the company with a Cease and 
Desist letter in November 2013 (Conley 2013a). This reiterated the 
Administration’s earlier decision to class 23andMe’s personal genome 
testing as a medical device requiring regulatory approval that includes 
evidence of the test’s clinical validity and utility for the risk information it 
provides. Issuing the Cease and Desist letter in 2013 appears to have been 
provoked by 23andMe’s failure to cooperate with the regulatory process 
(Brice 2013, Prainsack 2014a). The filing of a Class Action Lawsuit against 
23andMe, also in November 2013, suggested that the decision to file the 
suit was deliberately timed in order to capitalise on the FDA’s letter, which it 
relied on as part of the evidence supporting the suit (Conley 2013b). 
Subsequently, 23andMe has continued to market testing to USA residents 
that only includes ancestry testing and raw SNP data (if desired), although 
they do invite participation in health research on purchase of a test kit.  
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However, whilst cooperating with the FDA and having achieved approval 
for their test for carrier screening for Bloom’s syndrome (Janssens 2015), 
the company launched bases in Canada, the UK and the European Union 
(EU) in 2014. They are now selling modified versions of their former “full” 
range of health, carrier, trait and ancestry test to residents of Canada, the 
UK, Denmark, Finland, Ireland, the Netherlands and Sweden, as the Public 
Health Genomics Foundation had forecast earlier in 2014 (Brice 2014). In a 
surprising commercial move, the company also started selling test kits in a 
UK health and beauty retailer’s stores early in 2015 (see Figure 2.5). This is 
surprising on two counts. First, it is unclear why the company has chosen to 
market tests in a retail setting in the UK, although their press release claims 
this will “improve accessibility for UK customers” (23andMe 2015). Second, 
the only other attempt at shop-based retailing of personal genetic tests 
since Sciona’s brief partnership with the Body Shop was Pathway 
Genomics’ test kits in Walgreens’ shops in the US, which provoked 
significant reaction at the time and never got off the ground, as I will 
describe in the next section. Responses to 23andMe selling tests from 
Superdrug in the UK have included what are becoming the expected 
statements of concern from organisations such as GeneWatch 
(GeneWatch UK 2015) and in this instance, the Royal College of GPs 
(Meikle 2015), but essentially this move has resulted in comparatively little 
reaction. It is yet to be seen how successful sales will be from this outlet. 
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Figure 2:5 23andMe point-of-sale in UK health and beauty shop, May 2015  
(My photograph) 
 
Given the varied fortunes of the personal genomics market, basing a 
business model solely on selling personal genetic testing direct-to-
consumer has been shown to be an unlikely proposition for commercial 
success. Indeed Williams and Edge’s concept of “veto power” appears to 
have been of some influence here in that consumers have not adopted 
SNP genotyping in droves (Williams and Edge 1996: 878). The 
announcement early in 2015 that 23andMe has signed deals with large 
pharmaceutical and biotechnology companies (including Genentech and 
Pfizer) to provide access to their databases of customers’ genetic and 
health information finally made the company’s business plan public. 
Collaborating and selling access to customers’ data for research and 
pharmacological developments has been key to 23andMe’s business 
model since its launch, but has only recently been publicised (Herper 2015). 
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Other DTCGT companies  
Other contributors to the DTCGT market include Knome, who offer whole 
genome sequencing and Gene By Gene (which includes their formerly 
separate groups DNA DTC and Family Tree DNA), who offer whole 
genome or exome sequencing (without interpretation of the sequence), 
mtDNA sequencing, single-gene tests or carrier screening through a 
physician and ancestry testing DTC. Harley Street-based GeneticHealth 
offer online testing and were the company featured in the controversial ITV 
reality television programme “The Killer in Me” in 2007. With a similar trope 
relating to empowerment through knowledge, GeneticHealth’s website 
offers SNP testing and uses endorsement from its partnership with ITV to 
promote its services (see Figure 2.6). However, it is notable that dates on 
the company website are several years old (© 2005), calling into question 
its current authenticity (GeneticHealth 2005). 
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Figure 2:6 GeneticHealth UK website home page  
(GeneticHealth 2005) 
 
Pathway Genomics, based in California, offer genotyping (SNP analysis) in 
a similar model to Navigenics’, tests being ordered by physicians and 
genetic counselling being offered pre- and post-testing. In 2010 this 
company had an interesting, if short and unproductive foray into high street 
store marketing of its genetic tests. It partnered with the large US pharmacy 
chain store Walgreens, who agreed to sell DNA test kits directly to 
customers in their stores. No kits were ever sold because publicity about 
the Walgreens/Pathway Genomics deal resulted in the FDA sending a letter 
to the company noting they had no approval for their test, which appeared 
to be a medical device and resulted in the kits being withdrawn. 
Subsequently, similar letters were sent to online DTCGT companies (FDA 
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2010), to which they responded in private discussions and agreements with 
the FDA.  
 
Whilst not substantively different from other DTCGT companies’ SNP 
genotyping tests, The Walgreens/Pathway Genomics CLIA certified test 
seems to have crossed a divide from those available online, to being sold in 
shops. It is unclear exactly what the nature of this divide is as the issue was 
resolved by terminating the business agreement between Walgreens and 
Pathway Genomics but, in tandem with Sciona, it appears that having 
genotyping test kits physically, publicly available on the high street, (at least 
in the USA) constituted a greater threat than that posed by individual 
citizens procuring them online with the privacy of their own computer 
terminal. This is possibly because a legal loophole in the USA meant that 
DTCGT was at that time not necessarily seen as a clinical test because it 
was sold online to the public for various uses (Vorhaus 2010a) but when 
sold by a pharmacy chain store for disease risk testing, the implication that 
it is a clinical test became more difficult to avoid.  
 
Celebrity testing 
Although DTCGT companies appear to be falling like ninepins in this post-
economic downturn decade, having appeared in number in the late 2000s, 
the media often referred to high profile “spit parties” and celebrities’ 
experiences of being tested in their coverage of DTCGT as an emerging 
technology. With potential customers being attracted to DTCGT by 
promises of personalised, genomic information that would provide 
previously unknown information about their health (and/or ancestry), the 
use of celebrity as commodity (Ferris 2007) was also being marshalled to 
add to the hype and marketing of this deterministic new technology. 
Amongst many others, celebrities including Oprah Winfrey and Steven 
Pinker had stories about their genome analyses published in the media. 
Interestingly, both stories were characterised by the lack of validity of their 
tests: Winfrey was led her to understand that she was of South African 
origin and she publicly announced her membership of the “Zulu nation” 
whilst on a trip to South Africa in 2005. This was later undermined by 
geneticists and historians who pointed out that there was a lack of detail in 
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genotyping at the time Winfrey tested and that the Zulus were not involved 
in slavery migration, which was from West Africa rather than South Africa 
(BBC News 2005). Steven Pinker’s article on testing describes few 
surprises and several discrepancies between his genotype and phenotype, 
presenting a more pragmatic interpretation of the value of genotyping to the 
user (Pinker 2009).  
 
In a prophetic publication in the Hastings Centre Report, Silverman 
described the expansion of genetic testing from medical laboratories into 
private enterprise and forecast the proliferation of genetic testing marketed 
directly to the consumer. Whilst Silverman did not envisage direct-to-
consumer testing per se, his article sets the tone for subsequent authors’ 
publications on DTCGT. He does so by raising concerns about the impact 
of genetic testing on individuals’ behaviour and lifestyle choices in the light 
of results seen through the deterministic lens DTCGT companies portray 
genotyping information with. He ends his article suggesting that regulation 
is the only “moral influence that can be brought to bear” (Silverman 1995: 
S17). This will be examined in the next section on Moral Order, the third 
condition of possibility for DTCGT, after which I shall go on to explore the 
history of regulation of personal genomics. 
 
Moral order 
In liberal society moral order is central to a system of obligation and 
accountability for productive relationships between individuals and groups 
in society. Relationships between the public and healthcare professionals 
have been based on trust, whether on a more or less paternalistic basis, 
but the neoliberal movement towards health consumerism threatens this 
status quo. DTCGT is particularly problematic in this regard because of the 
tension it sets up between the public (users) and clinicians. Individuals in 
both groups are accountable to society, healthcare professionals being 
additionally accountable to patients, employers and their professional 
bodies. As part of this accountability the public are being encouraged to 
take responsibility for their health and manage their risk of disease. DTCGT 
is sold to facilitate this risk management and is seen as having personal 
utility for many purchasers (Khoury et al 2009, Bunnik et al 2011, Tutton 
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and Prainsack 2011). However, the autonomy lay individuals are exercising 
in relation to DTCGT challenges clinicians’ accountability to them, because 
many clinicians view the public’s choice to buy genotyping as lacking utility, 
being misleading and potentially harmful (Wade and Wilfond 2006, 
Wolfberg 2006, Van Ommen and Cornell 2008, Kraft and Hunter 2009). 
Alternatively, there is potential for doctors’ ignorance and scepticism to 
undermine the public’s confidence in the healthcare establishment, unless 
they take up Farkas and Holland’s call for doctors to assist the marketplace 
and consumers by guiding them through DTCGT with information (Farkas 
and Holland 2009). Keeping the public’s trust and engaging users, DTCGT 
companies and healthcare professionals in developing new relationships 
within a more democratic approach to health care are suggested as a more 
realistic way forward as the genomic era progresses (McGowan and 
Fishman 2008, Patch et al 2009). 
 
However, the ethical problematisation of DTCGT relates to the lack of 
clarity of its ontological status. Whilst it has emerged from research into 
human genomics, it is difficult to reduce DTCGT simply to the procedure of 
SNP analysis. The nature of genetic knowledge is wider than its biological 
basis because it affects people’s lives, their decision-making, their families 
and their health risk management. In this way, DTCGT has the capacity to 
cause harm in relation to anxiety, drastic interventions for the purposes of 
managing the risk of disease or complacency and lack of disease risk 
management, all on the basis of a test that is of doubtful clinical utility 
(Wade and Wilfond 2006, Wolfberg 2006, HGC 2007, Katsanis et al 2008, 
Wallace 2008, Patch et al 2009). Bunnik et al (2011) highlight how novel 
data are being produced by GWAS research, which both add to and alter 
previous DTCGT results, so customers may have to change their views 
about their health in light of shifting results and may be repeatedly exposed 
to an emotional rollercoaster each time they are notified about new GWAS 
associations with their SNPs. Concerns for the relatives who may be 
affected by genetic testing results, the vulnerable or those subject to 
surreptitious testing (testing people without their knowledge) and, in 
particular, children are all potentially difficult and can be viewed in 
juxtaposition to companies advertising fun for the family or purchasing 
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testing for others (whatever the motive) (Borry et al 2009, Kutz 2010, 
Udesky 2010, Vorhaus 2011). 
 
Privacy is suggested as a positive attribute and is related to autonomy in 
relation to buying a genotype test online. However, breach of confidentiality 
in relation to individuals’ genotyping data is problematic because potentially 
sensitive information used by third parties for discriminatory reasons may 
have significantly harmful effects. Despite the enactment of the Genetic 
Information Non-Discrimination act in the USA in 2009 (Conrad 2009), 
there are concerns about individuals’ insurance and employment should 
DTCGT data get into the wrong hands. As I alluded to earlier in relation to 
the take-overs of deCODE genetics and Navigenics, privacy and 
confidentiality could be threatened when companies go bankrupt and the 
fate of customers’ samples (if kept) and data is uncertain, regardless of the 
purchasers’ country of domicile (Foster and Sharp 2008, etc Group 2008, 
Udesky 2010). 
 
Anthropologist Mary Douglas suggested that shared classifications are 
central to moral order in human society and, without shared or commonly 
accepted understanding, disapproval is expressed and rituals are enacted 
to restore order (Davis 2008). The equivalents in respect of DTCGT are the 
debates for and against DTCGT published in the popular and professional 
media and the numerous calls for oversight of some kind to protect the 
public from harm. The history of overtures to policy and regulation of 
DTCGT are discussed next.  
 
Regulation 
The debate and activities related to policy and regulation of DTCGT 
illustrate the contingent and evolving nature of this technology. Their 
examination is particularly important in setting the scene for this study 
because of the interdependence of research into the social construction of 
technology and its influence on public technology policies (Williams and 
Edge 1996). Regulation of DTCGT needs to be understood in the context of 
a spectrum spanning those who view DTCGT as information which 
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neoliberal citizens have a right to access directly should they so choose, to 
those who view it through the same lens as clinical genetic testing and thus 
expect similar regulatory frameworks to apply for the protection of patients. 
Whilst some are anxious to avoid being seen as paternalistic, those at the 
regulation end of the spectrum call for government regulation of DTCGT 
companies, including control of the threshold of clinical utility of tests, 
laboratory quality standards, informed consent, test ordering and 
interpretation using healthcare professionals and protection of consumers 
from discrimination (Wallace 2008, Evans and Green 2009, Patch et al 
2009, Wright et al 2011b).  
 
A number of authors’ calls for regulation refer to a lack or failure of 
oversight and refer to public requests for involvement of healthcare 
practitioners and government oversight of testing. However these are 
usually vox pop surveys rather than based on users’ direct experience 
(Lenzer and Brownlee 2008, Boddington 2009). The more moderate view in 
relation to regulating DTCGT supports voluntary standards and ethical 
practice, the adoption of which would support companies’ marketing power 
and potentially prevent less scrupulous companies from moving premises 
to another country where regulatory controls are less restrictive (Gurwitz 
and Bregman-Eschet 2009, Hauskeller 2011). Some question whether 
regulation is required at all (Russo 2006, Wright and Gregory-Jones 2010); 
others propose patience while the innovative nature of DTCGT companies’ 
investments in personalised genetic medicine reap rewards in relation to 
the development of useful tools for users as is arguably emerging with the 
take-overs of deCODE Genetics and Navigenics in 2012. 
 
The overall lack of regulation of DTCGT on both sides of the Atlantic 
illustrates the influence of agencies on the shaping of DTCGT and relates 
to the specific challenges DTCGT presents, which are summarised as 
follows. Globalisation of information and trade enabled by the Internet has 
vastly widened the scope of access to DTCGT and undermined the power 
of local legislation to enforce regulatory oversight across borders (Jordens 
et al 2009). The fast moving pace of change with biotechnologies 
associated with genomics and, thus, products on sale and the DTCGT 
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commercial landscape make the moving target of DTCGT difficult to define 
and legislate for. The lack of consensus about what DTCGT constitutes 
makes oversight difficult. Different groups view it as personal information, 
an educational or recreational resource, or a clinical diagnostic test and 
each would require a different approach in relation to any oversight, which 
is no doubt why the patchwork approach to any regulatory oversight 
persists. I will now go on to examine the principal events of regulatory 
activity that bring us to the current state of assorted approaches to 
regulatory oversight. 
 
In the USA at federal level a number of factors contributed to a perceived 
lack of legal or political governance of DTCGT. The Food, Drug and 
Cosmetic Act (FDCA) prevents relevant companies from making false 
claims about and requires demonstration of the safety of their products. 
The FDA has responsibility for enforcement and this includes diagnostic 
medical devices; however, tests made by individual laboratories and 
marketed directly to consumers are not classified as medical devices but 
are regarded as “home brews” (Editorial NG 2002:553). Additionally, the 
CLIA requires specific certified analytical validity standards to be achieved 
by all testing on human tissue undertaken for diagnosis or treatment since 
1988 (Fraker and Mazza 2010, McBride et al 2010), but it has no statutory 
or regulatory requirements for proof of clinical utility or clinical validity (HGC 
2003). However, many US DTCGT companies apparently managed to 
avoid these requirements early in their evolution. This was largely due to 
the FDA loophole and because the nature of the tests offered was unclear 
as they were being sold directly to consumers rather than being 
administered by healthcare providers, and partly because the oversight 
requirements were rarely used (Vorhaus 2010b).  
 
In 2006 the Genomics and Personalised Medicine Act commenced its 
development in Washington, later to become the Genetics Information Non-
discrimination Act (GINA) proposed by then Senator Barrack Obama and 
signed into law by GW Bush in 2008 (Vorhaus 2010b). Early in GW Bush’s 
presidency, the Secretary’s Advisory Committee on Genetic Testing was 
reconstituted as the Secretary’s Advisory Committee on Genetics Health 
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and Society (SACGHS), which published its report into regulation and 
genetic testing in 2008. It highlighted the inconsistencies in oversight of 
existing FDA and CLIA requirements, the lack of understanding of the DTC 
tests available, the inconsistencies between tests offered and the dubious 
clinical utility of DTCGT. As a result, public health offices in New York and 
California sent Cease and Desist letters to DTCGT companies in their 
jurisdiction. Publication of the report resulted in more federal and state-level 
discussion about regulation and some increased surveillance and action at 
state level, which led to the closure of some companies and procurement of 
licenses to operate by others (notably the larger companies, 23andMe, 
deCODE genetics and Navigenics). Some companies (notably Navigenics) 
stopped selling directly to consumers but continued marketing DTC while 
selling via healthcare professionals or clinics (Vorhaus 2010a, Evans et al 
2011).  
 
In the UK, the Advisory Committee on Genetic Testing that was established 
in 1996 was subsumed into the Labour government’s Human Genetics 
Commission (HGC) in 1999. In 2002 the HGC began a consultation into 
regulation of genetic testing. The report from the consultation considers the 
issues related to all genetic testing and makes recommendations for 
controls of genetic testing. These suggest prohibition of DTCGT because of 
concerns about lack of counselling and uncertain or poor clinical validity 
and utility of tests available (HGC 2003). In the same year the European in 
vitro diagnostic medical devices (IVDMD) directive regulating diagnostic 
tests came into effect in the UK, to be enforced by the Medicines and 
Healthcare products Regulatory Agency. However, the IVDMD directive is 
enforceable only within the UK and not on kits bought by the public from 
abroad, thus highlighting the difficulties of regulating tests sold on the 
Internet from other countries, as noted by both the HGC and the FDA (HGC 
2003). Similar concerns were expressed in other Western countries but 
none were in a position to regulate tests bought by the public online from 
other countries. 
 
In 2010 the GAO published a report into its second investigation into 
DTCGT companies (Kutz 2010). The report was the result of a two-part 
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investigation into DTCGT and revealed genuinely worrying detail about 
some personal genomics companies’ practices. Notably, the initial 
investigation highlighted companies’ use of misleading marketing 
information, the lack of clinical validity and reliability of tests (by submitting 
samples from fictitious people and obtaining different results for the same 
samples) and results that differed from the individuals’ phenotypes (as with 
Steven Pinker). In the second part of the investigation undercover GAO 
staff contacted companies assuming the role of customers and the resulting 
report exemplified conversations in which advice about the deterministic 
nature of tests for disease risk was supported by a company representative, 
in one instance, asserting that the customer’s test result put them at high 
risk for developing breast cancer. In another instance, a caller was 
encouraged to submit her boyfriend’s sample for testing surreptitiously, in 
order to give him a surprise gift. However, the effect of this sensationalist 
report was to backfire on the GAO’s presumed intention to force legislation 
to regulate the industry, because its inconsistent approach and 
unrepresentative content (no companies were identified with specific 
examples of poor practice) rendered it confusing and ineffectual for 
informing regulation (Vorhaus 2010b, Ray 2011). 
 
Publication of the report prompted a flurry of activity in political and legal 
circles, in commercial genomics companies and in blogs posted by those 
with interests in DTCGT. An important milestone was the congressional 
meeting with representatives of the main stakeholders (companies, the 
FDA, the GAO and congress), in which the deficiencies in the GAO report 
were revealed, as it resulted in confusion and inappropriate assignment of 
all DTCGT companies’ practices to the lowest common denominator of the 
reports unidentified examples. However, the FDA then issued letters to 
individual DTCGT companies inviting private discussions to clarify the 
status of the companies’ products in relation to requirements for FDA 
approval. As a result, companies took various approaches to either 
changing the products to reduce the disease trait testing or only providing 
tests at a doctor‘s request. Notably 23andMe continued to trade as before, 
promoting its democratic and altruistic philosophy to attract customers. 
However, despite this, no change in the federal regulation of DTCGT 
ensued at that time (Jostins and MacArthur 2011). Subsequently, the FDA 
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issued 23andMe with a further Cease and Desist letter in 2013. In their 
view this was provoked by 23andMe’s failure to engage with the 
Administration’s process for regulation. As a result, the company stopped 
providing health reports to new customers in the USA and instead set up 
off-shore bases from which to sell testing to residents of other countries not 
affected by the FDAs jurisdiction, as described earlier in this chapter. 
 
In the UK, the House of Lords Science and Technology Committee 
reported on DTCGT in 2009 and suggested that the HGC draw up 
principles for practice, which, due to the perceived low risk of DTCGT under 
the European IVMDD, could be voluntary (House of Lords 2009). Having 
published “More Genes Direct” in 2007 to update information on 
developments in the DTCGT field (HGC 2007), the Commission then 
published its “Common Framework of Principles for DTCGT Services”, with 
the aim of providing a code of practice from which companies could trade 
and practice could be monitored when and if regulation was enforced. 
Covering all types of DTCGT, the Framework proposed practice standards 
in relation to transparency in marketing, informed consent and counselling, 
test and laboratory standards, test interpretation and data protection. 
However, the Framework seemed to ignore the potential for the Internet to 
provide DTCGT to the public across national (and jurisdictional) boundaries 
(HGC 2010). Like the SACGHS, the HGC was disbanded following a 
change of government and it is not apparent that their Framework has been 
adopted at national level in the UK or anywhere else. UK nationals are still 
at liberty to buy tests online without these principles being adhered to. In 
contrast, the Nuffield Council on Bioethics suggested that more research 
into the effects of DTCGT is needed before decisions are made, as 
supported by Prainsack et al 2008, Khoury et al 2009 and Leighton et al 
2012 (Nuffield Council on Bioethics 2010). 
 
In the EU in 2008 the Council of Europe produced an additional protocol to 
the Convention on Human Rights, which essentially advised that genetic 
tests must be administered under medical care and with counselling 
(Council of Europe 2008). This could have significant implications for 
DTCGT in Europe, except that the Protocol is essentially not binding in 
Europe unless member states sign up to it, which a number have not, 
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including the UK (Borry 2008, Kaye 2008). In 2009 Germany passed 
national legislation limiting the return of genetic tests results to physicians, 
preferably with counselling, although it appears that this is only applicable 
to tests bought from German companies within Germany’s geographical 
jurisdiction (Vayena and Prainsack 2013). Similar legislation exists in 
France and Switzerland but it is not clear how this is enforced with the 
online market (Borry et al 2010, Skirton et al 2012). 
 
Guidance published by various professional medical associations on 
DTCGT calls for some level of oversight and the involvement of healthcare 
professionals at some level, from discussion about testing to ordering and 
interpreting tests (Skirton et al 2012). The basis for these proposals, which 
are supported by others in ELSI academic circles, appears to be the 
association of DTCGT with clinical genetic testing and potentially diagnostic 
properties and the need to protect the public from the attendant possible 
harms, which they are thought to be unaware of. This much is evident from 
the statement released by the Royal College of General Practitioners when 
23andMe started to sell tests in a UK health and beauty retailer’s shops 
(Meikle 2015). However, the need for protection is not borne out by 
research findings. A small number of US-based studies have established 
that knowledge about genetic risk for disease appears not to alter 
behaviour, beliefs or perceptions of control, or cause distress to individuals 
in the medium to long term as will be discussed further in Chapters 4-6 
(Heschka et al 2008, Marteau et al 2010, Bloss et al 2011, Collins et al 
2011). 
 
DTCGT can be sold in the UK at the time of writing, owing to the testing 
being undertaken in a non-EU country and the kit not being classed as a 
medical device under the current EU directive for IVDMD; in addition, the 
collection device itself is marked with the Conformité Européenne (CE) 
approval symbol (Burton 2015). However, the IVDMD directive is being 
revised to a regulation that is unlikely to permit loose interpretations that 
have followed from scientific and technological developments since the 
directive was first produced. This may restrict the sale of genetic tests 
direct-to-consumer, but the 2012 draft regulation is still under negotiation at 
the European Council (GeneWatchUK 2015). 
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In contrast to the professional view, the little that is established about the 
public view indicates that DTCGT is generally viewed in relation to its 
personal utility, as individual information that is interesting, potentially 
useful and the consumer’s right to be able to acquire without imposed 
restrictions (Vorhaus and MacArthur 2010, Gordon et al 2012). These two 
juxtaposed views partially illustrate the foundations for the on-going 
uncertainty in relation to regulation of DTCGT.  
 
Conclusion 
Whilst DTCGT has emerged from research into human genomics and has a 
basis in biological science similar to more conventional genetic testing, it is 
difficult to reduce it simply to the procedure of SNP analysis. This is in 
common with clinical genetic testing, because the nature of any genetic 
knowledge is wider than just its biological basis due to the effect that 
knowledge potentially has on people in terms of their health risk 
management, their decision-making and the implications for their families 
(Featherstone and Atkinson 2012). However, companies market testing as 
providing vital knowledge to consumers and this sets up tensions between 
the public who use it and HCPs, who are sceptical of its value and 
concerned about the possible harms that knowledge might cause. 
Furthermore, there is the possibility of a potential drain on resources by an 
increase in referrals to clinical genetics services for counselling for DTCGT 
users. Given that these referrals result from private individual testing 
transactions and are additional to the current workload plans of NHS 
clinical genetics services, they have the potential to disrupt services and 
the trust-based relationship between the public and their HCPs as the two 
groups’ expectations diverge. 
 
Research conducted into DTCGT to date fails to support the concerns 
about harm to users or significant additional impact on healthcare services 
that have been emphasized in professional and academic literature since 
personalised genomics became available. Weblog posts support 
McGowan’s and colleagues’ findings that most users are educated, 
informed individuals who are curious and unlikely to be surprised by test 
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results or to regard them as deterministic (McGowan et al 2010, Bloss et al 
2011, Collins et al 2011). There is little empirical evidence of the impact on 
genetics clinicians, though much of the literature implies a lack of adequate 
knowledge about genetics or genomics in most general or family 
practitioners (Jordens et al 2009, Ormond 2009). 
 
Almost all the empirical work published to date reflects either provisional 
studies (research conducted on groups who have not actually engaged with 
DTCGT but are presented with possible scenarios) or is focused on North 
America. In the face of this notable lack of research I feel it is important to 
examine the implications of personalised medicine from the perspectives of 
people engaged in obtaining genomic screening for disease risk in the UK 
and genetics clinicians who may be called upon to help them with the 
results. The next chapter will discuss the methodology and methods I have 
chosen for this study in order to elicit how the discourse about DTCGT is 
being socially constructed and shaped in the UK context. 
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Chapter 3 : Theoretical and methodological 
approaches to the sociological study of 
genetics 
 
Genetic testing has long been researched by sociologists. In this chapter I 
shall review the sociological research literature on genetic testing to show 
how sociologists have investigated genetic testing previously, in order to 
situate and justify my study design. I shall relate the overarching 
theoretical and methodological concepts of my study to that literature and 
the work of STS scholars that has informed my use of SCOT as a 
conceptual framework. I shall complete the chapter with details of how the 
study was performed. 
 
Researching genetic testing  
Informative research into people’s responses to predictive testing for 
genetic disease includes a number of quantitative studies that attempt to 
measure individuals’ psychological responses to testing. Psychologists 
Theresa Marteau and Susan Michie and colleagues have conducted 
numerous survey-based studies to ascertain what psychological effects 
result from suspecting a familial genetic illness and being tested (or not) to 
establish genetic status (Michie et al 1997a, Michie et al 2001, Michie et al 
2002). These studies employ structured interviews and some include 
Quality of Life measurement questionnaires to assess psychological 
status, such as the Spielberger State-Trait Anxiety Inventory (Marteau and 
Bekker 1992). Non-directiveness of genetic counsellors has also been 
examined from a quantitative perspective by recording consultations and 
questioning counsellors and consultands before and after consultations, 
using structured interview schedules or questionnaires (Michie et al 
1997b). These studies are of relevance here because, whilst they are 
based on a realist perspective, their empirical work contributes to 
understanding people’s experiences of genetic testing and counselling.  
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One of the earliest research projects into the impact of genetic 
susceptibility testing on perceptions of disease risk was part of the multi-
centre Risk EValuation and Education for ALzheimer’s Disease (REVEAL) 
study. One element of the REVEAL project was a randomised controlled 
trial that sought to establish participants’ (adult children of people with 
Alzheimer’s disease) perceptions of their risk of developing Alzheimer’s 
disease after having had their risk estimated (Roberts et al 2005). The 
intervention arm of the study had disease risk estimated with inclusion of 
Apolipoprotein E genotype, unlike the control arm whose status was 
calculated on age, sex and family history only. The APOE4 variant of the 
gene is thought to contribute approximately 50% to the genetic risk of 
developing Alzheimer’s disease (Farrer et al 1997). Findings concluded 
that perceptions of risk are influenced by genotyping in those who tested 
APOE4 negative, but not those who tested positive (Marteau et al 2005). 
 
Continuing the quantitative theme and directly related to DTCGT 
(although not strictly ‘sociological’ research), Howard and Borry sent 
questionnaires to genetics clinicians in the EU to investigate clinical 
geneticists awareness of, and attitudes towards commercial genomics. 
Perhaps unsurprisingly, their survey found that this group of clinicians feel 
that it is inappropriate to conduct this kind of susceptibility testing without 
counselling (Howard and Borry 2013). Their work shares this approach 
with a number of studies of genetics clinicians and potential early 
adopters in the UK and North America conducted by bioethicists and 
healthcare researchers aiming to access disparate and relatively 
unfamiliar groups (Cherkas et al 2010, Gray et al 2009, Giovanni et al 
2010, Kauffman et al 2012, Leighton et al 2012, McBride et al 2009, 
McGuire et al 2009). 
 
However, survey research could be judged as being sterile, in the sense 
that it de-contextualises its data and the subjects who provide it from the 
social aspects of life that inform them, as Wynne suggested (Wynne 
1992). Howard’s and Borry’s work provides a good example of this. While 
their findings could be said grossly to mirror those from my study, their 
pragmatic approach to obtaining European-wide data with a survey is 
unable to obtain the in-depth nuanced views about the social aspects of 
clinicians’ views that this study has done by interviewing UK-practising 
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clinicians. In a similar vein, RCTs in health-related research could be said 
to provide data from a context in which it is so manipulated (in order to 
achieve the requisite control of variables) as to render it meaningless in 
the context of the populations for whom it is likely to be relevant (Rothwell 
2005). Thus, much of the sociological research into genetic testing adopts 
a qualitative, constructivist model in order to elicit the contextual, social 
aspects of people’s experience. 
 
I adopt a constructivist approach in common with many well-known 
sociologists who, whilst acknowledging the existence of physical reality in 
the shape of biological or medical knowledge, emphasise the importance 
of studying people’s multiple and socially organised responses to reality 
(Barnes 1982, Nicholson and McLaughlin 1987, Atkinson 1995). Anne 
Kerr notes that constructivism enables consideration of how people’s 
social worlds influence their engagement with technology in general and 
genetic testing technologies in particular (Kerr 2004). Constructing 
understanding of how their knowledge and experiences shape their 
responses to new technologies and thus the technologies themselves, will 
be covered next. 
 
The Social Construction of Technology 
The broad design of this study is to take a constructivist approach to 
understand how the new technology of commercially obtained SNP 
genotyping is being shaped by the discourses and actions of principal 
groups of actors engaged with it in the UK. Discourses in this context are 
understood as practices of sharing and developing beliefs and 
understanding through discussion, evaluation, interpretation and sense-
making with the purpose of producing knowledge about this technology 
(Lessa 2006). Rather than taking a realist position and researching the 
physical reality of SNP genotyping and the potential implications for 
disease or trait phenotype, which undeniably exist, I am instead seeking to 
construct knowledge about the social processes that influence individuals in 
their uptake or dismissal of this emerging technology in the UK. In other 
words, I am viewing SNP genotyping as a whole system, or assemblage, 
that is socially constructed and shaped by the beliefs, interpretations, talk 
and practices of the actors involved with it (MacKenzie and Wajcman 1999), 
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rather than simply as a laboratory test. Consequently it seems appropriate 
to use the SCOT framework to analyse how this emerging technology is 
being shaped in the UK context. I shall now examine the developments in 
STS that informed the development of technology studies generally and 
then examine the development of the SCOT framework in particular, 
considering relevant examples in order to justify its use in this study. 
 
The study of scientific knowledge (SSK) with its characteristics of 
impartiality and symmetry towards both truth and falsity in scientific beliefs 
emerged in sociology in the second half of the 20th century. The application 
of the principles of symmetry and impartiality were the basis for both Bloor’s 
and Collins’ respective programmes of work in the Strong programme and 
the Empirical Programme of Relativism (Collins 1981, Bloor 1991). In a 
rejection of both technological determinism and linear models of 
technological development that was in keeping with the developing work in 
science studies, it was proposed that SSK principles are just as applicable 
to studies of technology, given that both scientific and technological 
knowledge claims are socially embedded (Pinch and Bijker 1984, 
MacKenzie and Wajcman 1999). Several approaches to the study of the 
relationship between technology development and society have been 
proposed including the Social Shaping of Technology (MacKenzie and 
Wajcman 1991, Williams and Edge 1996), Actor Network Theory (Latour 
2005) and the Social Construction of Technology (Pinch and Bijker 1984).  
 
The Social Shaping of Technology approach assumes mutual shaping of 
society and technology (MacKenzie and Wajcman 1999); pivotal decisions 
at certain points during development of a technology influence which paths 
are subsequently followed as a result. This approach to technology studies 
was used by MacKenzie in his study of nuclear missile guidance 
technology in which he demonstrated how the technology’s accuracy was 
influenced by organisational and political factors rather than simply 
scientific or technological ones. MacKenzie suggested that the relationship 
of certainty about a technology’s capabilities is aligned to people’s 
understanding and proximity to it. Those who are directly involved in its 
development are less certain of its capabilities knowing its potential failings, 
those who are institutionally aligned to it or may use it are more certain of it 
whilst those whose loyalties are elsewhere are likely to be uncertain about 
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it (MacKenzie 1990). Whilst MacKenzie’s work on nuclear missiles 
guidance technology does not follow the SCOT framework per se it is 
relevant here because the relationship of proximity to technology and 
certainty in its capabilities can be applied to this study’s participants as I 
shall go on to illustrate in the section on expectations. 
 
Pinch and Bijker outlined their Social Construction of Technology 
framework advocating that both scientific and technological artefacts are 
social constructs that are influenced by social groups whose members 
influence the development and stabilisation of technology. As a direct result 
of the influence of SSK, they advocate that symmetry is the core principle in 
analysing technological developments, that both successes and failures 
should be examined in the same way so as not to privilege either or to draw 
conclusions about success or failure based on whether nor not a 
technology works. This principle of symmetry is applied across the four 
main concepts that make up the SCOT framework 
• interpretative flexibility,  
• relevant social groups,  
• closure and stabilisation 
• the wider social context. (Pinch and Bijker 1987) 
 
Important sociological studies of technology have included Pinch and 
Bijker’s well-known study of the bicycle and its evolution from early 
beginnings as the arguably dangerous Penny Farthing design favoured by 
speed-loving young men, to the more comfortable and stable version 
favoured by women, the basis of which design persists today. Their study 
of this evolution, whilst arguably not all-encompassing of the bicycle’s long 
history starting as it does at the end of the 19th century, does examine the 
relevant social groups’ influence on changes in design of the technology by 
dint of their interests in speed, safety, comfort and practicality (Pinch and 
Bijker 1994). More recently Paul Rosen extended Pinch and Bijker’s work 
with an examination of mountain bikes, to illustrate his critique of SCOT. He 
cites Pinch and Bijker’s lack of emphasis on the wider social context and its 
impact on technology development as problematic, as is their lack of 
detailed consideration of the membership and relative influences of the 
relevant social groups (Rosen 1993). 
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Similarly Klein and Kleinman’s (2002) critique of SCOT focuses on the 
contrast between using an agency-focused approach rather than including 
examination of structural concepts in analysing technological development. 
Their concerns relate to assumptions that the characteristics of relevant 
social groups are homogenous and equivalent in their membership, rather 
than examining group membership for their capacity to shape technology 
owing to their political, professional or economic power. This concern is 
certainly relevant to this study where the relevant social groups being 
studied in relation to DTCGT have origins and particular characteristics that 
influence their discourse and thus influence the disputes about DTCGT and 
its uptake, as the data will demonstrate.  
 
The SCOT approach facilitates productive investigation into the “black box” 
of genetics, using the phrase in the sense of “opacity” that Lynch et al 
(2010:17) refer to. SCOT can help develop understanding of how the 
relevant social groups of users and clinicians engage with genetic 
information in different and competing ways for social, economic, 
regulatory and professional reasons. Analysing these relevant social 
groups’ use of interpretative flexibility and sense-making practices, allows 
these differences and their implications to be illuminated and objectively 
understood, as does the influence of the wider social context of the 
provision of health care in the UK’s state-funded collective medical service. 
This understanding will illustrate the influence of human intervention on 
the current path that SNP genotyping is taking in the UK rather than 
assuming a technologically deterministic position that would absolve 
people from any responsibility in their engagement with it (Wyatt 2008). It 
will also illuminate the factors that are sustaining the disputes between the 
relevant social groups, or those that may offer opportunities for 
stabilisation of the technology in the resolution of the disputes and 
acceptance (or loss) of the technology. Given the potential impact of 
genetic information on people and their social networks, however that 
information is obtained, an exploration of the social construction of this 
technology seems the most pertinent approach to understanding DTCGT, 
and thus its impact in the UK. 
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Pinch and Bijker suggest that new technologies have different meanings 
for the different actors involved with them, citing users and producers as 
the key stakeholders involved (Pinch and Bijker 1987). Bijker adds to this 
by suggesting that the “technological frame” (Bijker 2010:69) is a group’s 
shared understanding of a technology is built by their shared experiences 
of knowledge or use of the technology. It can describe people’s actions 
and constructions of the technology in the sense of their knowledge about 
it, encouraging some actions or beliefs and discouraging others (Klein and 
Kleinman 2002). With this in mind it is an obvious decision to involve 
users of the technology in the UK as they will have direct experiential 
knowledge of DTCGT and thus some shared understanding that they 
associate with DTCGT (Pinch and Bijker 1984). In addition to including 
users, my decision to involve genetics clinicians was informed by 
evidence from the literature that this group would have a competing view 
of DTCGT compared with either users or producers of the product. In 
addition, being viewed as experts in human genetics, genetics clinicians 
may be called upon to interpret results and counsel patients in the event 
of any difficulty. This is because in the wider context of healthcare 
provision in the UK, genetics clinicians are the providers of professional 
advice and support about genetic conditions. Given that both users and 
clinicians constitute social groups for whom DTCGT has relevance, I felt it 
important to investigate each group’s understandings and contribution to 
discourses about the technology and the controversies that surround it, 
using SCOT as an interpretative framework. Representatives of these two 
groups recruited for this study, demonstrate power relations between 
groups and their competing discourses; they also illustrate the inter-group 
conflict, different technological frames and their potential influence on 
DTCGT. This more political understanding about how DTCGT is being 
shaped aligns with Klein and Kleinman’s critical review of SCOT and their 
suggestion that a more “structural” approach to analysing social groups 
and the wider context of technological development is required for SCOT 
to be comprehensive (Klein and Kleinman 2002:29). A more detailed 
description of the members of these groups is given in the Methods 
section later in this chapter, in accordance with Pinch and Bijker’s 
assertion that detailed descriptions of the relevant social groups are an 
important part of the analysis (Pinch and Bijker 1984). 
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Given that relevant social groups constitute the “unit of analysis” in SCOT 
(Oudshoorn and Pinch 2005), it is appropriate that this informs the 
theoretical approach of this study’s design, focusing as it does on the 
groups of users and clinicians. Having discussed the relevant social 
groups for the study, and described the importance of the wider social 
context of the NHS I now wish to explore the remaining concepts that 
have an important bearing on this study. These include taking a 
symmetrical approach to examining different actors’ contributions to 
shaping discourse about DTCGT, examining the interpretative flexibility 
applied to DTCGT, considering how expectations have contributed to 
shaping the technology, and adopting a reflexive approach. The relevance 
of each of these tools to this study and their importance in STS and 
sociological research in genetics warrants specific consideration, which I 
shall cover in the next section. 
 
Symmetry 
As I suggested earlier, the Strong Programme in the study of scientific 
knowledge is underpinned by the contention that all knowledge should be 
treated equally by sociologists (Bloor 1991). Whilst agreeing with Bloor’s 
principle of symmetry, Collins also notes that, where a controversy exists, 
the sociologist’s role is to observe the different aspects of the debate 
objectively and with symmetry in order to analyse it. No other approach is 
possible, as we (sociologists) have no way of knowing what the truth or 
point of settlement will prove to be, any more than those actors involved in 
the controversy have (Collins 1981). In applying this principle to the study 
of technology, this is certainly true in DTCGT, as the on-going debate 
about its advantages and risks attests. Both groups in this study have 
distinctive views about DTCGT and, by taking a symmetrical approach to 
the principal actors’ claims about DTCGT, I am able to observe and 
analyse the uptake of DTCGT in the UK context not in relation to its 
success or failure, but rather in considering how the relevant social groups 
view the technology and promote or undermine its success as a result. 
 
This principle of symmetry has been a crucial tool in this study, by giving 
equal representation to groups with different, sometimes opposing, views 
and different types of influence in their respective spheres. Application of 
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symmetry has also confirmed my position as a researcher, which is not to 
know how the debate will be closed or what the truth about SNP 
genotyping is. I am not in a position to know if the science is flawed, 
whether clinicians are wrong or users are right, or vice versa. My role is to 
note their views and experiences in a symmetrical manner. Consequently 
this study has evolved into a very different one from the bioethical study 
that I first envisaged. This is as a result of the application of both 
symmetry and the related tool, interpretative flexibility, which I shall 
discuss next. 
 
Interpretative flexibility 
In conjunction with the use of symmetry to approach different actors 
interpretations of genotyping, observing how they use interpretative 
flexibility is critical to understanding how different views of science and 
technology influence debates about the technology. Potter and Mulkay 
refer to interpretative flexibility in relation to interviewing scientists about 
scientific theory; scientists interpret theory differently according to their 
audience, and what they are trying to achieve by articulating their 
thoughts at any given time. Variation in accounting can be used as an 
analytical resource for making sense of persistent disagreements when 
people fail to adopt a theory that is seen as “correct” (Potter and Mulkay 
1985). Also, different interpretations of technology can influence the 
technology’s design and future use as Pinch and Bijker demonstrate with 
the example of the bicycle (Pinch and Bijker 1987).  
 
Williams and Edge have criticised SCOT suggesting that it is difficult to 
explain how disputes about technologies achieve closure (or stabilisation) 
using interpretative flexibility owing to the infinite possibilities that could be 
put forward (Williams and Edge 1996). However, whilst I will go on to argue 
that DTCGT is not yet stabilised in the UK context, the concept of 
interpretative flexibility is crucial in this study’s data as it is clearly 
demonstrated in the inconsistent and arguably self-contradictory views 
expressed by many of the participants in both groups, as well as the overall 
differences in beliefs about DTCGT between groups. I will show how this 
points to the on-going nature of the disputes about DTCGT in the UK. 
Interpretative flexibility is also an important principle to apply in examining 
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the debate about genotyping and GWAS, in examining how these 
technologies are variably interpreted in the different arenas in which they 
are debated, and in relation to the varied interpretations of SNP genotyping 
different companies produce. Martin Richards notes this particular aspect in 
his autoethnography of DTCGT, in which he received different 
interpretations of his SNP genotyping from each of the companies he sent 
his samples to (Richards 2010).  
 
While people’s views of a new technology or theory may be contingent 
and variable, depending on their proximity to it as researchers, scientists 
or adopters, they are likely to use interpretative flexibility to articulate 
variable expectations of the new theory or technology, depending on 
whether their audience is fellow research scientists or outsiders (Borup et 
al 2006). Using interpretative flexibility to influence expectations and the 
uptake of genotyping has been fundamental in DTCGT and it is to the 
sociology of expectations that I turn next. 
 
Expectations 
Expectations have been shown to play a central role in creating and 
shaping biotechnologies (Bijker 1997, Brown et al 2000, Brown and 
Michael 2003, Hedgecoe and Martin 2003, Borup et al 2006, Groves and 
Tutton 2013). They lend a technological innovation structure and 
legitimacy, driving its design and re-design and clarifying the roles of 
those involved in its development. “Enactors”, as Groves and Tutton refer 
to those creating the technology and expectations of it (Groves and Tutton 
2013:182), or the “core-set” of scientists (Collins and Evans 2002:242) 
use interpretative flexibility to articulate expectations of their new 
technology depending on whom their audience is comprised of (Borup et 
al 2006). In personalised genomics this flexibility hides uncertainties about 
the technology. 
 
Expectations evolve over time and alternate between hype and 
disappointment. This happens in the course of their being tested in arenas 
between their enactors and those who decide if and how technologies can 
be reified, referred to as “selectors” (Groves and Tutton 2013:182). 
Expectations of DTCGT are being tested by selectors in relation to the 
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ethical challenges it poses, its differences in approach compared with the 
clinical genetics model of testing and its technological contingencies. As a 
result, companies’ products and the expectations that partner them have 
adapted and changed. The regulatory landscape has seen considerable 
activity as companies have sought to establish themselves or adapted 
their businesses to circumvent local regulatory restraints, as evidenced by 
23andMe developing country-specific products for Canada and the UK in 
2014 (Picard 2014, Gibbs 2014). 
 
Examination of the sociology of expectations has helped me to 
understand early adopters’ experiences of DTCGT as well as reactions 
from clinicians. Because consumers have little use for uncertainty, people 
need to be convinced by hope rather than dissuaded by truth, given that 
hope maximises possibilities while truth minimises them (Groves and 
Tutton 2013). Being ‘further’ from a technology decreases uncertainty 
about it, as I indicated earlier when referring to Mackenzie’s certainty 
trough (Mackenzie 1990). MacKenzie suggests this may be an 
explanation for users’ engagement with technology and this could be 
applied to the users of DTCGT in this study. Genetics clinicians, whilst 
knowledgeable about genetics are likely to be more uncertain about the 
technology’s capabilities because they are not directly involved in its 
development or use and have competing interests in technologies used in 
clinical genetics around which they engage in boundary work. However, 
many early adopters of DTCGT are scientists knowledgeable about 
genomics. This could be because the wider scientific community only 
becomes privy to the detailed scientific knowledge about the technology 
late in the process and so only sees the less uncertain aspects of the 
technological innovation. Widespread publications about DTCGT have 
raised awareness about genotyping among those who are interested in 
genetics and represent the emergence of the kind of network that works to 
reduce uncertainty. For clinicians, scientists’ interpretative flexibility may 
be at work in terms of presenting more moderate expectations.  
 
Reflexivity 
The problem of reflexivity in STS has been discussed by many but 
possibly most engagingly captured by Malcolm Ashmore. The thesis of his 
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thesis cleverly explores the regress induced by taking a reflexive stance in 
studying the sociology of science and technology, shedding light on the 
approaches the principal scholars in the field have taken (Ashmore 1989). 
Whilst also acknowledging its limitations, others stress the importance of 
reflexivity - that is researchers’ transparency about their views and 
attitudes in relation to the research topic - when researching the 
implications of the new genetics for the public and genetics professionals 
(Kerr et al 1997, 1998). 
 
I feel that it is important to consider it here in relation to my own journey 
into STS. Having come from a healthcare background, I am acutely aware 
that my views about science generally and genomics in particular have 
shifted radically over the period of this study. This is as a direct result of 
employing a symmetrical approach to studying the actors involved in 
DTCGT and applying this to my own views. As a healthcare professional 
my opinions about genetic testing were characteristically asymmetrical 
and partial but have altered over the last four years as I have become a 
sociologist. Adopting a relativist position towards science and technology 
has enabled me to be less judgemental which, in addition to the obvious 
advantages of adopting a more open perspective, has facilitated much 
wider learning and understanding than I could have previously imagined. 
 
My awareness of this and the opportunity to apply the principles of 
symmetry and interpretative flexibility in action were brought into sharp 
focus by my experience with the geneticists at Lübeck that I recount at the 
beginning of the thesis. I feel it is important to acknowledge this change in 
order to provide some transparency in relation to my role and learning 
during the conduct of this study and the construction of its findings. My 
intention here is to align my attempt to be reflexive with Bourdieu. I am 
attempting to pay conscious attention to the effects of my own views in 
order not to attribute them to my participants or other actors involved in 
the study. I attempt to do this while simultaneously observing and 
incorporating my observations about these actors and their contributions 
to the study, either directly as participants or indirectly in influencing my 
thinking along the way (Bourdieu and Wacquant 1992).  
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Having considered the theoretical concepts that have informed my overall 
approach to this study I shall go on to consider the methodological 
aspects of the study design. By reviewing relevant sociological research in 
genetic testing I will justify the methods used for this study, showing how 
this approach has been successfully exploited in related research into 
genetic testing. 
 
Ethnography and interviews 
Prompted by the unprecedented developments in genetic research and 
diagnosis, many sociological and anthropological studies of genetic 
testing over the last half century have been undertaken, most of which 
adopt ethnographic approaches. This is apposite, given the importance of 
people and culture to these studies. In researching the work of genetic 
counsellors in an American paediatric hospital, Bosk gives a compelling 
justification for an ethnographic approach. He demonstrates how being 
present in the field facilitates the observation and description of everyday 
actions and understandings to expose the tensions and power relations 
that shape new genetic technology and practice (Bosk 1992). Feminist 
anthropologist Rayna Rapp conducted an impressively detailed and in-
depth ethnography of women undergoing amniocentesis at three different 
centres in New York in the 1990s. Her ethnography explored what was 
then a novel genetic technology and involved consideration of the 
technological transformation of pregnancy, reproductive and disability 
rights and scientific literacy in North American culture at that time (Rapp 
2000). Mike Lynch’s and colleagues’ ethnographic work on the history and 
developments of forensic genetics reveals society’s investment in a 
deterministic interpretation of this aspect of genetics, despite its 
contingent foundations (Lynch et al 2010). All these researchers provide 
revealing experiences achieved through encountering and interviewing 
the different actors involved and making detailed observations of every-
day practices and interactions in laboratories, clinics, mortuaries and 
offices. These rich and varied data provide powerful arguments for 
ethnographic research in clinical or forensic genetics, not least due to their 
challenging accounts and interpretations of practice in genetics made 
possible only by their immersion in the respective fields of enquiry.  
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Ethnography requires the immersion of the ethnographer in a social group 
for a period of time to observe behaviour and communication and 
interview group members (Hammersely and Atkinson 1995), also known 
as conducting fieldwork. Scott and Marshall describe fieldwork as any 
study that involves conversation with people, including asking them 
questions, whilst in a similar, if anthropological, vein Rabinow suggests 
that everything constitutes fieldwork (Scott and Marshall 2009, Rabinow 
2007). However, despite these arguably flexible interpretations of 
ethnography, an ethnographic approach to studying actors involved in 
DTCGT would be very difficult to achieve. This is because “the field” in 
relation to DTCGT in the UK, in the sense that Goffman understands “the 
field”, is a difficult concept to define (Goffman 1989). In the context of 
DTCGT the field is an unknown territory; users engage with this 
technology using a computer to access the Internet at unknown and 
potentially multiple sites. Their communications with each other about 
testing are conducted in multiple sites, including the workplace, 
recreational group meetings and, more commonly, online communities, as 
user participants reported to me. For genetics clinicians, there are very 
few (if any) geographical locations where they meet to explore personal 
genomics as a group and consultations with users of DTCGT are few and 
far between. Clinicians explained that they usually heard about DTCGT 
through their own reading (also usually in an online environment) or at 
seminars or conferences when the experience was didactic and short-
lived, as opposed to one of interaction in the field. So, in seeking to 
investigate actors’ understandings and contributions to shaping the 
discourse about DTCGT technology and the controversies that surround it, 
the most obvious approach was to simply ask them. Accordingly, I 
decided to conduct interviews with purposively sampled participants from 
groups of users and genetics clinicians. I shall go on to justify my choice 
of interviews as the method of data collection for this study by considering 
other researchers’ related work in this area of STS and medical sociology. 
 
In her exploration of the sociology of genetic disease, Anne Kerr 
rationalises the importance of interviewing as a method for constructivist 
research into the sociology of science and technology. She observes that 
giving the public a voice equal to that of perceived experts in matters of 
science and genetics, illuminates their understanding more effectively 
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than conventional research methods eliciting public opinion (Kerr 2004). 
Conducted in collaboration with Sarah Cunningham-Burley and Amanda 
Amos, Kerr’s earlier research into public and expert views of the new 
genetics adopts both interviews and focus groups. The latter are used to 
generate breadth and depth in discussing hypothetical scenarios relevant 
to new genetic technologies that might not evolve in a one-to-one 
interview discussion (Kerr et al 1998). However, interviews are specifically 
adopted in the parallel study with experts in order that participants’ views 
may be individually expressed and related to what the individual feels is 
important (Kerr et al 1997). 
 
Hedgecoe’s research into pharmacogenomics draws on data from 
interviews with clinicians and researchers working on Alzheimer’s disease, 
breast cancer and drug regulation and development related to these 
diseases. He situates his methodological approach within the STS 
research tradition, using interviews to privilege stories from groups such 
as clinicians, whose views are often ignored despite their ultimately 
fundamental role in the uptake of pharmacogenomics technologies. With 
this approach he is able to explicate the way pharmacogenetics is being 
shaped by clinicians and researchers, rather than users simply accepting 
the hype raised by those who seek to reify its expectations (Hedgecoe 
2004). 
 
Sociological research into people’s understanding and experiences of 
genetic testing has relied on interviewing as a method for accessing the 
views of those potentially or actually affected by inherited diseases. 
Hallowell and colleagues have researched the effects of BRCA1/2 
mutations on women and men in several studies, all using interviews as 
the primary method of investigation. These interdisciplinary studies 
involving sociologists and healthcare professionals have been able to 
show how people and their relatives perceive risk and responsibility in 
relation to their potential risk of breast or prostate cancer (Hallowell 1999, 
Hallowell et al 2004), as well as facilitating participants’ reconciliation with 
their genetic identity through narrative reconstruction (Hallowell et al 
2006). A study into polycystic kidney disease, a less familiar but relatively 
common genetic condition, used interviews to establish the extent to 
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which this condition is “geneticized” by sufferers, their relatives and the 
clinicians who care for them (Cox and Starzomski 2004:137). 
 
Research into genetic susceptibility testing also uses interviews to 
advantage in eliciting people’s ideas about the difference in implications of 
susceptibility testing from predictive testing, or their experiences of the 
former. Interviews conducted with participants in the REVEAL study, 
following their intervention for the RCT, demonstrated that genotyping did 
not substantially alter people’s embodied identity or lifestyle. Interestingly, 
it also indicated that these people felt that family history was a much more 
effective indicator of disease susceptibility than genotyping (Lock et al 
2007, Chilibeck et al 2011). People interviewed after genotyping for 
susceptibility to deep vein thrombosis mostly thought that the test was 
useful for making alterations to drug regimens that might add to their risk 
of thrombosis. However, they did not change their lifestyle in any other 
way or view the tests as providing information that indicated counselling 
would be helpful (Saukko et al 2006).  
 
In a smaller study, Harvey explored how clinicians in three professional 
groups responded to emerging genomics technologies implicated in type 
2 diabetes mellitus. As in Hedgecoe’s work on pharmacogenomics, this 
interview study was able to show how practitioners contribute to the 
“mutual reshaping” of genomics technologies in the clinic (Hedgecoe 2008, 
Harvey 2011:309). In two similarly small studies, the first empirical work 
on DTCGT users and clinicians, experiences of early adopters of DTCGT 
in the US were investigated using interviews, as discussed in Chapter 
Two (McGowan et al 2010). The same researchers recently followed this 
with a similar study in which they interviewed clinicians about their use of 
genotyping in their clinical practice. These doctors have been re-
positioned as the recipients of many US commercial genomics companies’ 
marketing and sales strategies following the concerns expressed about 
marketing directly to consumers. Despite these concerns, the study 
demonstrates that the clinicians involved rely largely on the commercial 
companies they contract with for understanding and interpreting genomic 
data. They describe having little additional, objective knowledge or 
judgement in relation to the genomic data provided (McGowan et al 2014). 
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As this review of sociological and related research into genetic testing 
demonstrates, interviewing is a method of long and commendable 
standing in STS and medical sociology. Potter and Mulkay stress this 
point in justifying its importance as an approach to illuminating scientists’ 
interpretative practices (Potter and Mulkay 1985). In my study, interviews 
give both users and clinicians equal opportunity and space within which to 
construct their individual experiences of DTCGT. Consequently, it 
privileges the account of neither group in doing so, which is important for 
reasons of symmetry. Secondly, given the lack of a physical field in which 
to observe practices and communication, triangulation of interview data 
with participant observation data was neither feasible nor appropriate for 
this study. 
 
Interviews as accounts and conversations 
In seeking to construct knowledge about people’s influence on discourse 
about personal genomic technology in the UK, I am interested in their 
ideas, their beliefs, the meanings they attach to these, their 
understandings about the sources that informed them and how they talk 
about these. My intention is not to establish what they do in relation to the 
technology. This has been documented elsewhere in various media, such 
as academic papers including auto-ethnographies, YouTube videos, 
company websites and the like (Richards 2010, Harris et al 2013, Harris 
et al 2014). Moreover, numerous sociologists have warned against 
conflating interview talk with representations of participants’ actions, 
instead suggesting that interviews allow constructions and interpretations 
of their social action (Potter and Mulkay 1985, Atkinson and Coffey 2002, 
Jerolmack and Khan 2014). Thus, the talk in interviews can be seen to 
construct knowledge through the accounts and narratives offered. These 
narratives enable participants to employ an approach to discourse that 
accounts for their actions (Scott and Lyman 1968:46, Arribas-Ayllon et al 
2011a). Garfinkel similarly suggests that people account for behaviour in 
certain social situations with descriptions or explanations of particular 
attributes displayed in those situations (Garfinkel 1967). Atkinson and 
Delamont stress the importance of rigour in relation to the use of accounts 
or narratives in qualitative research; that is, to avoid privileging personal 
accounts over other forms of data and to recognise storied aspects of 
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qualitative data as constructions that are culturally shaped (Atkinson and 
Delamont 2006).  
 
Recognising participants’ accounts as culturally shaped performances that 
retrospectively construct experiences and interpretations indicates the 
need to analyse the data thematically taking into consideration how 
participants talk as well as what they talk about (Holstein and Gubrium 
2004). Data need to be carefully analysed for topics and in relation to the 
participants’ rhetorical approaches, such as justifying or excusing their 
decisions or actions (Scott and Lyman 1968, Atkinson and Coffey 2002). 
In common with researchers in STS and medical sociology, whose work 
has been discussed earlier, my approach to analysis in this study is not 
only to examine the data for themes in terms of content but also to 
consider participants’ discourse, including their adoption of rhetorical 
styles that denote the use of justifications or excuses. Establishing 
inconsistencies and variation in accounts is also important, as these 
contribute to participants’ flexible interpretative practices in their 
construction of meaning about emerging technology (Potter and Mulkay 
1985). 
 
Having situated the broad design for my study within the context of an 
examination of related STS and sociological research literature, in the 
second half of this chapter I shall provide detail about the recruitment of 
participants, how the interviews were conducted and how the data were 
analysed. 
 
Producing the study: notes on methods  
In the second part of this chapter, I shall discuss the steps taken to 
perform the study, including gaining approval for the study, participant 
recruitment and data collection and analysis. I will address each of these 
aspects in the chronological order that they were undertaken. I describe 
this aspect of the study as a ‘production’ because of the social influences 
that mean scientific knowledge and technologies are produced rather than 
revealed.  
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Approvals 
The aim of a Research Ethics Committee (REC) is “to protect the rights, 
safety, dignity and well-being” of all actual or potential research 
participants (HRA n.d: para 3). Research conducted by university staff 
and students requires approval from the academic school or faculty REC 
as well as, in the case of NHS patients or staff, approval for health and 
social care research from the relevant NHS Health Research Authority 
(HRA). Different requirements exist for approval depending on the status 
of study participants (that is the relative risk to them of the research 
depending on either the research intervention, their perceived vulnerability 
or both). Projects such as this one are arguably of negligible risk to 
participants and approval is required to interview the public only from the 
academic school REC. This was achieved without incident in January 
2012 and I was able to begin recruiting DTCGT users to the study. 
 
Involvement of NHS staff requires approval from an NHS Research and 
Development Committee (as opposed to a REC). The process for gaining 
approval to interview clinicians from the Research and Development 
Committee was considerably more tortuous than that for the school REC. 
But having successfully performed this rite of passage to gaining approval, 
I was able to recruit clinicians to the study from September 2012. 
Approvals documents can be found in the Appendices.7 
 
Recruiting participants 
This study involves purposive sampling, including snowball sampling, to 
access the relevant social groups involved in influencing SNP genotyping 
technology in the UK. The decision to involve DTCGT users and genetics 
clinicians as two groups with interests in this controversial technology is 
key to understanding how the technology is being shaped in the UK. Mel 
Bartley suggests that investigation of professional and patient interest 
groups in medical sociology is often a starting point for examining the 
social interests of actors in medical scientific knowledge and technology 
                                                
7 The IRAS form submitted for approval by the NHS Research and Development 
Committee is not included as the PDF file is too large to import. Their approval 
letter is in Appendix  3: Cardiff and Vale University Health Board, R & D 
Committee Governance Review Approval. 
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and that this needs to be undertaken with symmetry and impartiality as 
the guiding principles of investigation, in keeping with the Strong 
programme of investigating scientific knowledge in health care (Bartley 
1990). Thus, participants were recruited from two relevant social groups 
with interests in DTCGT technology but whose views are likely to 
represent opposing or conflicting interpretations and knowledge claims, 
that is, users of the technology and genetic clinicians who might be 
approached to counsel them. The juxtaposition of these two groups’ views 
contributes to a symmetrical approach in the study. These two groups are 
involved to examine and contrast the different experiences and 
interpretations of DTCGT by the participants in both groups, giving equal 
attention to influential professionals and the public regardless of their 
perceived social positions in a hierarchy of power (Atkinson and Delamont 
2006)8 . In addition, the principle of impartiality is adhered to in my 
examination of the social nature of these actors’ views and reported 
engagement with the technology and their knowledge about it. For this 
reason, participation was invited from members of the public who had 
bought DTCGT and genetics clinicians who had counselled people who 
had bought DTCGT and who were willing to talk about their views on the 
subject. The users represent a relevant social group directly associated 
with the technology but one that is relatively disparate and disorganised. 
In contrast the genetics clinicians are not directly involved with the 
technology but represent an organised relevant social group by virtue of 
their professional identity and work in clinical genetics. 17 users and 16 
clinicians were purposively sampled and invited for a single interview; I 
shall go on to explain how this came about. 
 
                                                
8That said, the role of power in each group’s influence on DTCGT may not be as 
clear-cut as it first seems. The strength of professional power in shaping medical 
technology is challenged by the experiential knowledge of an informed and vocal 
group of early adopters of DTCGT technology. This group’s origins lie in the 
production of DTCGT because SNP genotyping sold directly to the public requires 
users (consumers) to purchase and thus ‘produce’ it. This could be interpreted as 
investing them with a more cohesive and powerful impact on the technology. In 
contrast, the genetics clinicians’ professional power has less impact because it is 
simply associated with DTCGT by virtue of their professional knowledge of human 
genetic testing.  
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Users 
The Internet was the area used for recruitment, as it is the environment in 
which DTCGT is marketed and sold. It was therefore assumed that test 
users would be familiar with looking for information relating to personal 
genomics online and would thus find invitations to participate on the 
Internet. When I started the study, for this reason I felt confident that using 
the Internet was the best way to recruit users. Unlike genetics clinicians 
who can be found in geographical locations and whom I assumed would 
be easy to enrol, this group were an unknown entity and recruiting them 
was a venture into uncharted territory. I anticipated that recruitment of 
these virtual people, who Brown and Webster describe as without 
embodiment, would be challenging and would require several approaches, 
as Temple and Brown suggest (Brown and Webster 2004, Temple and 
Brown 2011). Accordingly, I approached researchers with experience in 
recruiting participants online and gained valuable tips, such as the use of 
‘Google Ads’ linked to relevant search engine terms. My plan was thus to 
post about the study on several relevant weblogs, place a Google Ad 
linked to DTCGT companies and personal genomics interest sites and 
undertake snowball sampling via early volunteers, as outlined by Atkinson 
and Flint (2001). 
 
The selection criteria for participation included being a UK resident and 
having purchased DTCGT that included health information. This was due 
to my interest in people’s engagement with the health-related aspects of 
the technology and the relationship to HCPs and healthcare provision in 
the UK. It was initially unclear who would comprise this group of 
participants and thus it was surprising that contrary to expectation, 
recruitment of users was almost effortless. The majority of participants 
were recruited from one of two online groups, or were known to other 
participants and were approached by them and asked to participate. The 
groups are 
 
1) the UK branch of the International Society of Genetic Genealogists 
(ISOGG) http://isogg.org/ 
 
2) the weblog genomesunzipped (GU) 
http://www.genomesunzipped.org/ 
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A member of the UK branch of ISOGG found out about the study from my 
university research webpage within hours of it being published online and 
published a link to it on their website. Two members contacted me to 
volunteer within hours of this happening and were followed by several 
more over ensuing weeks. GU published my guest post to describe the 
study and appeal for participants on their weblog and several more 
participants were recruited from this source. As a result, the participants 
fell into two groups being primarily interested in either genetic genealogy 
(ISOGG) or personal genomics (GU), though a few were interested in 
both. Two participants were recruited outside of both these groups, one 
having heard about my study at a research conference at which I 
presented. Despite their different routes into DTCGT, all these people had 
bought a DTCGT that included health information obtained from 23andMe. 
Details about their individual backgrounds, tests done and primary 
motivations for testing are in Table 3.1. A summary of the user 
participants’ information is in Table 3.2.   
 
In a British Social Attitudes Survey report on public opinion about genomic 
science, Sturgis et al (2004) identified the socio-demographics of the 
section of the UK public more likely to follow debates about genomics. 
Their analysis of this group reported that the average age was 55-59 
years, that women were more interested in genomics and that this group 
were interested in biology and educated to GCSE level or higher, were 
more likely to have a genetic problem in their family, were interested in 
politics, read a broadsheet newspaper, had access to the Internet and 
probably had higher knowledge of genetics (Sturgis et al 2004). There are 
some commonalities between these data and those recruited to the user 
group in this study. In the user participants’ group the average age is 52 
years. 12 of the 17 participants are female; this supports Richards’s 
assertion that women act as genetic housekeepers in families (Richards 
1996). Whilst one’s education was unknown, the majority were educated 
to degree level (13). One of those who was not had an expressed interest 
in biology, as did the person whose education level is unknown, and 6 
were educated to MSc or PhD level and were, or had been, working in 
genetics. Whilst I did not establish their political views or newspaper 
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preferences, I do know that they all had access to the Internet. 17 users 
were recruited and interviewed, the first 16 over a period of four months.  
 
At the time I was recruiting to the study I was relieved to have so many 
expressions of interest in the study in such a short time and simply 
accepted the first seventeen volunteers as participants. In hindsight, 
relying on the Internet and snowballing to enrol users largely limited 
recruitment to two sub-sets of people who are particularly interested in 
personal genomics, that is people who work in genetics and genetic 
genealogists. This will have missed people who are more concerned with 
personalised medicine and health screening per se who would constitute 
a different relevant social group of actors with influence on DTCGT in the 
UK. As a result the structural characteristics of this relevant social group 
(individuals with knowledge of SNP genotyping) provide them with a more 
informed position from which to engage with DTCGT and to exert a 
specific kind of influence on the technology as a result of their informed 
position. It makes them more likely to be willing to share their experiences 
and enthuse others. Their enthusiasm for personal genomics and their 
informed starting point is likely to give a particular view of how DTCGT is 
being shaped that is less significant for the NHS. However at the time I 
recruited participants I anticipated that the experiences of any member of 
the UK public who bought DTCGT that included health information would 
constitute membership of this relevant social group of users of this 
technology. Whilst all the participants fulfil this criterion, in hindsight a 
different recruitment strategy might have resulted in a broader cross-
section of users whose views of the technology may have been different 
and thus led to different conclusions about their influence on it, and the 
potential impact on NHS services. 
 
However, it is worth noting that the users I recruited fitted the profile of 
early adopters that McGowan et al described in their study of early 
DTCGT users in the USA (McGowan et al 2010). 
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Table 3:1 User Participants' Information 
Participant 
identifier 
and 
pseudonym 
Age Recruited Ethnicity Closest 
blood 
relatives 
Education 
(highest 
award) 
Occupation Test(s) Cost Dates Motivation NHS 
Referral 
UP1 
Alan 
66 ISOGG White 
British 
(WB) 
Daughters BSc 
(Hons) 
Chemistry 
Retired 
Pharmaceutical 
Industry 
FT DNA 
 
23andMe 
 
 
$99 
2005 
 
2010 
Genealogy N 
UP2 
Ann 
53 ISOGG WB Sons Degree Editor, writer FT DNA 
 
23andMe 
 
 
$99 
? 
 
2010 
approx 
Genealogy N 
UP3 
Barbara 
61 ISOGG Ashkenazi 
Jewish 
WB 
Sons MA Local 
Councillor, 
retired social 
researcher 
FT DNA 
 
23andMe 
$299 2002 
 
2009 
Genealogy General 
Practitioner 
(GP) 
Oncology 
UP4 
Carol 
59 Friend of 
participant 
WB Son PhD Public Health 
Researcher 
23andMe $99 2011 Curiosity 
genetics 
N 
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UP5 
Christine 
45 Colleague 
of 
researcher 
Italian 
Australian 
Siblings PhD Public Health 
Lecturer 
23andMe $99 2012 Health N 
UP6 
David 
65 ISOGG WB Son FE 
Agricultural 
College 
Farmer Sorenson 
surname 
DNA, 
Y-DNA, 
FT DNA, 
Autosomal 
DNA 
 
23andMe 
unknown  
 
 
 
 
 
 
2010 
approx 
Genealogy N 
UP7 
Elizabeth 
66 Wife of 
participant 
WB Son Teaching 
Certificate 
Retired 
Primary School 
Teacher 
23andMe Free 
(offer) 
2011 Gift 
Genealogy 
N 
UP8 
Fiona 
33 GU WB Sisters BSc 
(Hons) 
MSc 
Scientist 
genetics 
23andMe $99 Jan 
2012 
Curiosity 
genetics 
N 
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UP9 
Geoffrey 
70 GU WB Son, 
daughter 
BA Retired 
publisher 
Oxford 
Ancestry 
FT DNA 
 
23andMe 
$99 + 
subs 
2001 
 
2002 
2008 
Genealogy N 
UP10 
Helen 
34 GU WB Parents Incomplete 
BSc 
Physics 
None, disability 23andMe unknown Oct 
2011 
Health N 
 
UP11 
Jane 
54 GU WB Sons Degree Finance 
Director 
23andMe unknown Jan 
2012 
Gift 
Curiosity 
Genetics 
N 
UP12 
Ian 
53 GU WB Sons Unknown Retired 23andMe unknown Jan 
2012 
Gift 
Curiosity 
Genetics 
N 
UP13 
Keith 
60 ISOGG Irish Brothers MSc Database 
consultant 
Sorenson 
Y DNA 
 
23andMe 
$99 + 
subs 
2010 
 
Sept 
2011 
Genealogy N 
UP14 
Kirsten 
48 GU WB Daughter, 
son 
PhD Statistician 
genetics 
23andMe $99 + 1 
year 
subs fee 
Summer 
2011 
Teaching 
resource 
N 
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UP15 
Laura 
43 Email from 
participant 
WB Brother PhD Computer 
biologist 
genetics 
23andMe unknown Summer 
2011 
Health N 
UP16 
Maria 
27 Email from 
participant 
WB Siblings BSc 
(Hons) 
PhD student 
genetics 
23andMe unknown Summer 
2011 
Curiosity 
genetics 
N 
UP17 
Nicola 
45 GU Irish Daughter 
Sisters 
PhD 
Molecular 
Biology 
Commercial 
biologist 
23andMe 
 
US private 
Exome 
sequence 
$99 
 
$900 
2011 
 
more 
recently 
Looking for 
neurological 
diagnosis 
N 
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Table 3:2 Summary of User Participants' Information 
Age Range: 27-70 years Mean: 52 (rounded) 
 
Median: 53.5 
Sex Women: 12 Men: 5 
Recruitment 
source 
ISOGG: 5 Genomes Unzipped: 7 
 Known to participants: 4 Known to researcher: 1 
Ethnicity 13 White British 
 2 Irish 
 1 Ashkenazi Jew British 
 1 Italian Australian 
 
Education  I unknown 
 2 further education level 
14 Degree level 
 3 Masters level 
 6 Doctoral level 
 
Occupation  5 genetics 
 2 public health (research 
and teaching, experience 
in genetics) 
10 various other 
occupations (non-
genetics/biological 
sciences) 
 
Test 17 x 23andMe (all) 
 5 x FTDNA 
 2 x Sorenson Y DNA 
 1 x Sorenson Surname 
DNA 
 1 x Autosomal DNA 
 1 x Oxford Ancestry 
 1 x whole exome 
sequence 
1 participant had 5 tests 
 
1 participant had 3 tests  
 
5 participants had 2 tests 
  
10 participants only 
tested with 23andMe 
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Referrals 6 told their GP  
(5 in a consultation for 
something else) 
 
1 referred to Oncology via 
GP 
11 did not discuss test 
results with any 
healthcare professional 
 
Clinicians 
Clinicians were recruited to the study using a number of strategies. The 
initial approach was by email to British Society of Genetic Medicine 
(BSGM) members from this project’s local NHS collaborator, a member of 
the BSGM Council. The BSGM is a professional society that represents 
healthcare professionals working in clinical genetics services in the NHS 
in the UK. Responses to the email were disappointing (n=2), so a 
combined approach to recruitment was used. This included leafleting 
delegates at a BSGM conference, snowball sampling by using study 
volunteers to suggest contacts in the field (Atkinson and Flint 2001) and 
contacting Regional Genetics Services in the UK to raise awareness of 
the study and ask for expressions of interest from the clinical genetics 
staff. Recruitment continued to be slow despite these additional 
approaches; my discussions with staff at Regional Clinical Genetics 
Services suggested that there was a paucity of experience of these 
consultations and that clinicians probably felt they were not eligible to 
volunteer. Consequently, the initial intention to recruit clinicians who had 
counselled users of DTCGT was widened to include any genetics clinician 
who had views about DTCGT and was willing to volunteer to discuss their 
views. These combined approaches resulted in 16 interviews being 
conducted over 11 months with genetics clinicians who had a variety of 
experience and professional backgrounds. See Table 3.3 for details about 
the clinician participants. 
 
Genetics clinicians are healthcare professionals who take referrals and 
see patients and families for genetic counselling and testing. There are 
three professional routes to this role.  
1. Medical doctors who wish to specialise in clinical genetics 
complete a postgraduate diploma for membership of one of the 
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medical Royal Colleges (either the Royal College of Physicians or 
the Royal College of Paediatrics and Child Health), after which 
they complete a 4-year specialist registrar training post in a 
regional genetics centre. 
2. Registered nurses or midwives who have post-registration clinical 
experience, have counselling experience and have successfully 
completed a course in genetics are eligible to apply for trainee 
genetic counsellor posts.  
3. Postgraduates with relevant degrees, such as genetics, biology, 
psychology or sociology, or allied health professional degrees 
including nursing and midwifery, may complete an MSc in Genetic 
Counselling and then apply for trainee genetic counsellor posts. 
(BSGM n.d.) 
 
Participants were from a range of the Regional Clinical Genetics Centres 
in the UK. Northern Ireland was not represented but all other countries 
were, with the majority of participants practising in centres across England. 
Collectively they represented a range of catchment areas including the 
South Coast, the Southeast, the Northeast, the Northwest and London. 
There were no volunteers from the Midlands. A summary of the clinicians 
and consultations for DTCGT can be found in Table 3.4. 
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Table 3:3 Clinician Participants' Information 
Participant 
identifier 
Profession Role Time in 
genetics at 
interview 
Education Consultations 
for DTCGT 
Tests 
consultands 
used 
CP1 Scientist Genetic 
Counsellor 
12 years PhD, 
MSc Genetic 
Counselling 
GP queries x 2 Unknown 
CP2 Doctor Consultant 
and 
Professor 
Clinical 
Genetics 
>13 years Medicine, 
Clinical 
genetics 
training, PhD 
GP queries 
 
Patient x 1 
Ancestry 
 
23andMe 
CP3 Scientist Genetic 
Counsellor 
3 years PhD, 
MSc Genetic 
Counselling 
Patient x 1 23andMe 
CP4 Doctor Consultant 
and 
Professor 
Clinical 
Genetics 
15 years Medicine, 
Clinical 
Genetics 
training, 
PhD 
Patient x 1 Sibling had 
personal 
genome test 
(not 23andMe, 
company 
unknown) 
CP5 Nurse Consultant 
Genetic 
25 years Nursing 
PhD 
Journalists for 
TV  
All 23andMe 
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Counsellor, 
Reader in 
Clinical 
Genetics 
x 3 
(not NHS 
consultations) 
CP6 Doctor Specialist 
Registrar in 
Clinical 
Genetics 
5 years (PT) Medicine, 
MSc and 
Clinical 
Genetics 
training in 
progress 
Patient x 1 Sibling had 
Personal 
Genome Test 
(LifeDNA, 
Italy) 
CP7 Scientist Researcher, 
Genetic 
Counsellor 
>5 years PhD, 
MSc Genetic 
Counselling 
None  
CP8 Scientist Genetic 
Counsellor 
2 years PhD, 
MSc Genetic 
Counselling 
None  
CP9 Nurse Principal 
Genetic 
Counsellor 
18 years Nursing Patient x 2 1) HD test 
2) BRCA test 
(Single gene 
mutation tests 
from USA) 
CP10 Doctor Consultant >17 years Medicine, Unknown  
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and 
Professor 
Clinical 
Genetics 
Clinical 
Genetics 
training, 
DM 
CP11 Doctor Consultant 
and 
Professor 
Oncogenetics 
>17 years Medicine, 
Oncology 
training, 
PhD 
Patient x 2 1) Ancestry 
2) Relative’s 
tumour 
genome 
sequenced 
and analysed 
by another 
relative who 
warned of 
mutation and 
need for 
testing 
CP12 Nurse Genetics 
Counsellor 
12 years Nursing, 
MSc in 
progress 
None  
CP13 Doctor Consultant 
Clinical 
Genetics 
>11 years Medicine, 
Clinical 
Genetics 
training 
None  
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CP14 Doctor Specialist 
Registrar in 
Clinical 
Genetics 
1 year Medicine, 
Clinical 
Genetics 
training in 
progress 
None  
CP15 Doctor Specialist 
Registrar in 
Clinical 
Genetics 
3 years Medicine, 
Clinical 
Genetics 
training in 
progress, 
PhD 
None  
CP16 Nurse Principal 
Genetic 
Counsellor 
>20 years Nursing, 
Midwifery 
None  
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Table 3:4 Summary of Clinician Participants' Information 
Profession Consultations 
for DTCGT 
Types of DTCGT 
16 Clinicians 
Interviewed 
12 Consultations 
by 8 Clinicians 
SNP Genotyping  
 
Other 
 
Doctors   = 8 
 
 
Nurses    = 4 
 
 
Scientists = 4 
Doctors     = 6 
(1x2, 4x1) 
 
Nurses      = 5 
(1x3, 1x2) 
 
Scientists  = 1 
(1x1) 
for common 
complex disease 
risk = 7 
(23andMe = 5) 
 
(1 consultation 
with sibling of 
testee) 
 
(3 consultations 
with journalists 
who tested with 
23andMe for 
media 
productions, not 
NHS) 
 
for ancestry = 1 
Single Gene 
Mutation = 2 
 
DIY tumour 
sequence = 1 
(consultation 
with relative of 
affected 
individual) 
 
Collecting data 
In justifying the theoretical framework for the study I referred to 
accounts and conversations in the context of constructing 
knowledge about the relevant social groups involved with DTCGT, 
their interpretative flexibility and the wider social context of this 
technology. This was achieved by talking with participants: I 
undertook one-off, face-to-face interviews with the participants in a 
venue and at a time of their choosing, in all but three cases. Two of 
the users and one clinician were interviewed on the telephone, as 
this proved much more convenient for both parties due to their 
distant locations and busy schedules. I had hoped to use video and 
voice calling software for interviewing via the Internet in these 
situations but, after an abortive attempt in the first of these 
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interviews, I abandoned this idea. The requirement for both parties 
to have sufficient, consistent bandwidth to support an uninterrupted 
conversation could not be guaranteed. As a result, the conversation 
was repeatedly disrupted by loss of sound or vision or both and this 
undermined the potential for establishing any rapport or useful 
exchange of ideas. I felt that what was lost in terms of visual cues 
was a trade-off worth making to have a fruitful conversation.  
 
This illustrates an example of what Silverman refers to as “trial and error”; 
it was entirely understandable to resort to telephone conversations with 
these three participants in the circumstances, but in hindsight the 
conversations we had were much less fruitful than the remainder that 
were conducted face to face (Silverman 2000:236). Without visual cues I 
found it difficult to build a rapport with the participant or to pick up on 
points to probe further and the conversations were thus more perfunctory. 
I found the lack of visual cues much more difficult than I anticipated and 
my concentration was noticeably affected by straining to hear people (I 
am slightly hard of hearing and I find the telephone the most difficult 
medium for conversation owing to the lack of opportunity for lip-reading). 
Following these experiences, which occurred early in the data collection 
period, I subsequently arranged to meet all the participants for interviews, 
despite their concerns about my having to travel. From these early 
experiences, I knew that the conversation would be much richer and more 
fruitful when conducted face to face. 
 
Ethical conduct 
I have already outlined how approvals for the study were gained, that is, 
the socially constructed regulatory process for sanctioning research in the 
UK and in the NHS in particular. However, the procedural activities that 
are required in order to fulfil the trust invested in researchers by RECs 
that Hedgecoe describes are distinct from conducting research in an 
ethical manner, particularly when interacting with participants (Hedgecoe 
2012). Whilst this is closely related to reflexivity, the situations I 
encountered that were related to ethical conduct provided important 
moments in my relationship with the participants. Consequently, they 
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influenced the resulting data and my analysis of it, albeit indirectly, and 
are thus worthy of inclusion in this discussion. 
 
Interviews started with completion of the participant’s consent form. This 
relied on them having previously read the study information sheet, which 
was included in the original study information on weblogs and in email 
invitations to participate. I also sent the information sheet and the consent 
form to all the participants as attachments to the emails arranging our 
meetings, with a reminder to read them before we met. I was surprised to 
find that many participants had not read these documents prior to meeting 
me. However, they were all happy to sign the consent form, although one 
or two people did take the opportunity to read the information sheet that I 
brought to the meeting before doing so.  
 
Signing the consent form provided an important opportunity for me and 
the participant to take part in an external activity together on a relatively 
neutral basis. It bridged the transition from meeting a stranger, with its 
attendant formality and social conventions, to the interview and its 
opportunities for disclosure of personal information. I came to appreciate 
this activity and the related conversation about it as opportunities to 
continue to develop a rapport and understanding between us before 
commencing the conversation about DTCGT. They also provided the 
opportunity to remind participants that the interview would be recorded for 
transcription but that they could ask to stop the interview at any time. 
More importantly, the transition hopefully helped participants to relax and 
thus feel more able to create their stories in their own manner (Charmaz 
2000). 
 
Confidentiality and anonymity are concepts that present challenges in 
qualitative research, as Walford and Saunders et al highlight, particularly 
when conducted within a specific interest group such as this study’s, 
where certain actors are well known in the social groups concerned 
(Walford 2005, Saunders et al 2014). Signing the consent form provided 
an opportunity to explore the potential for identification of participants by 
others reading the results of the research and what steps I would take to 
avoid this. I have given the users pseudonyms to protect their identity as 
far as possible, whilst simultaneously trying to maintain some individual 
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character through the threads of data, as Seidman suggests. Clinicians 
are identified only by profession to protect their identity, while maintaining 
the distinction between the two groups of actors in the data analysis 
(Seidman 2013).  
 
Interviews 
As I noted earlier, the purpose of the interviews conducted in this study 
was to encourage participants to explore their experiences and thoughts 
about DTCGT. To facilitate this, I intended to take a relatively unstructured 
approach to the interviews in order to provide a conversational exploration 
of individuals’ accounts and to probe certain points for further examination 
when indicated, as recommended by Kvale and Brinkman (2009). 
However, despite my wish to have as unstructured an approach to the 
interviews as possible, past experience of research interviews prompted 
me to develop an interview schedule as an aide-memoir of points to 
explore during the conversation, should these not have been covered 
spontaneously. This proved useful in more stilted interview exchanges 
(including those on the telephone), but the schedule figured less as my 
confidence interviewing increased. I opened and closed the interviews 
with broad questions to facilitate participants’ engagement with narrating 
their stories from their perspective. This was particularly useful at the end 
of the interview when asking the question “Is there anything you thought I 
would ask you about that we haven’t covered?” allowed participants to 
bring up points of importance to them which had not already been 
explored. In addition to seeking any final points that they deemed 
important in relation to the preceding conversation, it provided an 
opportunity to give participants the final word in their story, from the point 
of view of being able to choose both what, if anything, to add and how to 
close the interview. I also offered everyone the opportunity to follow up the 
interview with contributions on email if anything further occurred to them, 
but only one person did so, again someone I spoke to on the telephone. 
See Appendix  9: Interview Schedule for Users and Appendix 10: 
Interview Schedule for Clinicians.  
 
Interviews lasted between 45 minutes and an hour in every case and were 
digitally recorded. I made written notes during the interviews to record 
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points that I thought warranted more exploration later in the conversation 
and immediately afterwards to record my thoughts about the location, the 
process and my impressions of the interview. I transcribed the interviews 
myself as soon as possible afterwards, usually within twenty-four hours. 
This enabled me not only to recall the interview and its context clearly and 
to begin to familiarise myself with the data, but also to have a written text 
to study and prompt my memory later. The transcriptions were limited to 
the recorded speech, omitting pauses, hesitations or other minutiae, as a 
discourse analysis is not the principal focus of this project. 
 
In the following section I shall explore how I analysed the data, although, 
as Seidman suggests, separating data collection and data analysis into 
distinct activities is problematic, in that it is impossible not to think about 
the data as it is collected (Seidman 2013). 
 
Analysing the data 
Qualitative data analysis requires an organised approach to facilitate the 
sorting, managing and retrieval of relevant pieces of data as required. In 
line with many qualitative researchers’ suggestions I took an iterative 
approach to analysis in order to elicit the themes within the texts of the 
interview conversations (Coffey and Atkinson 1996, Creswell 2013). In the 
initial stages of the analysis there was scope for trial and error in the 
approach I took to this, and, as a result, I experienced both lows and 
highs during my engagement with the data, which I will recount in my 
exploration of how the data were analysed. 
 
During data collection, I undertook training in the use of computer assisted 
qualitative data analysis software (CAQDAS), specifically NVivo 10, as 
this software and the training to use it were available at the university at 
the time. Prior to conducting this project I have had some experience of 
analysing qualitative data on a few occasions, but the data sets were 
significantly smaller, so I had not used CAQDAS. Also I realised that there 
would have been significant developments in the software and I thought it 
would be beneficial to understand NVivo’s functionality and be able to use 
it at least to manage the data, if not more extensively.  
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After the training sessions I decided to abandon my ideas to use 
CAQDAS. Following the experiential learning in the sessions (participants 
took their own data to sessions to use for training), it was clear to me that 
NVivo would only add more steps to the process and probably take longer. 
I also found it distracted me from the data per se and focused my 
attention on the software programme instead. To put it another way, I felt 
that NVivo would come between the data and me, thus bringing a 
metaphorical cuckoo into the nest of the project. Having made this 
decision, I find Seidel’s references to the dark side of CAQDAS, what he 
refers to as “analytic madness”, resonant with my impressions of it, 
despite his having written about it over two decades earlier (Seidel 
1991:107). This confirmed my decision and consequently I analysed the 
data ‘by hand’. 
 
I transformed the interview conversations into texts by transcribing them, 
thus immediately giving me some familiarity with the content and food for 
thought. As transcripts were completed I read through them and 
considered the ideas that seemed to be emerging. With data from the two 
groups collected separately, I was able to learn from my initial approach to 
the first group’s data and try a slightly different approach with the second.  
 
From the interviews with users I generated paper copies of the transcripts. 
I used these to read, re-read, underline and make notes in the margins 
about emergent or in vivo codes, that is, those arising from the 
participants’ discourse (Strauss 1987, Ryan and Bernard 2000, Creswell 
2013). In addition, I made notes or memos about patterns and exceptions 
that appeared in the data and the ideas that occurred to me whilst reading 
the transcripts, and used the reflections I recorded about the interviews to 
inform my thinking with the data (Coffey and Atkinson 1996). Having 
completed this initial phase of organising and managing the data, I read it 
again alongside the literature for an inductive approach. With this iterative 
approach to reading, coding, memoing and referring to literature, the 
chaotic nature of qualitative data analysis was to the fore (Glaser 1999) 
and I identified with Adele Clarke’s reference to “the sea of discourses 
with which we are awash” (Clarke 2003: 559). However, this period of 
thinking with the data led to the development of early categories and 
classifications that I recorded next to examples in the data. At this point I 
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moved from paper to screen, the former becoming too unwieldy. 
Thereafter I relied on electronic versions of both groups’ sets of data, as 
keeping track of examples of the emerging classifications in the data and 
the codes, categories and themes was easier. 
 
Once I had undertaken these early steps in the analytic process I 
commenced writing up my findings, still working with separate data sets 
from the users and the clinicians, connecting the emerging themes with 
the literature in a more direct way. This aspect of the analysis was a 
revelation to me, in that it was while writing that the true analysis began 
and themes began to emerge from the mire that Wolcott refers to 
(Charmaz 2000, Wolcott 2001). From the perspective of these themes I 
went back to the data and using writing to explore my thoughts as Latimer 
describes, I was able to interact with the data, the literature and my 
constructions from the data, and I found this process surprisingly 
enjoyable and liberating. In addition to writing about the data, I have 
presented it several times to different groups and audiences, which has 
similarly informed my thinking with and development of the data analysis. 
From this iterative process I have developed the analysis of the three 
overarching themes presented in the chapters that follow (Coffey and 
Atkinson 1996, Latimer 2007).  
 
In the excerpts shown to represent my analysis I have used symbols, as 
indicated in Table 4.5, based on conventions described by Corden and 
Sainsbury (2006) and Roberts and Sarangi (2005). I have adopted 
transcription conventions where participants’ short phrases are 
represented within my text in quotation marks, but longer excerpts of data 
are presented in indented plain text. Verbal hesitations not relevant to the 
data have been omitted by a “light tidying up” to aid the flow of the text in 
common with Corden and Sainsbury’s findings in their research into the 
use of verbatim quotes (2006:18). 
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Table 3:5 Symbols used in data transcription 
Symbol Meaning 
 
… 
Ellipsis: represents analyst’s 
edit of the data 
 
[ ] 
Square brackets: represent 
analyst’s comment or 
modification of the excerpt 
(( )) Non-verbal communication 
 
Conclusion 
In outlining the conduct of this project I have described how I have 
undertaken it, the research traditions that informed the theoretical and 
methodological basis for the design and the realities of conducting this 
research as it has progressed. The few low points included the challenges 
of obtaining the required assurances from university administration in 
order to apply for NHS R&D approval, recruiting clinicians and feeling 
overwhelmed by data, all of which I share in common with many, if not 
most, researchers. These aspects were more than compensated for by 
experiences of recruiting users, developing a conversational interview 
approach and learning the value of writing in data analysis. Information 
technology challenges confirmed that talking face-to-face is the most 
rewarding mode of communication, but that handling data is better 
achieved electronically. 
 
Having described my approach to the study and the issues I encountered 
during the process, I shall go on to provide a representation of the themes 
that emerged from the data in the three chapters that follow. In them I will 
show how users of DTCGT and genetic clinicians in the UK socialise and 
personalise DNA and test the NHS as a consequence. 
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Chapter 4 : Socialising DNA 
As Novas and Rose have suggested, those who undergo genetic testing are 
not solitary individuals but are members of networks that pre-date their 
engagement with genetic testing (Novas and Rose 2000). This chapter 
explores the importance of social networks to members of both relevant social 
groups involved in this study, and their role in developing expectations and 
ideals in relation to genetic testing. 
 
The chapter has two main sections: the first presents my analysis of how the 
users socialise DNA and how their initial awareness of DNA leads them to 
engage in networks of actors with similar interests, which develops and shapes 
their expectations of DTCGT. In the second section, my symmetrical analysis 
of the clinicians’ socialisation of DNA shows how professional identity and 
networks in clinical genetics result in boundary work in respect of DTCGT. The 
moral work of the clinic and boundary work in relation to the scientific validity of 
SNP genotyping are used to frame clinicians’ understandings of DTCGT from 
their clinical genetics perspective and, I suggest, contrasts with and parallels 
users’ views where relevant. 
 
Arguably social practices around any shared interest or belief are opportunities 
to share individual understandings and experiences with others. Thus a 
distinction between personal or individual considerations about an artefact and 
the act of sharing these with others in a relevant social group could be viewed 
as moot. However, I would argue that there is a valid distinction between 
Socialising DNA and Personalising DNA to be illustrated by the data in this 
study. This chapter will show the importance of social networks in building 
participants’ technological frame of DTCGT and providing channels for them 
share their experiences. Actors’ ideas and beliefs about DTCGT are developed 
and shaped and made visible to others by interactions in their networks. The 
nature of what is shared with others in socialising DNA is qualitatively different 
from individuals’ personal reflections on DNA. Whilst elements of personal 
reflections coincide with what is shared socially, personalising DNA represents 
an internal re-imagining of identity incorporating newly found genetic 
information (whether that is the individual’s or in the case of genetics clinicians 
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in respect of aligning new understandings of DTCGT with their identities as 
genetic counsellors). This personal imagining will not necessarily be shared, 
and if it is may not be represented in quite the same manner as Chapter Five 
will demonstrate. Approaching this study’s data from the separate perspectives 
of socialising DNA and personalising DNA also provides one opportunity to 
illustrate participants’ use of interpretative flexibility around DTCGT. 
 
I start this chapter by analysing how participants’ networks and expectations of 
DTCGT demonstrate socialising DNA. I will show how important the networks 
that facilitate this process are in shaping expectations and supporting the on-
going development of this group’s identity practices after testing. The 
experiences of the two user participants who are deviant cases in this data will 
be incorporated in my discussion as a way of illustrating this theme (and that 
which follows), due to the sharp contrasts between them and the remaining 
user participants. 
 
Networks, expectations and responsibility 
For almost all the user participants a network was instrumental in introducing 
them to the possibility of DTCGT and engaging them in considering buying a 
test. Gibbon and Novas refer to sociality as identity practices and situate this in 
relation to Paul Rabinow’s term “biosociality”, which he coined in the 1990s 
(Rabinow 1996, Gibbon and Novas 2008). Rabinow used the subsequently 
popular term to suggest that the human genome project would provide a 
network of known genetic anomalies that would produce social groups with 
common (genetic) identities. Group members, with their common genetic 
identities and associated medical care and support, will also have commonly-
held narratives and traditions as a result of their social processes of sharing, 
providing support and achieving a sense of empowerment and belonging 
within their group. The genetic aspect of their identity provides a vehicle for 
them to collectively “experience, share, intervene and understand” their 
genetic identity (Rabinow 1996:102). The possibilities for the development of 
communities such as those Rabinow envisages is greatly enhanced by 
developments in information technology. These developments facilitate 
communication and thus social processes among individuals who are 
geographically scattered. 
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Whilst the users in this study are not known to have genetic illnesses in the 
clinical sense, by engaging with DTCGT they reify their genetic identity. This 
gives them a common, biological focus around which to engage in social 
processes with others who share the same experience. They do this by 
socialising with others who are similarly interested and identified as such, both 
before and after testing, face to face in occupational or recreational groups and 
virtually through the Internet. The latter can be aligned to the “new collective 
formations” Rabinow and Rose envisaged (2006:204).  
 
Critics of Rabinow’s concept of biosociality suggest that this is not a novel idea 
but rather a novel focus for more conventional (pre HGP) forms of sociality 
(Kerr 2004, Plows and Boddington 2006, Raman and Tutton 2010). There is 
some room for acknowledging this argument here in that the group of users 
recruited to this study appear to engage in sociality prior to buying DTCGT. 
This is through their membership of groups that introduce them to DTCGT and 
enable sharing of their common experiences and values in relation to it as I will 
go on to show in the data in this chapter. Their social practices could be 
described as simply social rather than biological. However the reification of 
their genetic identity and their engagement in social practices around this 
experience relates to a novel genetic technology, and although it precedes 
testing rather than resulting from it, it is arguably biosociality in the sense that 
Rabinow suggested.  
 
By virtue of buying DTCGT that includes health information, users in this study 
are members of a relevant social group that will contribute to shaping DTCGT 
in the wider context of the NHS. As previously acknowledged in Chapter Three, 
by virtue of the approach to recruitment to this study the particular structural 
characteristics of this group is important as it explains their ability to engage in 
social practices around DTCGT using various means of communication (owing 
to their economic and educational status) and their knowledge of genomics. 
However, there is a clear heterogeneity within this group; sub-groups including 
the genetic genealogists and those who work in genetics are likely to have 
different views about DTCGT that they circulate in their social networks which 
will thus have different effects on the potential for stabilisation of the 
technology (Klein and Kleinman 2002). 
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The clinicians’ networks are also fundamental in shaping their beliefs and 
expectations in relation to DNA and DTCGT in the context of the NHS. Though 
more implicit than explicit in the data in comparison to the users, practising 
genetic counselling provides these clinicians with membership of professional 
networks that influence their beliefs and ideals about DNA and how its 
characteristics should be revealed to patients. Genetic counselling is delivered 
in the UK by multidisciplinary teams consisting of doctors, suitably qualified or 
experienced nurses, midwives or allied health professionals and scientists 
(Skirton et al 2013). The clinicians in this study are doctors, nurses and 
scientists and are members of the NHS clinical genetic counselling network as 
well as of their individual professional networks. 
 
For the clinicians in this study, socialising DNA is about promoting genetic 
counselling as the responsible way to help people decide whether or not to 
elicit genetic information and handle the consequences of that decision. This is 
shown in the data by participants’ references to the importance of the moral 
work of genetic counselling. Boundary work is a key feature of this socialising 
theme in the data; this is expressed in relation to the work of the clinic by all 
three professions interviewed, but only by doctors and scientists in relation to 
the science of genomics. At first glance it might appear that because all the 
clinicians work as genetic counsellors, any consideration of their different 
professional backgrounds would not be pertinent to analysing the data 
generated. However, whilst the numbers of participants in each group is very 
small and the findings cannot be generalisable, there did appear to be 
professional differences in how clinicians focus on their beliefs about DNA and 
DTCGT. Thus, as with the users, it appears that different sub-groups within the 
relevant social group of genetics clinicians share slightly different 
understandings and may thus have slightly different effects on shaping the 
technology.  
 
The groups involved in this study socialise DNA in the sense of being 
members of groups or networks interested in genetics and with common 
identities and cultures due to their interests and/or occupations. Bijker’s 
introduction of the concept of a “technological frame” in relation to how social 
groups shape a technology refers to the communication about an artefact that 
is part of the socialisation around a new technology within its newly 
established relevant social groups (Bijker 2010:69). As users and clinicians 
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socialise DNA, each group constructs a technological frame in relation to 
DTCGT. Within the group of users and clinicians there are sub-groups with 
slightly different characteristics that influence their technological frames of 
DTCGT, but a common feature is their engagement or rejection of it through 
their sociality in groups. Starting with the users, I will explain how that 
socialising and the moral values held as a result are evident in the data. 
 
Users’ networks and new genetic identities 
Brown and Michael suggest the association between uncertainty and people’s 
proximity to technology shows a direct but inverse relationship; being ‘further’ 
from it decreases uncertainty about it (Brown and Michael 2003), also neatly 
described as “distance lending enchantment” (Collins and Evans 2002: 247). 
Potential users are less likely to have uncertainties about the future promise of 
new technology that might prevent them from engaging with it than the experts 
directly involved in its development. Brown and Michael indicate the 
importance of networks and activities in driving the expectations about new 
technology, which could also be equated with relevant social groups 
developing their technological frames around an artefact. This is key in 
considering how this study’s group of users became involved with DTCGT.  
 
For almost half the users the network that introduced them to DTCGT was 
ISOGG, a group to which many genetic genealogists belong and through 
which they share information about developments in their field, including the 
emergence of new technologies such as DNA testing for genealogical 
purposes. Ann is a key actor in the English group of ISOGG (a group 
administrator). A married woman in her 50s, she is very interested in and 
knowledgeable about genetic genealogy; she has published books on genetic 
genealogy and describes herself as a DNA enthusiast. Ann presented the 
initial entry point for herself and others she knows as being linked to their 
gradual movement from records-based genealogy to genetic genealogy and 
then on to package tests, which include both ancestry and health risk testing 
such as that offered by 23andMe. 
 
A lot of genealogists have taken part in the health tests 
because we’ve been using the DNA tests for our genealogy 
research so it’s a natural progression really, just out of 
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curiosity to see how it all works … I got involved with ISOGG 
because they have a mailing list where group administrators, 
all volunteers, can get together and talk and share 
experiences … I was just interested to see how the health 
aspects worked as well and having seen other people taking 
the test I knew how it all worked. (Ann UP2). 
 
The sociality of the network is important for her and others interviewed, not just 
for learning about new technological artefacts and how they “work”, but also for 
sharing experiences that develop their technological frame in respect of 
DTCGT that includes health information, and shape expectations of it while 
getting support from others in their trusted community. Ann describes “a lot of 
genealogists” testing and links this to her own decision being a “natural 
progression”. This implies that she views herself as part of this group, from 
whom she has learnt a lot and with whom she identifies herself. This is a 
demonstration of her membership of a relevant social group that is shaping 
DTCGT.  
 
The genetic genealogists in this study are all members of one or more 
genealogy organisations. With this shared interest, genealogists’ networks 
have spread the word about technological developments in genetic genealogy, 
engendering the expectation of increased personal information for genealogy 
and health purposes, widening their technological frame of DTCGT and 
influencing each others’ thinking and actions through this social network. 
Through this social network, individuals have encouraged and supported each 
other in venturing into DTCGT. Barbara, a woman in her 60s, has an 18-year 
long interest in genealogy owing to her family’s Jewish ethnicity and medical 
history. She describes how support from distant relatives found with genetic 
genealogy introduced her to 23andMe. 
 
23andMe came into view and they were advertising 
themselves in terms of health testing and I thought well this 
might be interesting. And I was put in touch with them 
because I’d already developed close bonds on the family 
lines with two people in particular, both based in America 
who both tested with FTDNA [Family Tree DNA – ancestry 
  99 
genomics company] … and they got to hear about all these 
things. (Barbara UP3). 
 
Barbara refers to developing “close bonds” with people who are already part of 
the network of adopters of SNP genotyping. These people had had experience 
of both genetic genealogy testing (with FTDNA) and had made Barbara aware 
of other possibilities, including 23andMe, which provided the additional 
information about disease risk. This was an important aspect of Barbara’s 
expectations of personal genomics owing to her family’s medical history. 
Through the sharing of interests and experiences, she gained information that 
shaped her understanding of testing and helped her decide to test with 
23andMe.  
 
Four of the users are men in their 60s, or older, whose primary interest is in 
genealogy; Alan, David, Geoffrey and Keith are all involved with online 
genealogy groups to varying degrees. They have all been aware of genetic 
genealogy for several years, having bought tests from ancestry testing 
companies in the very early stages of genetic genealogy. This demonstrates 
the importance of socialising in terms of their involvement in genealogy; others 
in their networks are involved and share the information that has led them to 
test with 23andMe. Geoffrey has had experience of genetic genealogy for over 
a decade.  
 
I’ve been interested in them [tests] more from the genetic 
genealogy side of things for a long time … when Oxford 
Ancestry were first doing it … it was a mitochondrial DNA test, 
quite elementary … and I suppose I was on email lists and 
things. FTDNA cropped up, about 10 years ago. They do 
mailing to the genetic genealogy-type people and so I got on 
from there. (Geoffrey UP9) 
 
As with most other users, Geoffrey is “interested” in testing because of his 
genealogy hobby. He is technically knowledgeable about DNA testing and has 
gained information from genealogy groups that has developed and shaped his 
interest and actions in genetic testing. He expected to enhance his personal 
knowledge, primarily in relation to finding relatives as a result of testing with 
23andMe; the health information was of secondary importance to him. For 
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genetic genealogists socialising DNA facilitates access to information about 
relatives and ancestral origins. Sharing information about genealogy is 
fundamental to its success, which is measured by increasing knowledge of 
relatives and their origins. Thus this subgroup of users circulate knowledge 
and experiences of DTCGT avidly in order to increase their ancestry data and 
thus influence uptake (and development) of DTCGT by others. 
 
The majority of the remaining participants are members of occupational groups 
involved in genetics and genomics, are related to members of these groups 
who could be said to have recruited their relatives to the group, or follow 
genomics developments online, including on the genomesunzipped website. 
Five users are scientists who are regularly involved in discussions about SNP 
genotyping at work in relation to laboratory research, statistics, ethical issues 
and personal views about testing. Fiona, Kirsten, Laura and Maria are all 
involved in genomics research, working in teams of scientists and 
bioinformaticians and they all referred to testing in the context of their 
workplace or discussions with their colleagues. Most of them contrasted their 
respective decisions about whether to test or not with what colleagues were 
saying and, in Laura’s case, referred to testing that was being offered to 
workers in her institution to compare with her DTCGT. 
 
Actually we’ve had an offer to have some genetic testing 
done here on site as well. They just started offering … a 
limited amount of SNPs that they’re checking and so I’ve put 
in for that. (Laura UP15) 
 
Helen’s and Nicola’s recruitment to networks is also evident, although their 
reasons for testing were different from others, both having chronic long-term 
conditions that they had failed to achieve diagnosis of by conventional 
methods in the NHS. Nicola is a commercial biologist who works in genomics 
and who described having contacts in the industry with whom she discussed 
genomics and who helped her think about testing and helped in her search for 
access to testing. She is thus a member of the sub-group of users interested in 
DTCGT by virtue of their work in genetics although she is also searching for 
personal health information. Helen’s networks are less immediately obvious 
than other participants’. Helen has suffered from a chronic condition since she 
was in her teens. Now in her thirties, this illness disrupted her undergraduate 
  101 
studies, leaving her unable to complete her degree or work since she was in 
her early twenties. She is socially isolated due to her incapacity and relies on 
the Internet for information about science and technology developments that 
might help her establish what is wrong with her and what interventions could 
be effective. She described having been interested in genetics for some time, 
attributing this to her mother’s work in genetics (her mother having had a 
career working in genetics), and told me how she subscribed to 
genomesunzipped. She is knowledgeable about genomics and SNP testing 
and described how she spends time researching genetics and biochemistry on 
the Internet whenever she is able. Her expectation is to find answers to her 
problems through genomics as more knowledge is developed about the 
influence of genetics on chronic problems like hers. In the meantime she 
decided to buy a test from 23andMe. 
 
I’ve been interested in genetics for ages anyway … I found 
out about it [23andMe], I came across the genomesunzipped 
blog – I subscribe to that – and they kept saying about the 
23andMe things and I thought I’d give it a go. (Helen UP10) 
 
Again, Helen’s interest is explicit and was frequently referred to in the interview. 
As with others, Helen’s initial interest in genetics prompted her search for and 
engagement with genomics networks. She demonstrates this by describing her 
subscription to genomesunzipped, which exemplifies her alignment with a 
genomics network. She shows how this network introduced her to 23andMe; 
her phrase “they kept saying about the 23andMe things” demonstrates how 
she is drawn into the social world of SNP genotyping. The Internet gives Helen 
access to communities such as followers of genomesunzipped and 23andMe, 
which she has joined despite her physical isolation. She is thus able to 
participate in socialising DNA and shaping DTCGT by virtue of her 
contributions to her online communities as Dimond et al suggest (2015). 
 
Whilst these two women’s principal motivation for engaging with personal 
genomics is centred on their ill health, their investment of hope in personal 
genomics has been informed by occupational or self-directed learning and on-
going engagement with networks in the form of online genomics interest 
groups, both having been recruited to the study from genomesunzipped. 
 
  102 
Two participants who were not recruited from genomesunzipped were 
academics in public health who were friends; Carol was encouraged to have a 
test by a biologist she knew well through work and she then persuaded her 
friend Christine to have one. Christine had wondered about taking a test for a 
while; hearing about Carol’s interest and experience of testing helped her to 
research the products and decide to buy a test. Christine was reassured by the 
information and perceived support she got from Carol and 23andMe’s website. 
 
I did like 23andMe because they did have people 
commenting … I read reviews from other people and I 
contacted them to know how easy it was and what was 
involved … and I had [Carol] to talk to as well mind you, so I 
did actually have a little chain of people … and even having 
them on websites was good to know. (Christine UP5) 
 
Christine specifically pursued others who had tested for information on their 
experiences, thus demonstrating the influence of the social - her “little chain of 
people” - on her developing knowledge and ideas about testing. She 
contrasted her expectation of enhancing her understanding of her genetic 
identity with her initial uncertainty and need for reassurance, which she gained 
through interaction with Carol and other testers.  
 
The majority of the users’ engagement with personal genomics seems to be 
facilitated by their role as what Latour might describe as actors in networks 
that circulate expectations about personal genomic testing technology (Latour 
2005). These expectations are uttered and become embedded in the networks’ 
culture, albeit tentatively. Their roles in these networks point to the social 
nature of their learning and decision-making about testing and the importance 
of becoming part of a relevant social group in gaining access to the group’s 
technological frame of the artefact. However, their membership of the networks 
and the existence of most of the networks in question precede their 
engagement with personal genomics for their own individual purposes. 
Rabinow’s work on biosociality suggests that genetics will provide a network of 
identities that individuals will join, resulting in social groups based on genetic 
characteristics, the ‘bio’ becoming the ‘social’ (Rabinow 1996). However, I 
suggest that in this group of early adopters of DTCGT in the UK, it is their 
networks and the socialising therein that enable them to learn about personal 
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genomics and join other users in sharing meaning of DTCGT technology and 
influencing its development. It is this learning that facilitates their decision to 
buy a test and begins to establish part of their genetic identity – a kind of 
reverse biosociality wherein the social enables the foray into accessing genetic 
information.  
 
Participants’ expectations of SNP genotyping are primarily to increase their 
personal knowledge, satisfying their curiosity and interest through their 
personal genomics. For the genealogists, the allure of finding unknown 
relatives is an important aspect of their on-going identity practices, whilst for 
some of the scientists it appears to be elevating knowledge from the mundane 
to something more transcendent and relevant to them individually. 
 
My assertion is reinforced by Jane’s and Ian’s experiences of testing with 
23andMe, which were distinctly different from the other users’ expectations. 
Jane and Ian are a couple with a family member who was a researcher in 
genomics at the time of this study’s commencement. Jane and Ian both clearly 
state that the final decision to have the test was theirs, but the original 
suggestion and information about DTCGT came from their relative. It would 
appear that their relative has more in common with the social group of users 
involved in genetics who are early adopters of DTCGT whilst Jane and Ian are 
not part of this social group. Their alternative entry point to personal genomics 
resulted in this couple’s distinctly different experiences from the other 
participants in this study, representing the different impact DTCGT appears to 
have on different types of users, and the possible contribution of these 
different experiences to the lack of stabilisation of the technology. Ian 
described his amateur interest in science and genetics, which may explain why 
some of his views are more related to the other users’, but neither he nor Jane 
has had any direct involvement in genetics or related networks. 
 
The test was a Christmas present from [name of relative] … 
asked us whether we wanted to have it and we thought about 
it and discussed it and me and my husband said yes. (Jane 
UP11) 
 
This was a Christmas present from [name of relative] 
although obviously they asked us beforehand. We [Ian and 
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the relative who bought him the test] both have an interest in 
science, we have a similar interest and we talked about it 
quite a bit, so we were sort of informed, myself more than my 
wife before we did it and I also have an interest in it just as a 
pop science thing as well, so I have some background. (Ian 
UP12) 
 
Here Ian, like other users, employs the word “interest” several times in 
describing how he came to have a test. This repeated use of the word 
could be seen as a justification for his decision to agree to have the test 
so that his decision does not appear to be naïve and to show solidarity 
with the relative with whom he shares a common interest in science.  
 
Jane and Ian having decided to have their tests, Jane’s family became 
intrigued by testing and her sister and mother subsequently bought 
23andMe tests also. Whilst direct personal involvement in a relevant 
network is not a feature in this family’s case, their kinship and indirect 
involvement through Jane’s and Ian’s relative has informed their 
understanding of testing and drawn them into a wider network interested 
in personal genomics technology, so they have been influenced by their 
relationships and the family network. However, this couple decided to 
test on the basis of their relative’s suggestion and sharing knowledge of 
personal genomics with them, rather than on the basis of their own 
learning about personal genomics through genetic genealogy or their 
occupation, as with the majority of the other participants.  
 
Jane’s and Ian’s lack of direct involvement in a genomics network explains 
their lack of exposure to the socialisation and networks that facilitated other 
people’s entry into thinking about DTCGT and others’ subsequent interest and 
curiosity as they learnt more about testing. So while Jane and Ian were 
introduced to DTCGT and were interested in it as a result of their relative’s 
sharing information about experiences of it with them, they had no wider 
networks to reinforce or ‘socialise’ them in personal genomics other than the 
immediate kinship of their family unit. As a result, their expectations of testing 
seemed different from the other participants’, being less specific and arguably 
vicarious, having agreed to be supportive of a relative’s enthusiasm for testing. 
They both refer to discussing SNP genotyping with their relative before testing; 
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the details of this discussion were not elucidated but it appears that they were 
not clear about how testing would work, what sort of information they would be 
given, or when they would receive it. Consequently, when confronted with 
results they were not expecting, both Jane and her husband Ian found this 
difficult to deal with. Jane explained her concerns, which related to genealogy, 
very early in the interview. 
 
So, tell me about it then, what was it like, how did you feel 
about it at the time? (Teresa) 
 
Well, umm, I suppose I was nervous about it but [name of 
relative] was very reassuring and didn’t push us into it; it was 
our own decision and I thought that it was just going to be 
just one test and that would be it and one set of results. What 
I didn’t expect was, and I don’t even know if [name of 
relative] knew, was that it would be continuous. So I’m 
continually getting emails and they are continually looking at 
my DNA test … and there’ll be an email saying there are six 
new results. And so that was something I wasn’t expecting, 
so to tell you the truth, umm, I don’t look at them any more … 
The surprise came in the ethnicity when I got an email from a 
gentleman saying that he had the same maternal genes as 
me so he thought that we were probably related. And then I 
went on and you can like map your ethnic origins and it came 
up with quite a strong probability that one of my grandparents 
was Jewish. And there’s nothing known about that at all [in 
the family] and when my sister got hers done, hers said the 
same thing and my Mum’s said not at all and so there was a 
bit of confusion there. That was very confusing for me and I 
talked to [name of relative] about it … you know the whole 
thing really for a while affected my identity and made me very 
curious and I couldn’t get to the bottom of it. My father’s dead 
and he was brought up as a Methodist in … in [x]-shire 
[England] and it’s like an old family you know that you can 
trace back and I wondered whether it was on my Mum’s side 
because her mother was brought up in London and in the 
East End but no, there was nothing on her side so there’s 
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definitely something on my Dad’s side. So you know that 
wasn’t something that I expected at all and umm, would not, 
so the experience was more upsetting than I expected. (Jane 
UP11) 
 
Jane’s assertion that she was not expecting repeated emails with new 
information suggests that she may have anticipated more deterministic health 
information rather than the probabilistic, contingent data her results were 
updated with. She repeats the words “continuous” and “continually”, implying 
intrusion by the test information into her life as Bunnik et al (2011) suggested 
people might. This is compounded by her distress in relation to the unexpected 
and unsought information about her ethnicity, as shown in her references to 
the confusion and impact on her personal identity. Unlike Jane, Ian was very 
positive about finding out the ancestry aspects of his test results. However, like 
her, he was not anticipating the updates to the test results and expressed his 
consternation about this repeated return to a state of uncertainty on receipt of 
23andMe emails in dramatic terms. 
 
So, probably about a month or two later I got an email from 
23andMe and I foolishly thought that the test was the test 
and that’s it. I didn’t really, obviously you participate in this 
thing and your information is used but I didn’t know they’d 
come back to me and say “Good news we’ve found more 
diseases you’re going to die of” and it’s like “Oh shit what’s 
this?” And of course there’s change and every time an email 
comes in every month or so there are like new diseases or 
changes to your propensity for the diseases, some have 
gone up, some have gone down and that is quite shocking 
actually and of the whole thing that is the worst part of it. It 
makes you realise that there is so much being found out all 
the time that you realise that your first test, the whole thing is 
in its infancy really, it was that and also they didn’t do an 
Alzheimer’s test but now they can do an Alzheimer’s test and 
here’s the results so here you go again. If you choose to read 
them you have got lots of information coming at you if you 
choose it, which is really good in many respects but it means 
you go through this ordeal quite often. (Ian UP12) 
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Why was it shocking? (Teresa) 
 
I just foolishly didn’t think they’d send me more information, it 
was just stupid really. In the modern day if you participate in 
something you get more information and that’s good but it 
wasn’t made clear, or maybe I just didn’t read all the 
information, anyway. I don’t think my wife knew either. (Ian 
UP12) 
 
Unlike other users’ experiences, Jane and Ian had not personally been 
members of genomics networks of any kind prior to testing, nor had they 
researched SNP genotyping. Consequently they were not party to enactors’ 
expectations of the technology or socialised into networks that would have 
facilitated this. Brown and Michael refer to the relative certainty of end-users 
(or “selectors”) of new technologies in their reference to MacKenzie’s certainty 
trough (Brown and Michael 2003, MacKenzie 1990). It is possible that this 
couple were not in a position to be identified with those selectors as they had 
not been recruited as actors in the personal genomics networks early enough 
to develop their own expectations of DTCGT. Although they demonstrated 
understanding of the nature of the test, their reliance on their relative for that 
proxy engagement in personal genomics networks appears not to have 
provided the socialising and understanding that other users conveyed. They 
suggest that they found continuous risk information shocking rather than 
empowering, possibly because it generates more uncertainty about their health 
and risks of disease. This points to the different experiences different types of 
users appear to have of DTCGT, which in turn illustrates the potential for 
different technological frames and impacts on the technology. 
 
Kinship was important for users who had a family history of chronic diseases. 
For these users there were expectations related to finding out what information 
their SNP genotype might reveal about their family health history or their own 
health concerns. Their expectations of testing in the context of the family were 
about gaining information that might shed light on a known family history of 
illness and were informed by the stories and experiences of the family’s ill 
health that were shared among the family network, as Richards describes 
(Richards 1996). Here, the network and sociality are familial and focused on 
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shared DNA. In addition, all but one of the participants who expressed 
personal or family illness as a factor in their decision-making to buy a test were 
members of established networks in either genetic genealogy or their 
occupational groups, as previously discussed. The socialising aspect of these 
networks seemed to give them the confidence to pursue testing for common 
complex disease risk (as well as genealogy) to gain additional genetic 
information to add to their existing knowledge about themselves and their 
family’s illness.  
 
Christine, the lecturer in public health, had a family history of gastrointestinal 
tract malignancy, both her parents having recently been diagnosed; her hope 
for information about her family cancer markers was an expectation of DTCGT 
in the hope that she could avoid the fate of her parents.  
 
We talked about 23andMe and I told her [Carol] about my 
unusual circumstances with my parents. So my mother died 
of [upper gastrointestinal tract] cancer … which is one in a 
million. And unfortunately just recently my father’s been 
diagnosed with [different upper gastrointestinal tract] cancer. 
So two in the family and even if that was the pathology it’s 
rare. (Christine UP5) 
 
Christine’s discussions about testing with her friend Carol gave her an 
opportunity to explore her expectations of testing with a friend who was familiar 
with DTCGT. Here she is describing how her distressing experience of her 
parents’ illness contributed to her discussion with Carol about DTCGT. She is 
sharing her family cancer history that she thinks may have a genetic 
component and discussing with Carol whether DTCGT could shed any light on 
this. In their discussion they are socialising DNA through talking about family 
illness anticipating that DTCGT may give Christine some information about her 
risks should she decide to test. Her expectation of finding out about any 
genetic component to her family history is presented in terms of her using the 
information to try and avoid developing cancer herself in future. 
  
Laura, who works as a computer biologist in cancer genetics, had envisaged 
testing in relation to her own health issues and her expectations of obtaining 
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relevant information were brought into focus by her father’s ill health and her 
brother’s anxieties about the impact of their father’s illness. 
 
It’s interesting from the point of view of looking at what I have 
tendencies towards and my family as well. My Dad’s been 
pretty ill and my brother’s been quite worried about his health 
as a consequence of his [own] genetic makeup … we all 
realise it’s just a tiny snapshot of your health and the things 
that contribute, but it’s a start. (Laura UP15) 
 
Laura refers here to her interest in what she has “tendencies towards”, 
although she is aware that SNP genotyping is not deterministic of health 
outcomes. But she situates her genetic identity within her family, 
acknowledging her identity as part of that immediate network and its cohesive 
view of genotyping with her phrase “we all realise”. She and her family have 
been socialising DNA by discussing their health problems and the possible 
genetic aspects of these as indicated by her brother’s reported concern “as a 
consequence of his own genetic makeup”. They have done this in the context 
of DTCGT and what it might reveal, albeit “a tiny snapshot”, about their shared 
DNA.195 
 
Novas and Rose argue that individuals are located in matrices of networks, 
notably in relation to genetics, in a “network of relations” (Novas and Rose 
2000:490), a point that is supported here by these individuals talking about 
illness in the context of their family network. The family ‘condition’ and the role 
it plays in the family’s story appear to be contributing, in part, to their thinking 
and expectations of their DTCGT.  
 
It seems clear from this aspect of the data that the social aspect of knowing 
people who had tested, finding out about testing through others’ experience 
and sharing one’s own experience with a knowledgeable and sympathetic 
person are important factors in deciding to buy a DTCGT, whether the 
networks providing that support are occupational, recreational or family-based, 
or a combination of these. This is also a feature of the role of Bijker’s 
technological frame in shaping these actors’ actions and interactions. The 
networks seem to be established in people’s lives prior to their deciding to buy 
a test, rather than being something they become part of having done so. So 
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rather than exemplifying Rabinow’s biosociality, these users (apart from Jane 
and Ian) represent the social networks Brown and Michael suggest enable 
engagement with new technology by reducing members’ uncertainty (Rabinow 
1996, Brown and Michael 2003). 
 
Having explored how users socialise DNA and are influenced by doing so, I 
shall go on to contrast how the clinicians’ social world of clinical genetics and 
genetic counselling are instrumental in shaping their views of DTCGT. 
 
Socialising DNA in the wings of the clinic 
The focus on the clinic as the site for studying medicine and its relationship 
with patients has been crucial for demonstrating how medical dominance and 
power are exercised, although Paul Atkinson highlights the disproportionate 
emphasis of sociological analysis of health care on doctor-patient consultation 
(Atkinson 1995). However, it is important to note that much (if not most) 
medical work is conducted in arenas away from direct interaction with patients. 
Thus, the basis for the clinician participants’ socialising DNA, as demonstrated 
when talking to me about DTCGT, are the ideals and beliefs developed and 
shaped in forums external to the clinic, although ready for and informed by 
practice in it. The idiom ‘in the wings’ also suggests that clinicians are waiting 
for consultations about DTCGT, which, for the most part, have yet to 
materialise for the majority of practitioners I spoke to. A low referral rate to 
clinical genetics services following DTCGT is in common with early, if non-
generalisable, research findings (Giovanni et al 2010, Brett et al 2012). 
 
For the clinicians, professional status as a healthcare professional (of 
whatever kind) and practice in genetic counselling provide the social milieu 
and networks within which their values and beliefs about DNA are shaped, 
shared, reinforced and confirmed. Whether their expressed values in relation 
to DNA and DTCGT are simply informed by the literature or are based on 
wider understanding and experience, professional identity and authority as 
genetics clinicians provides its own social context for these participants’ beliefs 
and ideals about DNA. The status and professional power of this relevant 
social group could be influential in shaping DTCGT in very different way from 
the users, not least because of the influential role clinicians are perceived to 
play in the wider context of the NHS that this study is concerned with. 
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The clinicians referred to DTCGT from a genetic counselling perspective, 
comparing the two models of genetic testing in a moral context. The principles 
of genetic counselling to inform, facilitate autonomous decision-making by an 
individual and/or family members in a non-directive manner, gain consent and 
maintain confidentiality were aspects of testing referred to when considering 
their views on DTCGT. Information giving was the principle that featured most 
prominently in the interviews, as promulgated by the professional bodies that 
regulate clinical genetics in the UK (BSGM n.d.).  
 
In talking about genetic testing, the clinicians promoted the morality of genetic 
counselling as embodied by their professions, demonstrating boundary work in 
relation not only to the morally problematic nature of DTCGT but also to its 
perceived technological deficits that contribute to the on-going difficulties with 
its stabilisation in the clinical community. Not only is DTCGT criticised (and 
neither stabilised nor accepted) within clinical circles, but also boundaries in 
relation to clinical genetics were expressed by all the clinicians regarding what 
is appropriate for patients to discover (about their genetics) or not – that is, the 
moral dimension to boundary work. In addition, the doctors and scientists also 
engaged in boundary work regarding what is scientific or not. Both these 
aspects of boundary work illustrate this relevant social group’s capacity to 
shape DTCGT negatively and asymmetrically in relation to users more positive 
technological frame. 
 
Joanna Latimer has written about how the medical profession increasingly 
aligns itself with science or identifies its work as scientific, particularly in 
respect of diagnosis as performed in the clinic and how medicine provides an 
obligatory passage point for the legitimisation of biosciences (Latimer 2013). 
This is important in respect of the clinicians’ socialisation of DNA because it 
explains the position from which they feel able to make judgments about SNP 
genotyping and perform boundary work in respect of judging DTCGT to be 
scientifically flawed compared with clinical genetics. As Gieryn suggests, 
boundary work is a practice undertaken by professionals when trying to 
exclude rivals, protect professional autonomy and monopolise an aspect of 
practice (Gieryn 1983). It is also a means of constructing a social boundary 
around what members view as legitimate science (in this case clinical genetic 
testing) to distinguish it from non-science (SNP genotyping) with the authority 
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to do so facilitated by their professional influence. I also suggest it explains the 
clinicians’ focus on identifying the problematic nature of DTCGT and the basis 
for their shared social struggle9 with the discourse of commercial genomics. 
 
In this section I shall demonstrate how the clinicians demonstrate professional 
authority and engage in boundary work in order to socialise DNA within a 
moral framework and restrict genetic testing to their shared world of clinical 
genetics. I shall also explore how they use the arguments of flawed science 
and misleading marketing of DTCGT to present their social views of DNA as 
superior to that of the DTCGT model. Finally, I shall examine their concerns for 
the public, whose understanding of genetics many of the clinicians appeared to 
frame within a deficit model therein illustrating this relevant social group’s 
assumption of being influential in respect of dismissing DTCGT in the wider 
context of the NHS 10. 
 
The moral imperative in boundary work for clinical genetics  
The genetic counselling model’s influence in socialising the clinicians’ views 
about genetic testing is evident from all of the clinician participants’ references 
to the non-directive counselling model when expressing their thinking about 
DTCGT. Most focused specifically on the concepts of diagnostic questions and 
informed consent and their centrality to genetic counselling, although a few 
also referred to helping people deal with difficult test results. The lack of 
opportunity to make people aware of the implications of genetic information 
and facilitate non-directive decision making through genetic counselling was 
referred to by many of the clinicians as an aspect of DTCGT that is of concern 
to them because no face-to-face pre-test counselling occurs. This participant, 
a scientist with extensive genetic counselling experience, represents a concern 
about the lack of counselling with DTCGT expressed by the majority of the 
clinicians. 
 
I’m interested in what motivates people to go for the test. You 
know, why do people trundle up to genetics in the first place? 
                                                
9 The struggle is ‘shared’ and ‘social’ in the sense of being commonly experienced 
across the different professions who provide genetic counselling. 
10 A deficit model is one where it is assumed that the public have a knowledge deficit. 
In this case it is in relation to knowledge of genetics and genomics (Dickson 2005, 
Jordens et al 2009). 
  113 
People have genetic tests for many different reasons and I 
do wonder then [if] that will probably be reflected in why 
people have DTCGT … you need to have a conversation 
about what the test can and cannot do for you. You need to 
ask questions about the detection rate for particular 
conditions depending on the ethnicity and the type of defect, 
what is the rate in that population. The difficulty for the public 
is that it doesn’t give you a yes/no answer. And also making 
them aware that certain genetic tests can affect life insurance. 
You need to make them aware that they need to be mindful 
of that. What answers were they wanting to the questions 
they were asking? So it’s not the test that’s important it’s 
giving people the strategies to cope with uncertainty. The 
people who go for genealogy tests, what does that mean for 
them? What if someone who has a 50 percent Viking 
inheritance suddenly is a genotype that’s recognised to be 
associated with Sudden Adult Death. Who owns that 
information? Does it get fed back? It’s Pandora’s box. Part of 
me thinks it’s Pandora’s box open and the worms are 
crawling out thank you very much and you can’t put them 
back in. (Scientist CP1) 
 
This excerpt illustrates the moral aspects of the boundary work she is 
engaging in, with her association of genealogical information to potential 
pathology and her reference to Pandora’s box, an expression she was not 
alone in using. In referring to needing “to have a conversation”, she expresses 
concern that people may test without being adequately informed and be 
harmed by receiving upsetting information, by subsequent discrimination, or by 
the uncertainty testing is likely to provoke. 
 
The relevance of family in genetic counselling and information giving was 
presented as a specific aspect of the moral work of genetic counselling. 
Although one of the clinicians suggested that the lack of predictive value of the 
DTCGT negated the need for counselling about the potential impact on family 
members, this scientist represented more widely expressed concerns about 
individuals not realising the potential implications for relatives when thinking 
about genetic testing. 
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Our job is to raise the issues that people wouldn’t necessarily 
think of or if they did think about them, might not really 
address. So yeah, I think what we do say to people is “If you 
get a result you don’t want, then what will you think and how 
will you talk to your family about that and how will you think 
about your children who then become at 50 percent risk? Will 
it make a difference to your life and is that in a good way or 
not in a good way?” I think those are the things that you 
wouldn’t necessarily [think about] if you were just paying 99 
pounds on the Internet, you wouldn’t necessarily go through 
that thought process. (Scientist CP7) 
 
Participants highlighted the importance of counselling face-to-face to establish 
the consultand’s understanding and facilitate decision-making, as the next 
excerpt illustrates. Some suggested that counselling was not always 
necessary and that telephone conversations could be a substitute in some 
circumstances. But the importance of interaction between professional and 
consultand was demonstrated by most clinicians, referring to people’s need for 
information, time to think about the potential meaning of test results for 
themselves and their families and how counselling changes people’s views of 
genetic testing. Here clinicians are engaging in moral boundary work by 
contrasting the questionable relevance of tests and lack of counselling or 
informed consent afforded by an online commercial genomics company with 
professional genetic counselling. This nurse describes in some detail the 
importance of face-to-face interaction in her counselling and its centrality to the 
moral work of genetic counselling consultations, points which other participants 
also made. 
 
I think there is a role for telephone counselling but it doesn’t 
anywhere equate to face-to-face. You can’t read somebody’s 
body language or the tone of their voice if you’ve never met 
them before to be able to pick up any concerns that they’re 
not voicing but if you saw them face-to-face you would say, 
“You’re looking confused there, would you like me to…” So 
that’s really my main concern that they’re going to be either 
getting a result that makes them feel that they’re definitely 
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going to get a cancer and what do they do with that result? 
Or they’re not going to get a result, which is far more likely 
and they’re going to then not be any further reassured and 
still have this unrealistic perception of what their risk is. You 
know as part of our counselling even if we can’t offer a 
genetic test we talk about health promotion issues such as 
lifestyle, diet, what screening opportunities are available 
etcetera but someone going DTC is not going to get that 
healthcare promotion side of things … whereas, I would like 
to think that coming to see us they’ve always got a named 
person that they can contact that they have met that 
hopefully they feel comfortable with contacting … and in 
actual fact our pre-test counselling should go over “If you get 
this result it means this, if you get that result it means that. If 
you get that result I will then refer you so that you can be 
followed up by this clinician; if not then it means that, talking 
about cancer again, it does not mean you will not get a 
cancer but it means that you’re at population risk etcetera 
etcetera. (Nurse CP16) 
 
As I will go on to demonstrate in Chapter Six in the section on Responsibility, 
clinicians were not necessarily opposed to the public buying SNP genotyping 
tests directly. However, the wider context of DTCGT in relation to the NHS is 
critical here. Clinicians’ socialising DNA within the clinical genetics world was 
demonstrated through their moral boundary work to maintain their institution 
and authority by approaching personal genomics from their genetic counselling 
perspective, and preserve their roles in the collective medicine provision of the 
NHS. For many of the clinicians this view was reinforced by the questionable 
validity and utility of the data DTCGT provides in contrast to the marketing 
hype of the companies marketing testing. I will go on to examine these aspects 
of the data next.  
 
Flawed science and misleading marketing 
In the last two decades, advances in genomics have been foregrounded with 
hyped expectations that have so far not been realised, despite the vast 
amounts of data generated (Franke 2010, Groves and Tutton 2013). This hype, 
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whether about the scientific capabilities of genomics or about the potential and 
deterministic value of SNP genotyping as described by commercial marketing, 
was used by clinicians to contrast the problematic nature of genomic data 
compared with that generated in clinical genetics. A majority of the clinicians 
referred to the uncertain state of the science that SNP genotyping is based on, 
problematising it in relation to their knowledge of clinical genetic testing. 
Uncertainty about the meaning of genomic data was key to most expressed 
concerns about DTCGT specifically and genomics generally and was 
expressed by doctors and scientists, giving an insight into this groups’ 
technological frame of DTCGT. In an example of socialising DNA from the 
clinicians’ perspective, one doctor training to be a clinical geneticist contrasted 
what she referred to as the “wishy-washy” nature of DTCGT with the detailed 
research studies on sequencing specific cancer and cardiac disease genes, 
supporting the widely-expressed view that standard public health advice for 
healthier living is as useful as any information DTCGT may provide (Van 
Ommen and Cornell 2008, Henrikson et al 2009, Cherkas et al 2010, 
Dickenson 2013). 
 
A consultant specifically related the uncertainties of GWAS data to diagnosis 
and clinical intervention, representing some clinicians’ concerns about the 
science of SNP genotyping well. 
 
On the whole we haven’t seen this great flood of extra 
information yet that’s had this impact from GWAS. And the 
SNP typing, the DTC, they are just the baby versions of them. 
They’re just taking the output of them and sticking them on 
some kind of testing platform be it a chip or a nucleotide re-
sequencing platform and generating data that I’m not sure 
then translates into any useful clinical intervention. You know 
if we’re still struggling at the research discovery phase of 
these I think then taking this to tell you “Oh look we can tell 
you your future”, is a bit naïve. It seems to me as well that 
many of these GWAS SNPs, the relative risks they come out 
with is somewhere between 0.9 and 1.1, or a relative risk of 1 
point something and you know that’s no relative risk at all in 
real terms. That’s just teasing out round the edges … and my 
criticism of them from everything I’ve read is so what? I don’t 
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think much of them. So, it’s a bit harsh but you can say 
‘snake oil’. (Doctor CP13)  
 
Here too there is evidence of socialising DNA in the phrases “everything I’ve 
read” and this clinician’s use of “we” referring to his department’s experience of 
referrals for DTCGT interpretation. 
 
Two counsellors, both with a molecular genetics background, contrasted the 
approaches to SNP genotyping that DTCGT companies use with their 
expectations of testing for similar diseases and questioned its validity, 
particularly in relation to the populations the GWAS studies data used by the 
companies were based on. This scientist’s example of cardiac disease details 
the contrast and possible impact of a DTCGT test versus those her service 
would offer. 
 
They say they would test for a 25 base-pair deletion in 
NYBPC3 which is basically one of the four genes that we’ve 
found the majority of the mutations in. And actually that 25 
base-pair deletion is not one that I encounter on a regular 
basis with my patients. So that’s interesting. I could name 
two other mutations in NYBPC3 that I would put at the top of 
the list if I was doing targeted mutation analysis but yeah, if 
you’re only testing for one mutation in one gene, if you didn’t 
know that we have thirteen genes that we currently test for 
that condition and the mutation can be anywhere in those 
genes then you might think “That’s it, I haven’t got that 
mutation and I’m never going to get that disease.” But there’s 
one in 500 people in the population who are affected by it so 
that’s not true … and they said it was more common in Indian 
populations or something like that so there’s a founder effect 
there, or something like that, that will be more relevant to a 
different ethnic group. (Scientist CP8) 
 
In pointing out the difference between sequencing genes for mutations that 
cause people’s illness and looking for SNP variations, this scientist is 
expressing her concerns about the different methodologies of different types of 
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genetic test. She suggests that people who buy SNP analysis will gain 
inadequate information from their test results and could be falsely reassured. 
 
The clinicians’ criticisms of DTCGT for disease risk seem linked to their 
concerns about the deterministic approach that DTCGT companies take to 
marketing their health genotyping services and illustrates their alternative 
technological frame of DTCGT on scientific grounds. Some clinicians voiced 
concerns about companies’ use of terminology that contradicts the uncertain 
nature of genomics knowledge, with the potential to mislead the public about 
the nature and value of the products being marketed. This consultant’s 
interpretation of the misleading nature of DTCGT marketing directly highlights 
professional concerns about companies’ deterministic rhetoric and their target 
market, a genetically deterministic public.  
 
Yeah, I guess I have a view that I’m not against cutting out 
the health professional; that doesn’t bother me so much as a 
feeling that a lot of people who use it at the moment are 
being misled. And they might only be being misled because 
their starting point about genetics is not quite realistic and 
that’s such a common thing for people to think it’s all about 
the genes. It is so common for people to think that a genetic 
test will tell you more than it often does but without being 
able to move someone back from that position a test can be 
quite misleading I think; particularly because it’s commercial 
and they want you to carry on thinking that. They don’t want 
you to think it doesn’t do very much. (Doctor CP4) 
 
The emphasis this doctor makes is on how the public are in danger of being 
misled by companies’ marketing approaches, because they do not provide pre-
test information in the detailed manner that a genetic counselling consultation 
would. She plays down the need for genetic counselling but simultaneously 
points out the necessarily deceptive nature of DTCGT marketing, implying that 
this could be harmful.  
 
Uniquely, this nurse expressed her understanding of the business plan for 
23andMe as being driven by biobanking, but contextualised this in relation to 
the companies’ marketing practices, echoing other clinicians’ concerns.  
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I didn’t buy into the argument that direct-to-consumer tests 
were a terrible thing because there were all these terrible 
ethical problems and they [users] were going to be incredibly 
damaged by what they found out … I suppose I personally 
feel that because nothing in there is very predictive, it wasn’t 
actually a health thing at all and that it was not very useful … 
I saw it as a consumer issue but with the challenges of 
getting enough information to people so that they understood 
what they were buying. And it seemed to me that actually 
that could never be met because if you gave the true 
information that what susceptibility testing offered was 
worthless then why would you buy it? If you gave the real 
information, you know “BRCA test has really significant 
information for you and your family, it’s available on the NHS 
free, available under certain circumstances” why would you 
buy it? So for me it was, it was never on that basis that this 
was so dangerous it should be forbidden. I felt it should not 
be offered because it was useless and things were being 
misrepresented … my impression is that most companies 
have gone out of business that were operating and that the 
major company 23andMe is actually doing something very 
different. It’s not marketing health-related tests like the 
impression given, it’s using that opportunity to get data and 
that potentially is what‘s going to drive its business from now 
on. Because it always struck me right back at the very 
beginning, where is the money in this? I couldn’t see where 
the money was. (Nurse CP5) 
 
This nurse initially dissociates herself from published criticisms of DTCGT and 
its potential harms. Instead she focuses on the morally problematic activity of 
companies selling useless products to gain data for future commercial uses 
under the cover of marketing useful information to the public (at least in the 
case of 23andMe). 
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Professional group differences 
Clinicians who questioned the scientific basis of DTCGT were all doctors or 
scientists. The four scientists all discussed the problematic nature of DTCGT in 
relation to the inadequate nature of SNP genotyping as compared with the 
detailed genomics research they were either familiar with or engaged in. Most 
of them also expressed insight into the tensions between the paternalistic 
nature of genetic counselling and public engagement with technology, as I will 
demonstrate in the final section of this chapter. One nurse also referred to the 
lack of validity of SNP genotyping in the context of tests provided by personal 
genomics companies. However, she has a PhD in genetics, like many of the 
medical and scientist participants in the clinician participant group. The 
remaining three nurses, who have gained genetic counselling posts and 
registration by experience rather than undertaking the MSc in genetic 
counselling, did not refer to the molecular genetics or the scientific basis of 
testing at all in their interviews. Their concerns seemed more focused on the 
moral aspects of genetics, judging by their references to the lack of genetic 
counselling principles in DTCGT as compared with their genetic counselling 
responsibilities. This illustrates the influence of different professional 
perspectives on socialising DNA and shaping the DTCGT from the different 
sub-groups in this relevant social group. Whilst there is undoubtedly common 
ground between the different professions working in clinical genetics, each 
professional group has its own values and identity and thus its own version of 
the technological frame of DTCGT. Nurses’ primary concern and their 
professional values focus primarily on caring, higher academic learning in 
sciences being a relatively recent development in nursing education. This is in 
contrast to doctors and scientists, whose identity is primarily founded on 
education in sciences. The foundations of these occupations are influential in 
the way the clinicians socialise DNA. One experienced doctor with leadership 
responsibilities noted differences between genetic clinicians on the basis of 
their professional background and education. This extract illustrates the 
differences between the professions well. 
 
It’s about understanding the data that the prediction’s based 
on, not believing what the company actually report and 
looking up the evidence the results are based on. I think for 
some genetics counsellors that must be quite difficult if they 
don’t come from that evidence evaluation framework like I do. 
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Some of them do, some of them very much do, but just not 
all of them. Genetic counsellors come to the profession from 
different places and they’ve been in it for different lengths of 
time and they have different skills. They’ve got very different 
backgrounds with different skills. Often those that come from 
nursing backgrounds for a long time are very good 
communicators and they have a really good understanding of 
disease and it’s breadth and of pathology and how that 
pathology impacts on people and they understand well about 
the genetic stuff they know. Particularly when they are junior, 
the concept of things like relative risk and numbers needed to 
interpret studies, to come up with a conclusion, 
understanding the process, can be less in-depth than 
perhaps someone with an MSc in Genetic Counselling who 
has an epidemiology degree who will just come in in a 
different place. People who come in with medical training do 
to some extent get layered on the stuff about how you 
appraise evidence and how much evidence you need to 
appraise something and I think that is part of genetic 
counselling training but it’s just not as embedded, not as 
deep. (Doctor CP2) 
 
The doctor points out the different skills that different professions bring to 
genetic counselling. She implies that nurses do not have the scientific 
grounding to be able to interpret evidence and communicate risk clearly, 
although they have excellent communication skills and that this might be 
problematic for interpreting DTCGT. This observation points to the social 
differences between professional groups; it highlights the influence that 
professional cultures have on how genetics clinicians’ technological frames of 
DTCGT differ. This is due to how they socialise DNA differently according to 
their profession and perceive those differences in their colleagues. 
  
In terms of professional cultures and their influence on their members’ views 
and practice, the other notable professional difference in the way clinicians 
socialise DNA is the manner in which the scientist counsellors and one nurse 
referred to the public’s engagement with genomics, as I noted earlier. In the 
next and final section in this chapter I shall show how clinicians’ and also some 
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users’ beliefs about public understanding of genomics are part of their 
socialising DNA and how different groups had different ways of seeing this.  
 
Public understanding 
Durant et al (1996) suggest that the word ‘public’ is used in contexts where it 
can have one of three meanings. The meaning inferred in the phrase ‘public 
understanding of science’ is that the public are people who are outside the 
knowledgeable group in question. These people lack knowledge or 
understanding of that group’s specialist, privileged knowledge and, in this 
instance, cannot socialise DNA in the same way the knowledgeable group do. 
In other words the public represent a social group with different understanding, 
knowledge and technological frame of DTCGT from the knowledgeable group, 
if indeed they have any. In the clinicians’ opinions about DTCGT their meaning 
appeared to be congruent with this on the whole; that is, the public are people 
who are outside the healthcare professions and genetics and who lack 
understanding of either genetics or the privileged knowledge of the healthcare 
professions. In considering the issues related to DTCGT generally (rather than 
in relation to specific consultations), the clinicians referred to the public’s 
knowledge and understanding of genetics mostly from a deficit perspective, as 
the preceding definition of the word ‘public’ suggests. Those who talked about 
this suggested that the public were unlikely to understand various issues 
relevant to genomics, and there were specific references to misunderstanding 
of relative risk or disease risk when expressed in percentages. This 
perspective was used to justify the need for the moral aspects of the boundary 
work exhibited, underpinning the need for genetic counselling so that the 
public would be able to exercise their autonomy from an informed perspective 
and not come to any (avoidable) harm. These clinicians were not alone in this 
view, as several of the users similarly suggested that the public, also referred 
to as “the man on the street”, did not understand genetics. By aligning with 
adopters of genomic technology, they distance themselves from the public who, 
in their opinion, would not understand it. In their study exploring lay expertise 
about genomics prior to completion of the HGP, Kerr et al noted that the 
dominant deficit model of public understanding of genomics is key to the 
maintenance of boundaries by government, scientists and healthcare 
professionals (Kerr et al 1998). In addition, they found that lay participants in 
their study also subscribed to the deficit model in respect of the (rest of the) 
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public’s understanding. Kerr subsequently noted that research participants 
who are recruited to studies as representative of ‘citizens’ often shift their 
identities towards a position of expertise, distanced from “the ignorant and 
amorphous public” (Kerr 2004: 123). This assumption does not appear to have 
shifted since then and is part of genetics clinicians’ rhetoric in socialising DNA, 
as the excerpts below indicate.  
 
Concerns about the public’s understandings of genomics being based on a 
deficit model appeared, for the clinicians, to be influenced by practitioners’ 
experiences of explaining genetic disease to patients and families in genetics 
clinics, but also perhaps by the more widely held view given that some users 
expressed it also. One scientist likened the public’s understanding to 
knowledge gained from watching a fictional North American television drama 
about forensic medicine, whilst a doctor represented the more widely 
expressed understanding among the clinicians that the public think genetic 
information is deterministic. 
 
People access tests for very different reasons and 
unfortunately I think the public do think its CSI. (Scientist 
CP1) 
 
I think that people often start off in a position where genetics 
is really something very important and very deterministic. If 
they don’t start from that position then I’m not so worried 
about it but I think it’s really common in UK society to think 
that genetics determines much more than, much more in a 
clear way than I think it does. (Doctor CP4) 
 
This expression of the public’s deterministic understanding of genetics can be 
compared with Fiona’s. Also a scientist, Fiona expressed opinions about the 
public’s understanding of genetics that represents other users who are 
scientists also. 
 
Even well educated people don’t know very much about 
genetics and have a poor understanding about genetics. On 
one level that’s a shame but at the same time it’s not an easy 
thing to change. (Fiona UP8) 
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Concerns about people’s knowledge and understanding were explicitly related 
to understanding risk by a number of clinicians who felt that the public were 
likely to misinterpret its meaning for them. One of the nurses expressed this 
clearly. 
 
 My fear is that quite often the information is put across to the 
patient and they become misinformed … they get “You have 
a higher risk of cardiac problems” mixed up with “You’re 
going to have a heart attack when you’re older, or you’re at 
risk of a heart attack.” Well yes that’s true but to a certain 
extent everybody is. There are lots of other parameters 
involved or appear to be in this mass-screening that people 
get and it’s not often specific, it’s in percentages. I suppose 
what I’m trying to say is people’s perception of risk is very 
different and when you give risk in a percentage it very much 
depends on where that person’s at as to how they’ll take that 
on board and I think in some cases it can become 
misinformation for them. (Nurse CP9) 
 
The nurse’s views show how her experiences in nursing and genetic 
counselling have led her to conclude that patients’ understanding of 
information is not always the same as that intended by the person giving it. 
She is concerned that the DTCGT companies’ results will be misinterpreted by 
some and this implies that harm could potentially result without the provision of 
professional interpretation that genetic counselling would offer. 
 
However, there were also some suggestions that the public is able to 
understand and deal with the information that DTCGT provides appropriately. 
A small group of clinicians, mostly scientists, referred to public understanding 
in more positive terms, demonstrating a perspective of the public as having 
resilience in relation to receiving genetic information. Also, some clinicians 
from other professions suggested that the public could access DTCGT without 
coming to any harm or causing them (the clinicians) concern. Neither an 
assumption that public knowledge is based on a deficit model nor 
understanding public resilience seemed to depend on experience of consulting 
with people who had used DTCGT. Indeed, there was also some ambivalence 
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with some clinicians expressing opinions that supported both points of view. 
This evidence of interpretative flexibility is resonant with Evans et al’s 
exploration of the public engagement with genomics. They noted that 
individual actors involved in public engagement with genomics often had roles 
in more than one group, which suggested that ambivalence was more likely in 
actors’ understandings rather than the habitually predicted pro-con dualism 
(Evans et al 2007). This could be interpreted as making the group’s 
contribution to shaping the technology more complex as technological frames 
will vary somewhat between and within relevant social groups, as indicated in 
this study’s participants. The following excerpt from one of the scientists is 
representative of an understanding of pubic resilience expressed by a number 
of other clinicians, framing it within a more objective view of the social world of 
genetic counselling. 
 
That traditional route is obviously tried and tested but I can 
see how it might put some people off because… I don’t know, 
it’s time consuming, you have to speak to various different 
people; you can see that for some people it might be 
attractive to click a few buttons on the Internet, send off your 
99 pounds… Because I mean let’s say your sister had a child 
with cystic fibrosis. You might go on the Internet and say oh 
yeah that means I’ve got a 50:50 chance of being a carrier. 
So the traditional route would be go to the GP get referred to 
clinical genetics. Obviously you have to talk to your GP, you 
have to wait however long you have to wait and then come 
up to clinical genetics talk to someone, you have to wait 
again for a result and then you have to talk to someone again. 
That against “Well I’ll just buy one of these, pay for one of 
these kits.” I suppose it’s just surprising to me that more 
people don’t do that now I think about it because that seems 
a more private way of doing it. And you don’t even have to 
tell anyone the result then … it could be that we are making 
more out of this potential psychosocial risk, we are worrying 
too much about the impact. Maybe people can cope with 
these things better than we think they can or just that you 
know, going through a course of genetic counselling is not 
actually helpful. If they are upset … then they’ll talk to their 
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family or their friends and that helps them adjust to it rather 
than talking to us. (Scientist CP7) 
 
This excerpt shows this participant’s reflexivity in considering DTCGT. She 
highlights the negative aspects of genetic counselling as experienced by 
patients in her particular specialist area of practice. As she does so, she 
concludes that there are potential advantages to DTCGT for the public, thus 
indicating insight into the potential for the public’s understanding and resilience 
and into alternative views of genetic testing and counselling. 
 
Conclusion 
This chapter has explored how DNA is socialised by participants in the study. It 
is clear that social networks are crucial in shaping the discourse about 
personal genomics. The technological frame of users may support 
engagement, as represented by the role networks play in facilitating users’ 
adoption of it, whereas that of clinicians is more hostile towards it, as 
demonstrated by their performance of boundary work to distinguish and 
distance their professional genetic counselling service from the contingent and 
challenging aspects of DTCGT. In the wider context of the NHS, users’ and 
clinicians’ views about the relevance of DTCGT to health care can be 
summarised as support for either personalised medicine or collective medicine 
respectively and these aspects of the data analysis will be explored in detail in 
Chapter Six. But the networks of the different social groups that the users and 
clinicians in this study circulate within appear to be in tension. McKinlay and 
Marceau suggest that the golden era of medicine is over, or at least shifting to 
a somewhat less gilded state (McKinlay and Marceau 2002), in that its 
autonomy and power are being challenged from numerous fronts, including 
technological, administrative, economic and public challenges. The users’ 
position in supporting the new technology of DTCGT could be interpreted as a 
challenge to existing medical hegemony, particularly when juxtaposed with the 
moral virtues of genetic counselling that the clinicians largely seem to promote.  
 
This body of data would suggest that healthcare professionals working in 
clinical genetics continue to assume medicine’s privileged status of power and 
authority, although some suggestions of public literacy in either genomics or 
healthcare decision-making are acknowledged. Alignment to a Parsonian 
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definition of professionalism, in which the ethics of care are based on service 
and altruism, is shown by many of these clinicians. However, these data would 
suggest that healthcare professionals in clinical genetics in the NHS perceive 
the divisions of knowledge and the relative power and authority attached to it 
along established boundaries of practice and expertise that other scholars 
have noticed remain intact despite expectations of change (Hedgecoe and 
Martin 2008). This supports the users’ views of medical paternalism in relation 
to genetic and genomic knowledge. It also represents these groups’ different 
technological frames of DTCGT as being based on the users side as being 
rights-based, democratising and challenging to medical paternalism whilst the 
clinicians’ is based on moral boundary work, professional authority and their 
perceptions of flawed science. 
 
Having considered the social aspects of participants’ beliefs and values about 
DNA, the next chapter explores how participants think about DNA on an 
individual level and how their experiences of DTCGT has influenced their 
thinking about their identity and subsequent embodiment of DNA, either in their 
individual lives as users or in their practice as genetic counsellors. 
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Chapter 5 : Personalising DNA 
Personalising DNA relates to the participants’ individual ideas about DNA in 
the context of SNP genotyping and incorporation of its perceived information in 
their own lives or genetic counselling practice. Whether they were introduced 
to genetics through their education and work, or through genealogy, the 
participants almost all had an interest in DNA and genetics that provided the 
impetus for their further learning and engagement with testing. This learning in 
turn appears to have provided the scope for people to engage in identity 
practices, as described by Gibbon and Novas (2008), or to consider how SNP 
genotyping might affect consultands’ identities. Their ideas and learning can 
then be incorporated into their lives, whether in the form of newly edited 
identities, life-style changes, or thinking differently about personal genomics or 
approaches to genetic counselling. As I noted in Chapter Four, socialising with 
others who have similar interests and knowledge will of course both influence 
and be influenced by individuals’ expectations and embodiment of DNA. 
However, personalising DNA as represented by individual ideas and 
embodying of DNA, is different from external sharing in that it is about internal 
imaginings and identity practices rather than publicly shared understanding 
and beliefs which will be shaped by and during socialising. This chapter 
focuses on how the participants expressed these individual expectations and 
ideas about DNA and incorporated them into their lives. Sharing SNP 
genotyping results with family, though it could be construed as socialising, is 
discussed in this chapter in relation to embodying DNA, due to the inseparable 
nature of imagining one’s own genetic identity in the context of kinship. 
 
The chapter is made up of two main sections and will commence by 
considering participants’ expectations and reflections on the DNA of SNP 
genotyping, what factors informed their thinking and led to users’ pursuing 
further knowledge and engagement with the technology and clinicians’ ideas 
about why people might decide to engage with DTCGT. The tensions between 
users’ and clinicians’ expectations will be illustrated by contrasting data from 
each group that relate to this theme. The second section will explore how 
participants embody DNA, that is, the impact results of DTCGT had on users’ 
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lives and on-going identity practices will be discussed as will experiences of 
clinicians who counselled people who had questions about DTCGT results.  
  
Expectations and reflections on DNA 
In their exploration of DTCGT company rhetoric, Nordgren and Juengst point 
to the centrality of individual identity in contemporary post-modern society 
(Nordgren and Juengst 2009). Likewise, the users of SNP genotyping in my 
study seemed to be seeking genetic information with which to inform (and 
possibly enhance) their accounts of themselves. The future-orientated nature 
of thinking about and committing to buying DTCGT links to people’s hope for 
information about themselves. They appear to hope that it will either be useful 
in relation to health or genealogy, or satiate their curiosity about themselves 
and their family and genomics more generally. The DNA test facilitates 
recreating their pasts as well as their futures in the light of their anticipated 
understanding of their extended (genomic) identity, as Brown and Webster 
forecast new medical technologies would (Brown and Webster 2004). 
 
I earlier described the majority of the users in this study as early adopters of 
personalised genomics, people with what Jenny Reardon refers to as 
“learnedness”. She describes early adopters as people at whom DTCGT 
companies initially specifically targeted their marketing strategies, in order to 
sell their tests and simultaneously increase their acquisition of data (Reardon 
2011:97). The quality of learnedness I suggest is based on users’ existing 
knowledge and inquisitiveness about genomics and their own bodies at the 
molecular level, that which Novas and Rose refer to as the “somatic individual”, 
and which they can now begin to realise in the form of DTCGT (Novas and 
Rose 2000:485). I use the word inquisitiveness to mean an interest in how 
knowledge about their genome might influence their thinking about their 
identity, whether in relation to genealogy, physical traits, disease risk or carrier 
status.  
 
Clinicians talk about DNA in the context of DTCGT by envisaging what the 
public’s motivations and experiences of testing might be, wondering how these 
individuals fare on their solo genetic testing journey without the institutional 
support of genetic counselling and expert interpretation of results. For both 
groups, prior knowledge of genetics is fundamental; this is emphasised by the 
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contrasting experiences of the two users who did not conduct research into 
personal genomics prior to testing, as I will show when discussing users’ 
reflections on and expectations of their DNA. 
  
Users’ knowledge, interest and curiosity 
In this section, I will present data about how this particular social group of 
users developed knowledge of SNP genotyping by learning about it from the 
Internet and how this knowledge affected their thinking about testing and their 
individual genetic identities. The significance of participants’ expressions of 
interest in personal genomics will also be explored and these two areas 
contrasted with Jane’s and Ian’s rather different expectations and ideas about 
their DNA.  
 
Knowledge 
Prior to obtaining results from testing, most users described reflecting at length 
on their expectation that SNP genotyping would reveal information about their 
genetic selves, whether in relation to genealogy, traits or disease risk and 
envisaged what this would be like from the reference point of their knowledge 
of genetics. It is clear that their knowledge and engagement with genetics was 
important in influencing their interest and expectations about their test results. 
Given the mixed background of the group of users, it appears that specialist 
prior knowledge was not a prerequisite for developing an interest in new 
genetic technology (assuming that only the genetic scientists fulfilled this 
criterion). Most users either felt they already had a sound working knowledge 
of genetics generally and SNP genotyping specifically, or spoke of developing 
that knowledge by undertaking extensive research into SNP genotyping before 
deciding to take a test. This aligns with Reardon’s assertion that personal 
genomics companies deliberately sought to attract followers who were 
knowledgeable and able to consent to SNP genotyping (Reardon 2011). It also 
indicates that participants’ learned, or extant knowledge of genetics equipped 
them with the vocabulary to extend their ideas about their DNA and entertain 
the possibility of reifying it by thinking about testing. 
 
The following excerpt from David demonstrates his commitment to learning 
about genetics from a genealogical starting point, but he indicates that this 
then widened to include health testing as well. 
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I first of all took a free test with Sorenson which gave me a 
first insight into what it was all about and it was quite a long 
learning curve but worthwhile spending all that time learning 
what it was all about and I became more and more interested 
in it … the primary reason for taking that test was for family 
history but I was also aware that there was a huge health 
side to the test and I was interested in both. I was interested 
in learning about any health implications good or bad. (David 
UP6) 
 
David had no background in genetics prior to becoming involved in genealogy. 
From this starting point he became increasingly involved in his family ancestry, 
which led him into genetic genealogy, in common with many genetic 
genealogists (Nash 2004). He indicates that he taught himself about genetics 
over time and became increasingly engaged with it as he learnt more, 
becoming as fascinated by the health aspects as the genealogical, regardless 
of the implications of what testing might reveal about him.  
 
Christine had more understanding of genetics from her science background 
and research in public health. Although she was initially introduced to DTCGT 
by a colleague and was apprehensive about confidentiality, she researched it 
thoroughly on her own before deciding to test. 
 
I read the fine print and all the rest of it and I was happy to 
(go ahead). I read reviews from other people, I contacted 
them to know how easy it was and what fees were involved 
and the fine print. I was hesitant at the start to send samples 
off like that but then I thought it was what I wanted and it was 
quite easy. It was easy, it was clear. (Christine UP5) 
 
Christine illustrates how she read about testing on the Internet and followed 
this up by contacting others who had tested. She describes practical concerns, 
which were partly informed by having worked with human samples in research 
laboratories earlier in her career. The simplicity of the testing process seems to 
have encouraged her to finally decide to buy a test to find out more about the 
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genetic aspect of her identity, which she had been contemplating for a while, 
as indicated by her saying “it was what I wanted”. 
 
Christine’s example also demonstrates how learning about SNP genotyping 
enabled her, in common with other participants, to develop new knowledge 
and language associated with personal genomics. This individual learning and 
the connections made during its acquisition appear to provide the skills and 
opportunities to engage in socialising DNA in communal forums providing an 
example of where personalising and socialising DNA intersect.  
 
Interest and curiosity 
It appears that DTCGT had influenced participants’ expectations to varying 
degrees, as indicated by their descriptions of their thinking about testing before 
deciding to buy and then while waiting for results. Most participants referred to 
their interest in personal genomics. Some explicitly expressed curiosity and 
two appear to have developed an arguably obsessive interest, having taken 
genetic genealogy tests with every company they could easily access. 
 
Use of the word “interesting” in conversation can have various meanings. It 
may mean indifference to what has been said but be voiced out of politeness, 
be used as a time-wasting tactic in polite conversation or actually convey the 
person’s interest in the topic in question, although on occasion this may be in a 
general, non-committal fashion (Urban Dictionary 2013). However, use of the 
word by these participants mainly appeared to convey people’s politeness and 
genuine interest in genetics, their imagining their own genome and learning 
more about it or their learnedness about personal genomics. All but two of the 
participants repeatedly referred to their interest in personal genomics generally 
and in their test specifically, in relation to both the process of testing and the 
results. Some users used the word repeatedly, notably Carol, David, Helen 
and Maria, demonstrating their genuine engagement, as shown in the following 
excerpt. 
 
This is really interesting. I’d be just fascinated to know, just 
fascinated to know on a personal level what I’ve got and what 
I haven’t got. (Carol UP4) 
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Carol’s repetition of and emphasis on her “fascination” suggests her interest 
and learnedness based on her genetic knowledge from her education and 
work in public health research. She suggests that she has envisaged that her 
SNP genotype will reveal certain characteristics about herself that have 
previously been hidden but which she may have encountered in her family and 
her work and have wondered about in relation to her own identity. This is akin 
to Armstrong et al’s portrayal of the concealed aspect of an individual’s identity 
being revealed by genetic testing. The genetic aspects of a person’s identity 
exist but are unseen, buried in their cells; genetic testing reveals them, 
rendering them visible. Unlike situations in which people have to change their 
identity due to diagnosis of illness or disfiguration, genetic information or 
diagnosis reveals a previously inaccessible aspect of identity (Armstrong et al 
1998).  
 
Three users who work in genetics, Fiona, Kirsten and Maria, all talked about 
wanting to see their own DNA data, rather than only researching and working 
with others’, to put their daily theory into personal practice. They have 
seemingly imagined what their own DNA might be like, in comparison to that 
which they encounter in their working lives on a daily basis, and are curious 
about what the reality of their own genomic information might reveal. Fiona is a 
genetics scientist in her 30s whose interest was related to her work. 
 
I suppose I was intrigued, I think because of the nature of the 
field I work in I’ve known about these things for a fairly long 
time and it finally got to the point where it would just be 
interesting to apply the things I know because of my work to 
something that was actually about me as opposed to 
something else. (Fiona UP8) 
 
Fiona demonstrates her interest and its relationship to her expectations of 
personal genomics in her use of the word “intrigued”. Referring to genetic 
information that is hers rather than someone else’s points to her hope to 
extend her own identity and individuality into the genetic so that she can have 
similar personal information to that she deals with daily. Maria, a young PhD 
researcher in genetics, has a similar wish to access her own genetic identity; 
she voices her imagining and motivation more strongly, using the word 
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“narcissistic” to focus her curiosity on her interest in her own genome, as 
opposed to those she works with in the laboratory on a daily basis. 
 
So I’d been interested in it for a while and … you know as a 
geneticist the idea of actually looking at my own SNPs was 
quite exciting … I was interested to see how accurate it 
would be and if I would find anything out and it was getting 
cheaper and really I did it for a narcissistic curiosity. It really 
wasn’t for disease risk information, though I did find that 
interesting as well, but you know as a geneticist the idea of 
actually looking at my own SNPs was quite exciting so that 
was the main reason really, curiosity. (Maria UP16) 
 
Maria seems to be challenging the SNP genotyping test by saying that she 
wishes to see how accurate it would be, presumably by comparing the results 
to her existing self-knowledge, but she also seems to be imagining her genetic 
identity and individuality as separate from, but in the context of, the genetic 
material she deals with on a daily basis. 
 
Juxtaposed with the word “interesting” is the use of the term “curious” which a 
few participants used in addition to Maria, in relation to their thinking about 
testing. Unlike the word “interesting”, which implies a justification and a more 
responsible and informed decision in relation to testing, “curiosity” could 
suggest something more trivial and unfocused than an (informed) interest. 
“Curiosity” was often used by participants as a kind of excuse for their decision 
to take a test (Scott and Lyman 1968). The way the word was used by most 
participants reduced the individual’s responsibility in relation to deciding to test, 
due to their (often implicit) suggestion that giving in to curiosity was something 
they were not fully in control of, undermining informed decision-making. Kirsten, 
who works in bioinformatics, puts it well. 
 
Genome testing’s been around and affordable for a couple of 
years now; I did mine last summer so I was slightly late on 
the bandwagon. I did it because I was starting to do 
methodological work in this area, how to put together SNPs 
and environment models and I had a PhD student working in 
  135 
it, so I’d done some of the research and read some of the 
papers about, you know, how we do it and what the problems 
are and giving seminars on the statistical aspects of it and 
you know, just curiosity in the end just got the better of me. 
(Kirsten UP14) 
 
In this extract, Kirsten conveys the influence of her work on her decision to test, 
another example of putting the theory into practice by experiencing the reality 
of testing and of a prior knowledge base informing knowledge and the decision 
to engage with SNP genotyping. However, she does also acknowledge her 
thinking about her own genome in her throwaway remark “curiosity in the end 
just got the better of me” and suggests that her final decision to test was based 
on the desire to know exceeding her caution and self control.  
 
Christine, the public health lecturer with an interest in genetics and a family 
history of cancer, referred to being curious about her results while waiting for 
them to be posted in her 23andMe account.  
 
I was excited too … well the whole possibility because I know 
how many tests there are and they had claimed there was a 
thousand SNPs and I was really, really quite curious by that 
stage. (Christine UP5) 
 
The anticipation of having her genetic identity revealed is conveyed by 
Christine’s excitement and her emphasis on her curiosity by repeating the 
word “really”. She suggests that the quantity of information that will be 
available is important in reifying her DNA.  
 
Interest and curiosity were taken a step further by a few participants, mostly 
genetic genealogists, who either described having several tests or specifically 
referred to an “addiction” to DTCGT. Genealogical DNA testing includes 
autosomal, mitochondrial and Y chromosome DNA analysis, comparing SNPs 
or haplotypes from the individual’s DNA with others from similar lineages, 
cultures or historical groups. These tests are available from companies 
including Sorenson, Oxford Ancestry and Family Tree DNA and preceded 
testing for common complex disease risk. Those interested in genealogy are 
familiar with DTCGT, having previously tested with one of these genetic 
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genealogy companies or knowing others who have. Indeed, two of these 
participants described testing as addictive.  
 
Having done four tests, David, a lifelong genealogist, was the most 
experienced user of DTCGT. It is important to point out that his wife, Elizabeth, 
volunteered the information in the interview that David has Asperger’s 
syndrome and this may explain his engagement with genetic genealogy and 
DTCGT in a more intense way than other users’. However, this does not 
undermine his knowledge or interest in personal genomics and he expresses 
his curiosity vividly. 
 
After my free test with Sorenson, I then took a paid-for test 
with FTDNA, a YDNA test on more markers and lots more 
flexibility and help from that company. They give you a better 
insight into what the results mean. And then the autosomal 
DNA test became available first of all from 23andMe … so I 
hummed and hah-ed for a while but got so intrigued I couldn’t 
resist ordering a test even though it was expensive. I just 
went ahead and placed an order and it’s been really 
interesting … I couldn’t wait to see them [the results]. If you 
haven’t taken such a test yourself you have no idea of the 
anticipation of waiting for the results, it’s a great experience 
really. Waiting, waiting, waiting and then bang the results are 
there, you dive in and try and understand it. (David UP6) 
 
David’s striking explanation of his experience of testing illustrates his 
impatience to extend his understanding of his genetic identity. In a manner 
similar to Kirsten, he describes a loss of self-control in being unable to resist 
ordering a test. His description of waiting for the results of the test is 
emphasised by his repetition of the word “waiting”, thus conveying his 
excitement about the future possibilities inherent in getting his test results in a 
very similar manner to Christine. The waiting culminates in his diving into the 
results to try and make sense of this new information about himself as part of 
his on-going identity practices. 
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Clinicians’ imagining DNA 
Some of the clinicians also referred to identity practices and reflecting on DNA 
from a personal genomics perspective. Most of them imagined DNA from the 
perspective of users of DTCGT, but a few others mentioned a personal interest 
in the concept of DTCGT, using similar tropes as the users. This was mostly 
prompted by the context of counselling a patient who had bought a test, but 
demonstrates the seductiveness of thinking about one’s own DNA and genetic 
identity. Two scientists (CP3 and CP8) and a very experienced nurse (CP9) all 
referred to being interested in finding out more or having a DTCGT. However, 
they were all quick to be dismissive of disease-risk testing, due to its lack of 
utility and concerns about it provoking anxiety. This could be interpreted as an 
illustration of the distinction between personalising DNA and socialising DNA 
and the interpretative flexibility required for members of the clinicians group to 
move between these points. After considering DTCGT from the perspective of 
their won DNA they reassume their professional group’s discourse and 
technological frame of DTCGT. 
 
I would probably be quite interested in doing it [genetic 
genealogy] because it’s so bloody vague it’s not going to tell 
you anything in reality but I can appreciate that because of 
the field I work in and I have a better understanding of 
genetic tests than most people and I would be interested in 
doing that, but I also know it doesn’t mean a great deal in all 
honesty. But I couldn’t do it for anything else, personally … 
we all have innate curiosity but there are so many 
uncertainties [in genetics] and I wouldn’t want to get hooked 
on a piece of information that preyed on my mind that in 
reality was irrelevant. Because I’m just as vulnerable to doing 
that as anyone else, when you’re worrying about your own 
health you do. (Nurse CP9)  
 
This nurse’s comments are interesting because of the contradictory nature in 
which she phrases them and her interpretative flexibility. She expresses her 
interest in uncovering genealogical aspects of her genetic identity, but then 
immediately acknowledges that it would be unlikely to tell her anything 
meaningful and then repeats both assertions in slightly different ways. She 
goes on to refer to her “curiosity”. This indicates that she has thought about 
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her own DNA and genetic identity. However, she excuses it by assigning her 
interest to a commonly held human behaviour, describing it as “innate” rather 
than something she is specifically interested in, thus distancing herself as a 
genetics counsellor from the public who might engage with DTCGT. She 
seems to imply that she is curious to extend her identity into the genetic realm. 
However, she simultaneously expresses caution, possibly because she 
imagines herself in the place of her consultands, with the potential for being 
distressed by aspects of her disease-risk in a manner more linked to genetic 
essentialism. This view is similar to that proposed by Alexandra Plows, who 
suggested that geneticised accounts of one’s identity have the potential to 
eclipse the additional aspects that comprise that identity (Plows 2011). This 
nurse’s response is also indicative of the tension between the personal and 
professionally social, accessing her own DNA and engaging in the powerful 
moral boundary work of the genetic counselling clinic she did along with the 
other clinicians, as demonstrated in Chapter Four. 
 
For some clinicians, personalising DNA was related to thinking about the 
perspective of people who want to engage with DTCGT. They talked about 
SNP genotyping in relation to the public, envisaging users’ motivations and 
experiences. Despite the intrinsic tensions between the moral boundary work 
of the clinic and imagining personal genomics I referred to above, three 
clinicians, two scientists and one junior doctor (CP8, CP9 and CP14) 
acknowledged people’s desire to find out about their genetic identity and their 
ability to think about genomics in a meaningful way.  
 
I suppose they start from a position of wanting to know 
something and if they realise it’s commercially available you 
know, why not? I think from looking at the website and 
understanding it a bit more and also from anecdotal stuff that 
I’ve heard there are two groups of people. There are people 
who are going to approach it from a health point of view and 
there are people who want to approach it from the genealogy, 
ancestry point of view. (Scientist CP8) 
 
This scientist acknowledges people’s interest and curiosity, their wish to 
discover aspects of their genetic identity, whether in relation to their health or 
  139 
genealogy. Her personal research into commercial SNP genotyping had 
extended her knowledge of DTCGT and thus enabled her to imagine DNA 
from a different perspective. Another doctor anticipated, as did a number of the 
users, that people who would engage with DTCGT would be knowledgeable 
about genomics. 
 
I would imagine that people doing the direct-to-consumer 
tests would have done a bit of reading and would have 
thought about it. I think your average person on the street 
who wouldn’t have thought about it wouldn’t go for it …There 
will be people with a certain amount of awareness and the 
ability to look through these kind of Internet sites and know 
about family history and that kind of thing. So I think they’ll 
need to have a certain level of knowledge or understanding 
before they go to the direct-to-consumer test. (Doctor CP6) 
 
This doctor envisages that those who engage in genetic identity practices are 
likely to be knowledgeable about genetics or in a position to educate 
themselves about it. She uses the expression “person on the street” to refer to 
a public who are not knowledgeable or in a position to develop their knowledge 
outside the learned group in question (as I discussed in Chapter Four). This 
indicates her assumption that those who engage with DTCGT are less likely to 
be harmed by the experience on account of their prior knowledge, unlike some 
of the people she encounters in her practice who might be.  
 
Worrying about DNA 
Interest and curiosity about genetics appear to be dynamically associated with 
knowledge and learning, both prompting and being the result of people’s 
discovery. The majority of participants framed their experiences of learning 
and thinking about personal genomics positively, describing how they 
imagined their DNA whilst anticipating the arrival of their results. However, as 
demonstrated in Chapter Four, Jane’s and Ian’s experience was different from 
other users’. The heterogeneity they contribute to this study’s users’ group 
could also be interpreted as belonging to a different relevant social group in 
relation to shaping DTCGT, one in which group members have less knowledge 
of genomics or understanding of the test’s capacity to provide useful 
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information. They are the couple who had their DTCGT bought as a gift and I 
shall examine their alternative experience of anticipating their DNA, before 
going on to explore the expectations and reflections of those whose 
motivations for testing were related to health. 
 
As outlined in Chapter Four, Ian described himself as having an interest in 
“pop-science” and genetics, which he shared with the relative who bought the 
tests for him and his wife. However, neither he nor his wife had any formal 
education in biology or genetics, nor did they undertake any research into 
genetics or personal genomics, beyond talking with their relative, prior to 
deciding to test. They were persuaded by their relative’s enthusiasm and 
agreed to testing on that basis but had not been socialised into the world of 
DNA testing which seemed to give them a different experience of DTCGT, at 
least initially. Jane described being nervous about testing beforehand and 
having no preparation for the reality of receiving the results. Ian describes 
having similar expectations of his DNA after Jane’s concern at her results, 
which were received two weeks before his. This gave him additional time to 
dwell on what his genetic identity might reveal. 
 
Jane got her results first and she was really nervous and I 
hadn’t thought about that until she got hers. She looked at 
them at work and then at home and saw something in the 
email that made her think she’d been tested for something 
and she was really worried about it and it made me think this 
is quite a thing we’ve taken on, so by the time I got mine I 
similarly had my heart in my mouth and got really worried 
which is silly because we knew, I particularly knew, it would 
only raise your propensity by a matter of percentage points, 
it’s not a death certificate but … (Ian UP12) 
 
Jane’s reaction seems to prompt Ian to think about testing from a different 
perspective than previously, as indicated by the phrase “this is quite a thing 
we’ve taken on”. He then appears to consider the possibility that his genetic 
identity may contain something sinister and communicates his anxiety in 
relation to this in his use of rather powerful terms including the phrases “heart 
in my mouth” and “death certificate”. However, his subsequent use of the word 
“silly” suggests he later decided the anxiety was unwarranted. 
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Despite the difference in Jane’s and Ian’s experience of DTCGT, neither of 
them had initially been concerned about reifying their DNA through SNP 
genotyping and neither had specific health-related concerns that informed their 
imaginings or their decision to agree to accepting their relative’s gift. A few of 
the users had specific health-related concerns that influenced their thinking 
and I shall discuss these next, before completing the section on Imagining 
DNA, by discussing the tipping point in the decision to buy a DTCGT. 
 
Genetic identity and health 
The concept of a genetic identity influenced some users’ responsibility in 
relation to their health and this was used as a justification for testing. For Helen, 
Laura and Nicola, SNP genotyping was a way of getting health-related 
information independently of any healthcare professional, as this had proved 
unhelpful in their efforts to shed light on their chronic health-related problems. 
Barbara and Christine had pursued DTCGT partly out of concern about their 
family health histories, as had Keith, although his motivation was primarily for 
genealogical information. Rather than feeling anxious about potentially 
alarming information, most of these participants, along with the majority of 
users, referred to the disease-risk aspect of testing as knowledge to be used 
responsibly by themselves and possibly their relatives in the future. This could 
be explained as a normative responsibility to gain knowledge about their health 
through genotyping, which is rooted in understanding public health and a 
Kantian duty to the self (Jeske 1996). It also presents an additional biological 
facet to individuals’ manifold identity practices, as Novas and Rose suggest in 
their discussion of genetic identity (Novas and Rose 2000) By the powerful 
associations with personhood, it also indicates a moral basis for people’s 
thinking about their genetic identity and its implications for their biological kin. 
This is demonstrated in cancer genetics research including Hallowell et al’s 
study of women with breast and ovarian cancer (Hallowell et al 2003). 
Responsibility in relation to one’s health is also related to the third theme in 
this study, Testing the NHS and will be discussed in more detail in the section 
on Responsibility in Chapter Six. 
 
Nicola pursued testing because she imagined her genetic identity contained 
discrete information about an inherited disorder that conventional medicine 
  142 
could not and would not elicit. She was interested in her results for herself but 
also for her child, as she felt, in common with those who undergo genetic 
counselling and testing for inherited conditions, that this was a familial problem 
that could influence her child’s future. 
 
There’s something going on in my family; I need to know 
what it is not just for me but also for my child so I can guide 
them in their career choice and things like that. (Nicola UP17)  
 
The moral basis for her decision to test is framed in her responsibility for her 
own health, but she emphasises her responsibility in relation to the health and 
future well being of her child, a common justification for clinical genetic testing 
(Hallowell 1999). Results had implications for her child not only physically but 
also in relation to how Nicola parented the child to best deal with the potential 
impact of her genetic identity in future. 
 
Barbara, the genetic genealogist, had a significant family history of malignancy 
on both parents’ sides of her family. Her mother’s death from cancer, in 
association with her Jewish heritage, was the original trigger for her interest in 
genealogy, as she had wanted to trace her family lineage and health history.  
 
I’d already got hundreds and hundreds of birth, marriage and 
death certificates for my family so I knew the causes of death 
as well as the fact a lot of my family had died from different 
cancers which again is a common thing with Jewish 
genealogy, so on my mother’s side out of four siblings three 
of them died from cancer and on my father’s side, out of six 
surviving siblings four of them died from cancer, all different 
ones. So this concerned me. So I thought if this testing was 
available I’d like to know what genes I’d got or not. So I 
thought is it better to know or not know so I did think about 
this for a very long time, do I want to know or not because I 
had the option of, at that time on 23andMe you could opt 
either for just the family tree testing or the health testing or 
you could have both as a package. And I decided to go for 
both as a package. (Barbara UP3) 
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Barbara uses the phrase “better to know or not know” and emphasises her 
considered decision. This is indicative of her decision to exercise her 
autonomy and responsibility in relation to gaining information and potentially 
making choices about her health and lifestyle, which are overshadowed by her 
risk of cancer demonstrated in her family history and her Jewish heritage. This 
decision is in line with Chadwick’s assertions that genetic testing provides 
individuals with information that provides a basis for autonomy in relation to 
choice and responsibility, whether simply to oneself or to others (Chadwick 
1999).  
 
Helen and Laura both pursued SNP genotyping for information about life 
altering chronic health problems. Helen describes how she viewed any 
information as helpful and, as did Laura, imagined that gaining information 
about her genetic identity could hold potentially important information, if not 
now then in the future.  
 
I got a test because I’ve been very ill for 17 years and unable 
to work or do anything since I was in my early twenties. I’m 
desperate to try and find out anything that might explain any 
of it or give some clue as to something I could do that would 
help because it’s just got worse and worse ... there’s family 
history that suggests it’s at least partly inherited. So I thought, 
hang on, other ones [SNPs] that are relevant to this are 
included in the 23andMe profile and I’m interested anyway 
and there’s the ancestry, which is interesting and there’s all 
the rest of it and something might be useful in future so I just 
did the whole lot. (Helen UP10) 
 
Using the words “desperate” and “anything”, Helen shows how she has 
invested significant hope in accessing her genetic identity, imagining that it 
could provide some answers to her problems, if not now then in the future. 
This empirical discovery about herself aligns with Nordgren’s and Juengst’s 
observation that accessing one’s genetic identity, particularly when it is framed 
in the discourses of new technology and mainstream science, can be 
reassuring (Nordgren and Juengst 2009). This would be particularly 
understandable for Helen and Laura, who had failed to find diagnostic 
information, let alone treatments, elsewhere but who continued to invest hope 
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in the future utility of their test results. Their hopes in the future potential of 
SNP genotyping are different from Mokyr’s assertion that early hope in new 
technology usually results in later disappointment in relation to the truth that is 
revealed (Mokyr 1991). Perhaps this is because the uncertainty of SNP 
analysis has already been revealed and thus the hopes invested in genotyping 
in its earliest stages have been modified for those coming to it a few years 
after companies like 23andMe started. The inherent lack of ‘truth’ or certainty 
in the test results leaves the way open for people’s hope to shift from the 
DTCGT itself to future possibilities for the interpretation of their data or broader 
developments in genomic analysis for health (Arribas-Ayllon et al 2010, Tutton 
2012). 
 
Having discussed participants’ learnedness and curiosity in relation to 
imagining DNA, I will now go on to explore the tipping point. This refers to the 
point at which users decided to buy a test and commit to establishing or 
extending part of their genetic identity, having previously contemplated 
personal genomics in imaginary and theoretical terms or in a more limited way. 
 
The tipping point  
Whatever the users’ individual expectations of DTCGT and motivations for 
pursuing it, almost all decided to buy DTCGT at a certain point after a period of 
deliberation. I refer to this as the tipping point, although the metaphor is not 
being used in strictly the same sense that it is usually employed. Here I shall 
first outline the origins of the phrase and then discuss it in relation to the 
participants’ decision to purchase a DTCGT. 
 
In the 1950’s sociologist Morton Grodzins wrote about the “tip point” or tipping 
point, in relation to changes in racial demographics in American cities 
(Grodzins 1957:34). He described both African Americans and real estate 
agents using the phrase to describe how the racial demographic of a 
population in a given area would “tip” (from a Caucasian to African American 
majority); once a threshold number of African Americans had moved into an 
area the majority of its remaining Caucasian population would move out. 
Gladwell used the term rather more recently in his book “The Tipping Point”, 
since when it has become more widely used (Bhatanacharoen et al 2004). 
Gladwell refers to three rules that result in a sudden shift in group behaviour: 
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the Law of the Few, the Stickiness Factor and the Power of Context (Gladwell 
2000). A dramatic change in behaviour requires 
1. a few key people who drive or initiate the change by spreading the word about 
the issue by virtue of their knowledge, by knowing a lot of people, or by their 
charismatic nature and skills of persuasion, 
2. the new thing to be memorable so that it sticks in people’s minds, 
3. the context in which it is happening to be apparent and relevant to others; that 
is, the environment needs to support the move. 
 
I would not suggest a tipping point has been reached, in any literal sense of 
uptake of DTCGT in the UK. However, I would suggest that within the group of 
the UK’s early adopters of DTCGT, there are key factors that relate to each of 
Gladwell’s three rules. First, uptake of testing can be seen to relate to key 
people in genetic genealogy and genetics research who have acted as “key” 
selectors (my emphasis of Gladwell’s rules) and been instrumental in setting 
up networks of support and information dissemination about testing (see 
Expectations in Chapter Three). Members of ISOGG and genomesunzipped 
spread the word about DTCGT within their respective communities, raising 
people’s awareness of it. Second, 23andMe have a captivating approach to 
their marketing that is likely to “stick” in people’s minds. This includes their 
tropes of democratisation of genomic data, their invitation to interact with their 
DNA and alter their life-styles in accordance with results and an apparently 
altruistic commitment to genomic research that their community embraces. 
Finally, and as will be seen from the data below perhaps most importantly, the 
“environmental context” has to be conducive, and I would argue that this 
context is the financial environment. The most common criterion mentioned by 
almost every participant as a deciding factor, after his or her period of 
deliberation about buying a test, was the cost. Whilst not everyone paid the 
same price for their tests, the majority paid a fee of $99 because they 
purchased the test either when 23andMe were doing a promotional sale or 
during the period when 23andMe dropped the price of the test itself. However, 
the real incentive for most of the users appeared to be a price reduction or 
advertisement of a special offer, regardless of the actual cost of the test. This 
pattern of decision-making in relation to purchasing goods is supported by the 
economic theory of the Law of Demand in which the price of goods is inversely 
related to the demand for them; the cheaper a product becomes, the more 
people will buy it, assuming other factors remain constant (Hildenbrand 2014). 
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The decision to buy was made after a period of deliberation and the terms that 
describe the financial basis for the decision provide evidence of a justification 
for it. SNP genotyping became cheap enough to justify the purchase, rather 
than it being an expensive and impulsive decision. What this also indicates is 
that most people considered their decision to test for some time and followed 
the companies’ websites, using their information and changes in prices to 
inform their decision.  
 
The genetic genealogists’ networks update them with current developments in 
genetic genealogy and genomics. ISOGG has a wiki where members post 
information and updates that facilitate the communication of current events 
and links to other similar online resources. The participants who are genetic 
genealogists either bought a test at the price it was advertised when they were 
particularly interested in it (Barbara and David) or, more commonly, described 
watching the updates on various websites and then spotting a reduction in 
price or a special offer (Alan, Ann, David, Geoffrey, Keith). 
 
Ann, a local administrator for the England group of ISOGG, describes her 
decision to buy a test. 
  
I eventually got involved when 23andMe had a sale and they 
were selling the test for 99 dollars just for a couple of days so 
I, coz I think it was 399 dollars at the time which I thought 
was, I just didn’t think it was worth it, but at 99 dollars I 
jumped in to try it. (Ann UP2) 
 
Ann’s reference to getting involved “eventually” shows how she had debated 
buying a 23andMe test for some time (in addition to the genetic genealogy 
tests she had taken earlier). The special offer at a reduced, affordable price 
“for just a couple of days” gave her the impetus to buy the test. 
 
David, Keith and Geoffrey describe similar situations, where advertisements of 
special offers persuaded them to buy after a period of thinking about testing 
with 23andMe (i.e. obtaining further genealogical information and additionally 
extending their genetic identity in relation to physical characteristics, disease-
risk and carrier status). David judged his test to be expensive but managed to 
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get a free one for his son and another for his wife as a special offer, which he 
felt offset the price he paid for his own test. 
 
Users who were scientists were similarly influenced by the price, as indicated 
by Fiona and Maria, who demonstrate the importance of the price in tipping 
them to their decisions to get a test. They had watched the prices reducing 
over time, whilst they were debating testing, and decided to buy the test when 
the price (for 23andMe) reached a point they considered reasonable. 
 
And it [23andMe test] finally hit the price-point where I 
thought “Yeah, it’s not a lot of money”. (Fiona UP8) 
 
Also influenced by price, although not paying for it personally, Kirsten selected 
her test on the basis of cost, having investigated various companies’ products. 
 
So I did my homework and I looked at primarily 23andMe and 
deCODEme and deCODEme was well over 1000 dollars at 
the time … I’ve got a slide in a seminar I give that shows the 
shopping basket with the figure down at the bottom and 
everyone is always appalled when I show it; and 23andMe 
was down at, I think I paid 200 dollars for my test, so I went 
for that one, just purely on price. (Kirsten UP14) 
 
Although she says the price drove her final decision, Kirsten had also looked 
into what different companies offered and chose 23andMe as being cheaper 
whilst providing similar information. She justifies her choice on the basis of 
personal research, as well as the price, and seems to be trying to provide 
evidence of that justification by describing students’ reactions to her decision, 
which align with hers. 
 
Carol and Christine both decided to buy a test after being introduced to testing 
by others and then researching SNP genotyping for some time. The basis for 
their decision was that it was affordable to them. Christine considered the price 
of DTCGT in the context of costs of sequencing, demonstrating how the 
amount of money involved is key to most of these users’ final decisions to 
engage with DTCGT. 
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I mean I certainly wouldn’t pay 1000 pounds to have my 
genome sequenced properly, but paying 150 quid to find out 
SNPs and that, is accessible. (Carol UP4) 
 
Unlike Carol, Helen and Laura were interested in WGS to shed light on their 
health problems. But their views on the costs of testing were still key in terms 
of tipping the balance in relation to their decision to test with 23andMe 
because for them it was an affordable option. Like Carol, they said that WGS, 
whilst important to them, was not affordable which perhaps equates to SNP 
genotyping being a justifiable expenditure. 
 
Personalising DNA relates to people’s imagination about their genetic identity 
facilitating embodiment and the experience of embodiment, influencing the 
imagination thereafter. Whilst acknowledging this dynamic, I feel it is 
necessary to separate imagining from embodying DNA in order to give due 
consideration to participants’ thinking about DNA and their experiences of SNP 
genotyping as part of personalising DNA. Contrary to concerns about 
DTCGT’s capacity to cause harm outlined in Chapter Two, the users in this 
study appear to view personal genomic information as expanding their identity 
practices and satisfying curiosity in a fashion that could be construed as 
relatively light-hearted, given their final decision to test seems linked to saving 
money. This is further supported by evidence of their general lack of behaviour 
change, which is demonstrated in the following part of this chapter. Next I will 
examine how users embody their DNA following SNP genotyping and the 
parallel experience of clinicians who were involved in counselling DTCGT 
customers. 
 
Embodying DNA 
In using the phrase ‘embodying DNA’ I refer to the process of using newly 
acquired knowledge of DNA (in this instance by SNP genotyping) to develop or 
change one’s feelings, understanding of identity and corporeal behaviours or 
practices of the body. In proposing that genomes are “incorporated”, O’Riordan 
suggests that genomes are embodied in individuals’ lives in both thoughts and 
bodily practices, influencing them in multiple arenas rather than simply in 
altered behaviours (O’Riordan 2010). 
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In this section I shall initially consider users’ experiences of testing and 
receiving results and the impact embodying DNA had on their identities. I will 
follow this with an exploration of the clinicians’ experiences of embodying DNA, 
which focused on interpreting concepts for disease risk. This invites 
exploration of how referrals for consultations for SNP genotyping interpretation 
were made to their departments and how consultations were experienced, as 
well as consideration of how SNP genotyping is being mobilised in a different 
manner in one clinical setting. 
 
Identity and embodiment 
Although Rabinow’s proposed biosociality argument implies that people adopt 
a genetic identity that goes on to influence their sociality, Novas and Rose 
suggest that genetic identity practices are only a part of people’s identity within 
their multifaceted worlds and the plurality of both their identities and the 
networks they are engaged in (Novas and Rose 2000, Rabinow 1996). 
Novas’s and Rose’s suggestion is more congruent with my data, which show 
users’ reactions to their DTCGT is an extension of their identity within the 
context of the multiple aspects of their identities, rather than simply a 
genetically deterministic one. Whilst participants described embodying DNA as 
being actively aware of this additional genomic aspect of their identity, few, if 
any, demonstrated any embodiment in the sense of anxiety or altered body 
practices that were sustained beyond a few weeks in common with previous 
research findings (Van Ommen and Cornell 2008, Bloss et al 2011, Kaphingst 
et al 2012). 
 
To examine how the users engaged in identity practices through SNP 
genotyping, I will discuss how their embodiment of their DNA through learning 
and understanding, incorporating health information and discussing their 
results with family members contributed to their identity. Finally, I will explore 
participants’ contradictory views about their DNA and how they subjectively 
contested the aspects they were unwilling to embody. 
 
Many of the participants described genomic information as valuable to their 
identity. Alan, Ann, Laura and Maria all specifically referred to embodying their 
DNA in relation to valuing having this additional knowledge about themselves, 
suggesting that embodiment was empowering. For genealogists Alan and Ann 
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and chronically ill Helen there was an attraction in having their raw DNA data 
to ponder and manipulate. 
 
I satisfied myself and others that you can interpret … data 
applied to genealogy data and make connections. (Alan UP1) 
 
Alan, a committed genetic genealogist and retired chemist, shows how he 
used his raw data productively. In respect of his genealogy he extended his 
knowledge of himself and his relatives and his ability to use genomic data 
effectively in doing so. His phrase “satisfied myself and others” demonstrates 
the relationship between personalising DNA and developing the language and 
skills to socialise it.  
 
An extension of genetic identity was realised by the potential for finding 
relatives with genetic genealogy. Whilst most users found their genealogy 
results interesting or, in Jane’s case, distressing (as outlined in Chapter Four), 
of the genetic genealogists only Alan, Geoffrey and Keith reported finding 
useful data in the form of new relatives. The others either did not comment on 
it or felt it was disappointing, but this subset of participants was already familiar 
with genetic genealogy.  
 
Others described their learning and understanding in relation to the process of 
SNP genotyping and how results are communicated, in addition to extending 
their own identity into the genomic. Ann, Fiona, Kirsten and Maria all valued 
having the opportunity to experience the process of testing from getting 
information and buying the test online to embodying their DNA through the 
practice of spitting and then mobilising their DNA using the Internet as the 
portal through which to access it. All these women referred to being interested 
in the process. Fiona specifically referred to the practicalities of producing a 
sample. 
  
It was interesting just to go through the process and get the 
tube and generate quite that much saliva! (Fiona UP8) 
 
Conveying the patience and effort required to produce the sample represents 
Fiona’s commitment (and by extension that of all the users) to move from 
imagining their DNA to embodying it. Kirsten expressed her experience of the 
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beguiling effect of the embodiment of her SNP data on the computer screen, 
despite her expertise in dealing with this type of data in her daily work.  
 
When I drilled down into it I carry the [x] allele for [x condition] 
which of course confers a high risk and so most of it came 
from that single variant, so I started to get slightly more 
impressed at that point because I thought it is actually, you 
know I’m picking up something that I had some interest in or 
something I thought I should be at increased risk of. And then 
after that the numbers dropped off fairly substantially we 
were down to an increased risk of 1.23 for [site] cancer or 
something, which is neither here nor there really. But it’s 
quite seductive when you look at that screen and it’s your 
results there … I was quite surprised how seeing those 
numbers - your numbers - in print on the screen gives them a 
level of value beyond what you might expect. (Kirsten UP14) 
 
Her references to the seductive nature of seeing her results and her numbers 
on the screen shows the initial impact of embodiment of her genetic identity; 
her identity and risk materialise on the screen. In common with other users 
who were scientists, Kirsten was clear about the contingent nature of SNP 
genotyping data, but this description conveys how powerful the initial 
impression of her data was for her personally despite this knowledge. Carol 
and Christine, the public health researchers, described similar responses to 
their first impression of their results, being initially mesmerised by some of their 
disease-risk results. For all three this initial fascination appeared to abate 
within weeks of having the results, as I will explore in the section on 
Contradictions and contestation. Prior to that, the next section considers 
people’s responses to the disease-risk aspect of their test results and how they 
embodied their DNA in relation to them. 
 
Embodying DNA for health 
Most users’ reactions to the health aspects of their tests ranged across a 
spectrum from scepticism or disappointment, to being initially somewhat 
mesmerized by the disease risk information. In those for whom the main 
motivation for testing was health-related, a lack of relevant information resulted 
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in their returning to future hope and expectations. Only one user, Barbara, 
sought further advice from healthcare professionals as I shall demonstrate 
shortly. Participants who tested for genealogical or general curiosity viewed 
their health risk results as conveying interesting information but nothing they 
should take specific action for, other than the generally established knowledge 
that exercise and diet are the key factors for a healthy life. They largely viewed 
results as providing only part of the picture rather than being deterministic. 
They were also informed by and justified their results in relation to, their family 
health history, their lifestyle and environmental factors that are known to 
influence the onset of common complex diseases.  
 
Some users relied on moral justifications for testing when referring to disease-
risk results. Receiving results from the SNP genotyping appeared to have 
influenced some users’ perceptions of their potential for developing certain 
common complex diseases, resulting in their expressions of the need to be 
vigilant and think about their lifestyle in future, or advise family members of 
how they might be affected but without provoking anxiety. This normative 
responsibility to gain knowledge about their health, which is rooted in public 
health and a Kantian duty to the self, may have been affirmed by 23andMe’s 
reliance on the tropes of personalisation and responsibility in relation to health 
information; both genealogists and scientists suggested that the moral aspect 
of embodying DNA is relevant, irrespective of original motivations for testing. 
 
David’s references to finding this knowledge useful, both now and in the future, 
is representative of many of the users’ views on this point. 
 
It’s nice to be aware of that and watch out for any signs in the 
future … it’s better to know than not know because you can 
do something about it. (David UP6) 
 
He uses the phrase “better to know than not know”. This is indicative of 
David’s decision to exercise his autonomy and responsibility in relation to 
gaining information and potentially making choices about his health and 
lifestyle, although he had not in fact made any changes. This is entirely in line 
with Chadwick’s assertions that genetic testing provides individuals with 
information that provides a basis for autonomy in relation to choice and 
responsibility, whether simply to oneself or to others (Chadwick 1999). 
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Having had extensive experience of consulting with healthcare professionals 
for her chronic health problem, Laura similarly identified that genomic data 
gave her the novel advantage of autonomy in relation to managing her health.  
 
It’s nice to know more about myself … it doesn’t worry me. I 
like to have as much information as possible. I know it’s a 
tiny snapshot but I like having control … it gives you a 
chance to plan. (Laura UP15) 
 
Laura’s quest for information shows her interest in extending her 
understanding of herself, here by embodying her DNA. She assumes the value 
of this information for health is limited but appears to value it in a qualitative 
sense, in that the impression of autonomy and control it provides are 
paramount for her. 
 
Disease-risk information was of primary interest to a few of the users and I will 
consider these people’s discussion about their health results next. Barbara, 
Christine, Helen, Laura and Nicola had all tested in order to try and reify their 
imagined genetic causes for their health concerns. These included a familial 
history of malignant disease or an experience of other chronic illness which 
conventional medicine had not been able to help them with.  
 
Helen, Laura and Nicola were all interested in SNP genotyping as a means to 
extend their identity practices independently of conventional health care. Helen 
and Laura were interested in gaining any new information possible. When SNP 
genotyping did not reveal anything specifically related to their troubles, they 
both justified their decision to test with the interesting nature of the information 
gleaned, embodying their DNA by investing hope in the future potential of their 
genomic data. More specifically, Nicola described searching for a diagnosis, 
which arguably equates to establishing some certainty in the face of an 
indeterminate future. The following demonstrates the importance of extending 
her identity practices in this way. 
 
I decided 23andMe offer genetic testing, I’m going to spit in a 
tube and send it off to them. And I did that and I got the 
results and I was fascinated by them. The reason that I found 
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it interesting was that when you have a condition for which 
there is no real clinical diagnosis you never really know 
whether you have it or not. I read a book on [disease]; the 
first chapter I went to was genetics. And in that chapter he 
said, “Why bother with genetics? We can’t give you a cure 
even if we know what’s wrong with you.” And I threw the 
book in the fire in frustration because it’s not just about 
getting a cure. It’s not about directing drugs because of my 
genotype. It’s about understanding what is going on in my 
family so that I know what I’ve got, you know and getting a 
diagnosis is almost just as good as getting a cure. So this 
was my thought process behind the whole thing. (Nicola 
UP17) 
 
In common with many other participants, including Laura, Nicola is a biologist 
with extensive experience of genetics and so had knowledge and experience 
on which to imagine her DNA. However, it is clear from this excerpt that 
extending her identity into the genomic so that she could embody her DNA in 
the form of a diagnosis for her problem was her overriding concern at that time. 
She clearly indicates her frustration with a professional view that genetic 
identity is irrelevant due to the lack of effective treatment and pursued her 
identity practices in this arena, like Helen and Laura, to be able to have some 
autonomy in relation to her health.  
 
For Helen, Laura and Nicola, their bodies have represented sites of 
contestation between numerous actors, including medical professionals, blood 
and tissue samples, technologies for investigating and embodying aspects of 
their anatomy and physiology, texts that circulate as a result of consultation 
and investigations and family members who support them. Their experiences 
have rendered them de-centred and transformed into objects for others to 
challenge as sites of social contest, as Foucault suggested in discussing 
medicalisation (Foucault 1994). These women have arguably embraced SNP 
genotyping as a means to extend and assert their identities through their DNA 
in a novel network, where they are in a position to exercise autonomy and 
authority as actors rather than as passive objects.  
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Barbara and Christine were both interested in SNP genotyping because of 
their family histories of cancer, although this was not their only motivation for 
testing. The elevated risk of a specific cancer in Barbara’s test result linked 
directly to this family history of the same type of malignancy (not breast 
cancer) and this prompted her to seek medical advice. 
 
And it seemed to show I had a particular gene which seemed 
to be the same one my father had because he died of [site] 
cancer. So then I thought, well what shall I do with this? I 
thought I’ll go and ask my doctor (GP) and ask “What shall I 
do?” So I went to my doctor and they referred me to the 
[name of specialist cancer centre] Hospital being only down 
the road. So I went to see this lady who was the lead for 
breast cancer … non-breast cancers were of more interest to 
me but the health community was concentrating on the 
breast cancer issue rather than the other ones for [Jewish] 
women. We did a family tree, I knew sufficient information to 
show her where all these cancers lay [who was affected in 
the family]… I took along the print that I’d got off 23andMe. 
So she explained to me, it’s not got to be just one marker it’s 
got to be a range of markers and they’re going to interact 
with each other. And she explained that the biology would 
interact with the environment so you need to take into 
account what happens in your lifestyle what you eat and all 
this sort of thing. I was relieved, one marker wasn’t it, there 
had to be more … several people have told me since, rather 
more cancers were from an environmental background rather 
than a genetic one, but that the mixture of the two would set 
it off. (Barbara UP3) 
 
Barbara describes her initial concern at finding a marker in her SNP 
genotyping results that seemed to correspond with a risk for the same 
malignancy that had caused her father’s death. In trying to establish whether 
this marker would be a problem for her health in the future, Barbara was able 
to provide important family history detail at the consultation. Despite seeing an 
oncologist who specialised in breast cancer (rather than the site her family tree 
indicated), Barbara describes being reassured by the explanation that 
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environmental factors were as important in cancer development as the genetic 
ones and that genetic predisposition was polygenic. Her embodiment of her 
DNA shifted to incorporate the narrative from this consultation as well as her 
SNP genotype and family history, in line with Kelly’s assertion that experiences 
including knowledge of risk and genetic counselling are significant in genetic 
embodiment (Kelly 2007). 
 
When embodying their DNA, most users demonstrated integration of this new 
aspect of their identity into their existing, complex and compound identities, 
although this was often problematic, in that some aspects were more easily 
integrated than others. In the following section I will explore the contradictions 
in participants’ justifications for incorporating or rejecting different aspects of 
their DNA. 
 
Kinship and belonging 
Sharing SNP genotyping experiences and results with others is an aspect of 
Socialising DNA as discussed earlier in Chapter Four. However, this activity is 
also part of embodying DNA, in that it facilitates people’s sense of individually 
belonging to a group with whom they share knowledge, experience or 
embodied DNA (O’Neill 2007). Family bonds and memories contribute 
significantly to people’s identities and are influenced by their embodiment of 
their DNA, which is why this aspect of the data is discussed here.  
 
Whilst not everyone decided to share their results with family, the majority did 
so. Some users indicated that sharing their test results with family members 
both added a genetic dimension to the familial aspect of their identity and 
provided a vehicle (through the discussion about common physical traits) for 
more serious discussion about disease risk, or, in Jane’s case, ethnicity. 
Christine, David, Elizabeth, Jane and Laura all told me about discussing 
results with family members who had been tested, looking for similarities and 
differences. Two genealogy group members, Ann and Keith, described sharing 
test information with others in their groups. Three people referred to the traits 
information specifically, which related to learning about themselves and family. 
For Christine, whose parents had both recently been diagnosed with terminal 
cancer, sharing her test results with her siblings (who do not have her science 
background) was important. She initially talked about discussing physical traits 
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and then went on to share her raised risk of particular cancer markers relevant 
to their parents’ illness. 
 
It was lovely to read about familial traits because on the side 
of the results they also talk about phenotypes, someone can 
curl their tongue in the family…so it was pitched at a level of 
seriousness but it was also quite fun [like] “Do you sneeze in 
the sun?” and that. We talked about [who had what in the] 
family … there were [site] cancer markers and that was 
something I shared with my siblings as well, apart from the 
general practitioner mentioning to us we might have a familial 
problem … having two parents suffer so much, thinking you 
don’t really want to go down that way either. (Christine UP5) 
 
Christine indicates using the trait SNP results to reconnect with her siblings 
through shared memories of family traits. She also said it was important that 
they were aware of her cancer marker results, as she interpreted this genetic 
aspect of her identity as supporting the warning from the family GP about a 
familial aspect to their parents’ diseases. This suggested that Christine and her 
siblings would use this knowledge to exercise vigilance in relation to their 
health in future in order not to “go down that way either”.  
 
Barbara decided not to share her results (including her increased risk of 
cancer) with her family, including her two children who were in their twenties. 
She explained that they knew about the family health history of cancer and did 
not need to know about her DTCGT results at this time in their lives. Barbara 
appears to have confined her avid interest in genetic genealogy to her own 
identity practices, rather than sharing results and encouraging other immediate 
family members to test, unlike other users. This struck me as a contradictory 
decision compared with other users and Barbara’s interest in her wider family’s 
health history. However, the following section will demonstrate more specific 
examples of the thorny issue of users’ selective approach to embodying DNA.  
 
Contradictions and contestation 
O’Riordan describes embodiment as problematic when it challenges the 
individual to have to assimilate unwanted characteristics into their identity 
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(O’Riordan 2010). Participants appeared to be selective about which aspects 
of their SNP genotyping to incorporate into their identities and which to reject 
or ignore, mostly relying on the argument that SNP genotyping is known to be 
of limited validity and utility to explain which to ignore, thus demonstrating 
interpretative flexibility (Bijker 1997). Having mulled over their results for a 
while, others suggested that they realised ignoring public health advice 
because of their test results was probably not sensible. Several of the users 
contradicted themselves when telling me about their interpretations of their test 
results. Their accounts bear a striking resemblance to O’Riordan’s descriptions 
of “preferred readings” of the genome, in that not all the users adopted the 
novel genomic aspect of their identity without disagreement or a lack of 
embodiment in terms of altered behaviour, despite expressed intentions to do 
so (O’Riordan 2010:4).  
 
Nicola’s interpretation of her results demonstrates interpretative flexibility. She 
initially used her test results to try and explain the signs and symptoms of an 
undiagnosed complaint. The negative results in her SNP variant was later 
undermined when she was diagnosed with the condition she had suspected. 
This is why she refers to “how limited 23andMe are”, but she then immediately 
goes on to attribute a different physical abnormality to her test results as well 
as her tendency to overeat. 
 
And I also had a lot of fun going through my 23andMe results 
because it’s, I do find it fun. I’m very much aware because of 
my background that it’s very, very limited in terms of scope 
across the genome. One of the questions in my own head, 
because I couldn’t get to see an NHS consultant, I was trying 
to self-diagnose, was “Is there any chance I could have 
[chronic disease]?” So I looked at the risks in the SNP call 
out [results] and it said I had no increased risk. So this really 
puts it all in context how limited 23andMe are but still it was a 
starting point for me. At least I could explain my [physical 
abnormality] and I also know I have a genetic tendency to 
over eat, it’s not just greed! So I do find it fun. (Nicola UP17) 
 
This acknowledges the lack of utility of SNP analysis, but cannot totally 
discredit it in relation to traits that appeal, showing her embodiment of her DNA 
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in a discriminatory fashion and her essentialist interpretation of the results 
despite her knowledge of genomics. 
 
Carol, Christine and Kirsten (all female scientists in their 40s) describe being 
initially captivated by some of their results, but this did not last, nor result in 
any changes in their understanding of the contingent nature of DTCGT. Carol, 
in particular, reacted deterministically to some of her results initially but then 
resumed her former lifestyle choices. 
 
Having seen that I don’t have my mother’s diabetic genes, or 
risk factors, then I thought “It’s OK to eat sweeties” ((laughs)) 
because I haven’t been eating them up until that point. It was 
like being given a free pass on the food front for a month and 
then I thought, “Just stop being silly and go back to what you 
were doing before.” I’ve got over it now but it did make me 
think, “Yeah I can do different things behaviourally” because 
there are certain things; I mean I’m less likely to get 
melanoma than most people so I’ve been out in the sun … it 
is impacting on my behaviour in potentially unhelpful ways, 
umm, but you know it’s like, again next week I’ve got to go up 
and have breast screening which, umm, oh it’s just awful. I 
don’t have any BRCA genes so is there any point in my being 
screened? I mean there probably is because there are other 
causes of breast cancer but you know, it’s making me 
reconsider those sorts of choices. (Carol UP4) 
 
This example plainly shows how Carol has embodied her DNA in working to 
understand and assimilate its challenges to her identity. She seems initially to 
use the results to justify engaging in potentially risky behaviour (eating what 
she likes and sunbathing). This is despite her knowledge and understanding of 
public health and the role genetics plays in the aetiology of common complex 
diseases. She describes having to make decisions about her lifestyle, which 
encompass both her prior knowledge of public health, her knowledge of 
genomics and the novel genetic aspects of her identity. She seems to have 
achieved a balance, as evidenced by the phrase “I’ve got over it now but it did 
make me think”, and later in the interview she justified her decisions by saying 
“it’s SNPs so there could be mistakes, anomalies.”  
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Many participants referred to making room for uncertainty in SNP testing, 
whether in terms of the inadequacy of current knowledge related to genomics 
and health risks or in relation to understanding the small part genotype plays in 
common complex disease development. Fiona, one of the scientists in her 
early 30s who has had a long-term condition since childhood, excused the 
anomaly between her results and her actual health as being due to bad luck.  
 
That was the most surprising thing was that I was not even at 
normal risk for that I was at low risk for it. When you go and 
look at it there are several alleles some of which I’m on the 
negative side for and some of which I’m on the positive side 
for and they decided that the positive ones are more 
protective than the negative ones are bad and I suspect that 
actually means they are probably all independent things and I 
was probably just unlucky. (Fiona UP8) 
 
Despite telling me that, as a genetic scientist, she had a clear understanding of 
the contingent nature of SNP genotyping information, this excerpt indicates 
that Fiona initially looked for genetic answers to her condition. She was 
evidently surprised that the results contradicted her phenotype, but she 
attributes this to luck, arguably identifying with a genetically essentialist 
interpretation at this point.  
 
Brown and Webster suggest that because genetic testing is inherently linked to 
our sense of self and individuality, it is compelling in relation to both fascination 
and anxiety (Brown and Webster 2004). Whilst the majority of users clearly 
demonstrated fascination at the prospect of delving into their genetic identity, 
most conveyed a sense of pragmatism about the deterministic nature of SNP 
genotyping in relation to health. Whether this was influenced by their 
knowledge or research into the poor validity of SNP genotyping, or their 
unwillingness to embody their DNA by incorporating disturbing results and 
change into their identity (or both) is not clear. 
 
Before moving on to discuss clinicians’ embodiment of DNA, it is worth 
mentioning that Jane’s and Ian’s reported experiences of embodying DNA 
seemed to converge with other users’ experiences, despite their obvious 
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differences in socialising and imagining DNA. Both shared their results with 
family members and expressed intentions to act on some results by employing 
health screening, demonstrating the normative responsibility towards their 
health that I discussed earlier in this chapter.  
 
Genetic risk as embodiment 
Clinicians’ experiences of embodying DNA from SNP genotyping relates to 
helping consultands to understand and, in turn, embody their own DNA. 
Genetic counselling in this context helps people understand the concept of risk 
and the meaning of the numbers associated with their SNP variants. All the 
clinicians involved also described used their more conventional surveillance 
tools, including taking a detailed family history from the consultands, 
demonstrating an adherence to their group’s professional procedures in 
approaching DTCGT that could be interpreted as strengthening their case in 
relation to their views of DTCGT.  
 
In this final part of this chapter, I shall first outline how potential referrals for 
interpretation of DTCGT to genetics departments were handled in the 
departments the participants worked in, as this contributes to understanding 
the context of the limited number of consultations that occurred. I shall then go 
on to discuss how the clinicians embodied DNA in the consultations that were 
described to me, or in other ways and their learning and thinking as a result of 
those experiences.  
 
Many of the clinical genetics professionals described how their departments 
had anticipated a deluge of referrals of patients for discussion of DTCGT that 
had not so far materialised. This was empirically supported by the difficulties 
recruiting clinician participants to my study, as outlined in Chapter Three. It is 
also unsurprising, given the evidence from the users’ interviews that showed 
they did not seek referral. As demonstrated in Table 3.1 earlier in this chapter, 
of the 17 users interviewed only Barbara had been referred to a hospital 
consultant by her GP and that consultant was an oncologist specialising in 
breast cancer rather than a clinical geneticist. Literature published at the time 
personal genomics companies proliferated anticipated increased referrals to 
healthcare services for interpretation of personal genomics tests (etc Group 
2008, Lenzer and Brownlee 2008, Jordens et al 2009). It is likely that the 
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clinicians in this study were aware of this and that it had influenced their 
expectations of having increased referrals of worried-well DTCGT users from 
GPs needlessly taking up scarce clinical resources. Along with the knowledge 
circulated about SNP genotyping this may have contributed to their 
understanding of DTCGT and its potential to cause people unnecessary 
anxiety. With the professional rhetoric associated with genetic counselling, this 
technological frame could be interpreted as employing their obligations to 
support their case against DTCGT in the wider context of the NHS by working 
to exclude DTCGT users from their clinical work. 
 
Only one clinician reported that her department would see anyone who was 
referred. Half of the clinicians indicated that their departments would discuss 
the referral at triage, as with any other referral. They would only agree to see 
the person if their department’s usual referral criteria applied; that is, the 
person being referred to discuss their DTCGT also had a family history of 
illness with a known genetic connection. The remainder of participants either 
did not know about their department’s referral criteria or had no policy for 
DTCGT referrals because there had been none so far. Only one of the 
participants familiar with the referrals and triage for their department was 
aware of a referral being ‘bounced’ back to the GP (refused) and described the 
consultant’s emphatic response to the referral. 
 
We’ve had one patient that was discussed at the weekly 
meeting that someone said, “This came in from the GP who 
said the person wants to discuss their results.” And I can’t 
remember what test it was but it was a kit (DTCGT) and the 
lead consultant went “Nah, we’re not touching it with a 
bargepole because we don’t know what to advise, what to 
say. We don’t want to get caught up in that.” (Nurse CP12) 
 
Though this excerpt reports someone else’s response to the referral, the terms 
in which it was conveyed to me imply an authoritative, but simultaneously 
revealing, response. The phrase “we’re not touching that with a bargepole” 
suggests a powerful message to the entire department that they do not want to 
be held responsible for any advice they may give these consultands, while the 
phrase “we don’t know what to say” suggests that this novel technology is 
outside the realm of current clinical genetics practice in that department. This 
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could be explained by the provisional nature of both the technology and the 
data it yields, arguably being outwith the core set expertise of this group. It 
could also be seen in terms of this relevant social group’s response to the 
technology; using their normative processes and conventions as robust 
platform from which to make their case for not engaging with the technology. 
 
In view of most departments’ policy of not seeing people simply to explain a 
DTCGT, I wondered if referrals had not been processed beyond the initial 
enquiry. But most of the clinicians suggested that referrals were never made, 
rather than being refused and returned to the GP. Most clinicians expressed 
surprise, as they had anticipated a deluge of referrals to interpret DTCGT 
following the publicity and publications associated with the launches of the 
high media profile personal genomics companies. One doctor equated the lack 
of referrals to a lack of uptake of DTCGT by the public, though it was not clear 
to me how she reached this conclusion. This could be interpreted as her 
projection of her own understanding of the lack of utility of DTCGT onto the 
public.  
 
The interesting thing is it seems that the public have already 
realised it’s not that useful. We’re not being inundated with 
people having had it at all. (Doctor CP11)  
 
Of the 16 clinicians interviewed, half had counselled someone in relation to 
some type of DTCGT and 2 had additionally discussed enquiries about 
DTCGT results from GPs11. Some of these referrals were made because the 
person also had a family history of cancer and was concerned about their own 
risk of developing a malignancy, or they were anxious about their health in 
relation to another long-term condition of which there was a history in the 
family. In the consultations that were described, the clinicians generally 
established the patient’s concerns and proceeded to discuss the relative risks 
to the patient on the basis of the knowledge provided by the test in question 
and their family history. Further testing was offered as indicated. Given that 
                                                
11  Most of these consultations were for referrals agreed to either because the 
consultand fell into the category of acceptable referral due to family history of genetic 
disease as well as having bought DTCGT, or because they were referred to one of the 
departments that had no agreed referral criteria. 7 consultations were for DTC SNP 
genoptying for common complex disease risk. CP5’s DTCGT consultands were all 
journalists and their consultations were non-NHS. 
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patients had been referred to the Clinical Genetics or Oncogenetics 
Department (in one doctor’s case), it is understandable that clinicians 
described these specific consultations in the context of their usual genetic 
counselling consultations, as illustrated below. 
 
I explained at the beginning of the consultation we were 
mostly going to be focusing on his family history of cancer 
because that was his reason for referral and that was the 
reason we were seeing him in clinic, but that I was willing to 
look into and try and interpret his 23andMe analysis if he’d 
like me to. What he was most anxious about, was his 
23andMe analysis had told him that he was a significantly 
increased risk of diffuse [site] cancer. Now that rings alarm 
bells for us because there is an inherited pre-disposition to 
diffuse [site] cancer and it’s a horrible condition, that was 
quite a long way down probably about half way down the 
page but the marker wasn’t in the gene we look at and he 
had no family history [of that site of cancer]. But the things 
that were at the top of his list of risks he completely ignored. 
One was osteoarthritis and the other was non-cancer related, 
they were clearly things he wasn’t worried about and they 
were the only things that he was a significant risk for. The 
next things on the list were [site] cancer and [site] cancer but 
their increased risks were something like 0.2 percent to 0.26 
percent and that was an increased risk! I think that numbers 
are really hard. We come across this all the time when you’re 
trying to deliver information to somebody about a risk in a 
way that’s meaningful to them. If it’s at the top of a list and it’s 
in bold and it’s got an up arrow saying “increased risk” that all 
means far more than the numbers that say 0.2-0.63. 
(Scientist CP3) 
 
This scientist described the consultand’s reaction to his test results being 
driven by his anxiety about developing a specific cancer (of which there was a 
history in his family, though it was not the type of cancer referred to above). 
She was able to allay his concerns and explain the meaning of the 
percentages that the report presented, giving additional interpretation to the 
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report, shifting the consultand’s understanding and thus his embodiment of his 
DNA. She was interested in his fixation on one particular result in the report, 
which, with his family history, led to him embodying his DNA in a more 
deterministic manner. But she also pointed out the difficulty people have in 
understanding risk, an opinion voiced by several of the clinicians.  
 
One senior nurse recounted her experience of counselling a journalist who 
bought a DTCGT for the purpose of making a documentary. In contrast with 
the previous example, this consultation appears to have facilitated the 
consultand’s embodiment of his DNA in a more considered manner, having 
adopted a blithe approach initially. 
 
I think it’s actually a really complex area because there are a 
lot of things that get confused. In clinical care we have an 
idea of what a ‘test’ is and it’s about solving a clinical 
question and you know at a more public health level we have 
an idea of what screening is but again that’s very bound by 
conditions and what we can do about it. It seems to me with 
DTCGT the sort of susceptibility testing I think is what 
everyone got very engaged with and everyone has got 
excited about. [One of the journalists] he had a 23andMe test 
but on discussion with him it also emerged he had a positive 
family history of breast cancer and was Jewish. And he 
presented a documentary about this. The documentary was a 
very personal documentary about his genes but he said, he 
did get it [understand the significance of genetic information]. 
He got it because actually once his family history became 
apparent because of his ethnicity and actually he found out 
there was a real genetic test he could have that might explain 
his family history and the fact he lost [his mother], he got the 
power of that highly predictive genetic information and [it’s] 
not necessarily something you want just to receive on a 
computer screen without context. So he really did get it and 
he said to me that he’d gone into it thinking this was all a bit 
of a laugh and it was all completely meaningless and it 
suddenly wasn’t. (Nurse CP5) 
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It appears from this nurse’s explanation that two things influenced this 
consultand’s views about genetic testing. First the timing of his DTCGT in its 
coinciding with his mother’s illness and subsequent death from breast cancer 
brought the potential of genetic information into a sharper focus than it might 
otherwise have done. Second, his meeting with this nurse led to the offer of a 
“real genetic test”, that is, one that is more predictive of breast cancer, which 
would potentially influence his and his family’s genetic identity more than his 
DTCGT. However, the nurse describes how giving him more information and 
interacting with him personally helped him to view his and his family’s situation 
differently. She demonstrates this by emphasising how his understanding and 
thus his embodying shifted, illustrating the power of clinicians’ group protocols 
in conventional genetic counselling.  
 
Two doctors, CP4 and CP6, had both seen siblings of people who had bought 
DTCGT and were concerned about the results. CP6 had seen the sibling of 
someone whose family had a history of a long-term condition and offered this 
view on the basis of her experience in the consultation. 
 
I think its going to be one of those heart-sink ones whenever 
they come up because we would still go back to first 
principles when anyone came in with a direct-to-consumer 
test. Well what is the family history, is there something that‘s 
going on? And try and work through it that way because that 
would then try and put a clinical picture to what this piece of 
paper is saying. So it’s an almost back-to-front consultation in 
a way; coming with a result and then trying to work it out. 
Doctor CP6  
 
This doctor’s use of the term “heart-sink ones” illustrates the difficulties she 
and other participants identified in trying to help consultands embody their 
DNA through SNP genotyping. It represents the tension between the two 
relevant social groups in this study. Users of DTCGT approach genetic 
information and its embodiment through DTCGT but this approach causes 
consternation for clinicians because theirs is different and founded on socially 
shaped, agreed and accepted counselling approaches. Whether her concern is 
due to the lack of control over the process because the patient has instigated 
testing, as indicated by saying “it’s a back-to-front consultation”, or the lack of 
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utility of the data generated, or both, is unclear. However, in common with 
other clinicians, she demonstrates the use of tried and proven techniques in 
clinical genetics (in contrast to indeterminate SNP genotyping), including 
recording a family history to establish the indication of familial genetic disease. 
This doctor and other clinicians used this approach together with genetic 
counselling principles to help consultands embody the genetic aspects of their 
identities. 
 
As well as users learning from their extension of their identities into the 
genomic, some of the clinicians described corresponding learning and thinking 
about DNA. This was from their experiences of either counselling people about 
DTCGT or using SNP data in future clinical work.  
 
Two clinicians referred to taking the opportunity to learn about how commercial 
genomics companies present information about genetics and SNP genotyping 
as well as their presentation of results and the basis for data analysis. Having 
studied genomics company websites, they felt that there were examples of 
good practice that could be learned from. In particular, the scientist who saw 
the man concerned about his risk of diffuse [site] cancer stated 
 
The results themselves, I actually have to say I quite like the 
way they’re presented. I think we could learn something from 
the way they are presented; nice slick swishy website with 
lots of information and graphs and things. They use a nice 
pictogram of a hundred people and then they colour them in 
to show what the risk is; and so this one, which was 0.23 
percent or whatever, one little man had his feet coloured in 
((laughs)) and I think that’s a really good way of showing risk. 
(Scientist CP3) 
 
The graphics and presentation on 23andMe’s website appealed to her and 
gave food for thought about alternative approaches to demonstrating risk in 
consultations, which could be drawn on in the future. She suggested that these 
approaches to presenting information provided effective means for 
communicating test information in a fashion which individuals could make 
sense of. 
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One clinician was eager to explain to me how SNP data is being used in 
oncology research, a demonstration of how SNP genotyping is being mobilised 
differently in different networks. This doctor’s research work uses SNP data in 
a research project where people with a family history of a specific cancer will 
have SNP genotyping. Particular variants are thought to be linked to an 
increased susceptibility to this cancer and are being researched as a potential 
method of screening for increased risk.  
 
In my work, a lot of what we’ve found now is in SNP profiles; 
so of the common cancers it’s yielded the most SNPs so 
we’ve now got 78 SNPs [in this study] what we do is offer 
primary biopsy and then retrospectively SNP profile them. As 
you know at the moment there is no screening … so it’s in 
the research setting we’re looking at the role of SNP profiling. 
(Doctor CP11) 
 
This demonstrates the doctor’s engagement with SNP genotyping technology 
in her work. Her enthusiasm for its application arguably shows her work to 
enrol support for this emerging novel application of SNP genotyping although 
this is still within her social group’s context as a clinician working in the NHS 
rather than in a commercial DTC context. 
  
Conclusion 
Novas and Rose might describe DTCGT as engaging in “practices of the self” 
as participants work at imagining and embodying DNA through their own or 
others’ thoughts and experiences (Novas and Rose 2000:503). Although 
writing before the advent of DTCGT in relation to single gene disorders, they 
propose that individuals who work to uncover their genetic selves are 
incorporating new identities into their existing identity and self-actualisation. 
This is arguably more directly relevant in individuals with single gene mutations 
linked to disease than varying risks of common complex diseases, as Novas 
and Rose suggest. However, the possibility of establishing a new genetic 
identity characterised by inheritance of SNPs associated with their ancestry, 
traits, disease risk or carrier status can be interpreted as identity practice, as 
demonstrated in this chapter by exploring how the participants think about and 
embody DNA individually. Clinicians’ contributions provide an extension to that 
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practice whilst simultaneously providing opportunities for their own learning 
and reflexivity in relation to their clinical genetic practice and identities. 
 
This chapter and the one preceding have explored participants’ experiences in 
relation to DNA, both social and personal. In the third theme from the data, 
participants’ experiences associate the implications of knowledge about DNA 
from DTCGT to the wider context of healthcare provision, specifically the UK’s 
NHS. In the next chapter my analysis indicates stark contrasts between the 
two relevant social groups of participants as they align themselves to either 
personalised or collective medicine. This demonstrates most clearly the 
importance of power relations between these groups and the influence of the 
wider social context of the study in the NHS in contributing to the on-going 
nature of the disputes about commercial SNP genotyping technology in the UK. 
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Chapter 6 : Testing the NHS 
 
The importance of the NHS in the national identity of the UK was exemplified 
by its inclusion in the opening ceremony of the 2012 Olympic games in London 
(and this coincided with the data collection for this study). More recently a 
Commonwealth Fund report and a national UK survey both suggested that the 
NHS rates more highly than other developed world healthcare models in its 
provision of health care and in the UK population’s support for it (YouGov 
2014). Indeed, public support for the NHS has been unstinting since its 
inception in 1948 (Klein 2010). However, whilst this is perhaps predictable, it is 
arguably a superficial and simplistic representation of an organisation in which 
so many have vested interests, with those interests resulting in different 
visions of the NHS obligations and how they can be met. The NHS represents 
the wider social context shaping DTCGT in the UK. The participants in this 
study generally presented diametrically opposing views of commonly held 
beliefs about the NHS when talking to me about personalised genomics in the 
context of the NHS. Unsurprisingly, this took the form of users’ support for 
personalised medicine, (though not necessarily at the expense of the NHS), 
while the clinicians support collective medicine and seek to protect the NHS. 
The data illustrate these conflicting views and the tensions that arise when 
expectations of both personal and collective medicine are applied to the NHS 
and it is subsequently found to be lacking. Such tensions raise questions about 
what the NHS’s obligations to the UK public are, particularly in the face of 
increasingly neoliberal national and international policy, public expectation for 
more individualised health care and the on-going challenge of funding a 
contemporary public health service. In the data these tensions focus around 
three themes related to responsibility, empowerment or expertise, and 
regulation, each of which I shall examine in turn. 
 
Responsibility  
The beginnings of a more personalised focus for health care in the UK can be 
associated with policy responses to criticisms of a culture of dependency that 
was thought to result from welfare services provided by the state after the 
Second World War. In addition to political moves towards neoliberalism since 
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the 1970s and the encouragement of self-sufficiency, a focus on individuals 
being more involved and responsible for their health and wellbeing has 
gradually become more evident (Nuffield Council on Bioethics 2010). Evidence 
of this in health policy can be found in the Thatcher government’s white paper 
“Working for Patients” in its aim to “give patients greater choice” (Klein 
2010:153). The concomitant shift in health policy from sickness treatment to 
health promotion and subsequent governments’ and policy writers’ repeated 
emphasis on “personalisation” have resulted in expectations that individuals 
will exercise autonomy and responsibility in relation to their health and 
exercise choice in relation to intervention or treatment decision-making 
(Arribas-Ayllon et al 2011b). DTCGT companies’ marketing strategies 
capitalise on all four of the P4 medicine attributes - Participation, 
Personalisation, Prediction, Prevention (Hood and Friend 2011) - and this has 
increasingly been used as a model for public health since the completion of the 
HGP (Groves and Tutton 2013). 
 
However, responsibility is not solely a feature of personalised medicine. It is 
also fundamental to collective medicine. Responsibilities in collective medicine 
fall to individuals’ duty to the population and the common good, including 
engaging with vaccination programmes or preventing the spread of 
communicable diseases, while the health service has a duty of care to patients 
by managing resources and rationing services (Klein 2010, Dickenson 2013). 
These features are shown in the data, with some of the users talking about 
personal responsibility to gain information to manage health and disease risk 
and how SNP genotyping can provide information that facilitates this. The 
clinicians were more focused on their responsibility for providing genetic 
counselling to consultands and protecting the NHS more widely from the 
potential drain on scarce resources that privately initiated testing could cause. 
 
Some of the users made few, if any, references to responsibility for health and 
conveyed the impression that they viewed testing as providing personal rather 
than medical information. This corresponded with a suggestion from one 
clinician who was explaining why she thinks referrals to interpret DTCGT have 
not been made to clinical genetics clinics. 
 
There are some certain aspects of public perception that see 
genetic testing as somewhat different; not a medical 
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investigation but as an identity investigation or something like 
that so I’m aware that, that that’s where the appeal for over-
the-counter genetic testing comes from. (Doctor CP4) 
 
This doctor contrasts the professional view of genetic testing as providing 
potentially troubling medical information about illness that may require 
intervention with what she thinks the lay understanding of genetic testing is. An 
“identity investigation” implies that genetic information (specifically SNP 
genotyping) is trivial, rather than providing serious health information to be 
acted upon and indeed demonstrates her interpretation of the public 
personalising DNA.  
 
The users who did refer to the health information in DTCGT in relation to 
responsibility and health care referred to three issues in relation to this: the 
role of DTCGT in providing information to help people take more responsibility 
for their health, the lack of involvement of a healthcare professional in 
discussing DTCGT results and concerns about NHS staff’s lack of 
engagement with personal genomics. In the data there is evidence of tension 
between the personalisation inherent in users’ expectations and the belief that 
the NHS cannot or will not engage with personalised medicine, as 
demonstrated by Nurse CP11’s earlier cited extract “we’re not touching it with 
a bargepole”. An interesting feature of these users’ interviews was their use of 
tropes including the importance of knowledge and the future promise of 
genomic knowledge in relation to personalised health care. In his writing on 
“Forceful Futures”, Van Lente suggests the futures of technologies are fixed in 
specific languages, based on McGee’s proposal that collective publics use an 
“ideograph”, a vocabulary that guides their behaviour and beliefs in acceptable 
ways. In Van Lente’s argument, as in personal genomics, this enables early 
adopters to assume a collective belief in the future promise of the technology 
thus strengthening their technological frame (McGee 1980, Van Lente 2000, 
Klein and Kleinman 2002). I feel that this is evident in the user participants’ 
discourse of personalised medicine. 
 
Along with Fiona (a geneticist), Carol and Christine (public health academics) 
both referred to the potential for genotyping to arm people with information that 
could enable them to take responsibility for their health and prevent future 
disease, thus reducing the burden on the NHS. Two of the genealogists spoke 
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in a similar vein; Barbara indicated that, although she had no background in 
genetics or health care, she too thought that genotyping could be valuable for 
preventative health care. 
 
But it [DTCGT] would have a benefit because it’s come leaps 
and bounds, if it means you can prevent something 
happening. What concerns me is we should be adopting 
preventive health care but we’re not; we’re waiting until 
someone becomes very ill before we’re even treating them 
…[it’s] worse with all the cutbacks. This is where I see 
genetics things coming in…have a programme mapped out 
for you to avoid getting ill and dying which would cost the 
NHS a lot, so it would have a preventative role … there’s a 
lot we don’t know which will be coming through in the next 
few years … but it could have a preventative role. (Barbara 
UP3) 
 
Barbara’s suggestion is that the beleaguered NHS could benefit financially 
from using genomic information to prevent illness and lower the costs of 
intervention and terminal care that result. She seems to view the NHS as 
currently being reactive rather than proactive, as providing treatment for 
sickness rather than health promotion. By suggesting a shift towards 
prevention, she is demonstrating the tension between personalised and 
collective medicine, in addition to reproducing sentiments proposed by 
commercial genomics companies’ marketing material. I should note that none 
of the participants claimed to have acted on their DTCGT in terms of making 
lasting changes to their lifestyle for the purposes of future disease risk 
management, whether or not they referred to the potential value of personal 
genomics in doing so.  
 
The majority of the participants did not seek a consultation with any healthcare 
professional about their DTCGT. This is similar to earlier US-based research 
findings about early adopters of DTCGT (McGowan et al 2010). It does not 
support concerns that DTCGT will result in overburdening of healthcare 
services with consultations and subsequent investigations for the “worried well”, 
as mentioned by some clinicians and which is a concern repeatedly forecast in 
the ELSI literature (Goldsmith et al 2012). However, three participants told 
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their GP about their test results at an appointment arranged for another reason 
but felt their GP was not interested in their test results. There was a general 
perception that the NHS is under pressure and that it is not realistic to expect 
hard-pressed doctors to know everything and respond appropriately or to 
expect that genomics is currently relevant to general practice. Thus, people did 
not bother to tell their GPs about their test, as it was not immediately relevant 
to their consultation or was not seen as directly related to the collective 
medicine the NHS provides. Christine viewed this from a public health 
perspective, first acknowledging the demands on primary care in the NHS, 
then suggesting how personalised genomics could help. 
 
I could talk about this forever and if I went to see a GP I think 
the biggest fear for them is they’ve only got 5 minutes and 
you know more than they do … the worried well…I think 
that’s who the tests could end up being attractive to and I 
don’t think that’s a bad thing either. They may stay away from 
your [doctor’s] door actually. (Christine UP5) 
 
Christine observes that GP appointments are not compatible with her sharing 
her interests in health care and personal genomics (she had stated earlier in 
the interview that she did not feel there was anything specific that needed to 
be discussed with her GP). She anticipates the GP’s response as being one of 
anxiety in the face of a patient with expertise, although she relates this to 
managing time-limited appointments rather than exploring the issue of 
professional versus patient expertise. She suggests that the information 
DTCGT contains could relieve pressure on primary care by alleviating anxiety 
in those who take up time with unfounded health concerns, a view that 
contradicts the ethical arguments against DTCGT on the basis of increasing 
anxiety among testers. 
 
Laura and the two couples I interviewed (David and Elizabeth and Jane and 
Ian) all expressed concerns that in their experience the NHS was not 
sufficiently engaged in genomics. They all felt that the NHS should take more 
of an active role in utilising genomics for health promotion rather than leaving it 
to individuals to pursue genomics independently. Jane and Ian were strongly in 
favour of public health services, as well as genomics; Jane did not see them 
as incompatible, as she shows here. 
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It should be available to everybody, they should choose 
whether or not to have it, the GP would explain what it was 
about and they would make a decision to test on that basis 
… I do think it should be supported by the NHS definitely, it 
should go through the NHS and it would save them a lot of 
money. (Jane UP11) 
 
Jane is explaining her vision for how the perceived problems with commercial 
genomics, such as the lack of counselling, could be avoided if genotyping were 
adopted by the NHS for health screening. Her suggestion to offer genotyping 
to everyone through the NHS represents her vision of the choice to have 
individually tailored health care provided free at the point of delivery by the 
NHS, seemingly blending personalised and collective health care and merging 
individual responsibility with collective provision. The tensions between 
personalised and collective medicine, particularly in respect of funding, do not 
appear to concern her, given the net saving.  
 
Some participants referred to obtaining genomic test information in stronger 
terms. They felt that having their genomic data was their right. Two of these 
were Helen and Laura, who had originally sought DTCGT to shed light on their 
health problems. Their expression of “rights” seemed linked to their need to 
exercise their autonomy following difficulties with healthcare professionals who 
appeared to act in a paternalistic manner. Ann, the self-professed DNA 
enthusiast and genealogist, took this entitlement further. She echoes Helen 
and Laura and the democratisation of genomic information argument that 
23andMe rely on, which is echoed by some bloggers on genomesunzipped 
and demonstrated in McGowan et al’s research on early adopters of DTCGT in 
the USA (McGowan et al 2010). 
 
People should have the right to their own genetic information, 
not via a doctor or anyone else. (Ann UP2) 
 
This asserts the personalisation argument in much stronger terms. Ann 
supports the view that genomic information is the individual’s personal 
information rather than privileged knowledge to be held and interpreted by 
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medical institutions in the manner of Foucault’s interpretation of professionals’ 
clinical gaze over patients (Foucault 1994). 
 
However, democratisation does not only apply to genomic information. The 
NHS is a social democratic organisation, set up by the state and run as a 
public service to provide collective medical care for the nation. Although they 
appeared to place as much and perhaps more, value on the institution of the 
NHS as the users, the clinicians’ impression of responsibility was centred on 
their service provision. The other side of the democracy coin is represented by 
the clinicians’ opinions about rationing to protect scarce NHS resources from 
profligate spending on privately generated health information.  
 
The Nuffield Council on Bioethics report on personalised health care discusses 
the possible implications of increasing access to health information by 
individual UK consumers (specifically body scanning and genotyping). In 
addition to considering the possible benefits and harms of these sources of 
individualised health information, the report outlines the potential impacts on 
the NHS both financially and ethically. Increased uptake of NHS services to 
investigate the sequelae of personally accessed testing or scanning represents 
a drain on NHS resources, a loss of solidarity gained from combining risk and 
distributing services to encompass the vulnerable and disadvantaged as well 
as provoking debates about the fair and equitable use of public resources 
(Nuffield Council on Bioethics 2010). Several of the clinicians in the study 
referred to the first of these impacts by describing the collective responsibility 
to ration health services. This is to protect resources in order to provide a 
service to those genuinely in need of genetic counselling, though it was not 
clear on what basis these judgements are made.  
 
Many participants, despite lack of evidence of it existing, expressed the 
obvious tension between DTCGT and NHS Clinical Genetics. They were 
concerned about the potential for scarce resources to be taken up by 
counselling the public who had bought DTCGT independently and then been 
referred to NHS genetics services for help, though most would not be seen at 
the departments whose staff I interviewed unless additional criteria applied. 
Clinicians with administrative responsibilities in their departments expressed 
concerns about service provision and set DTCGT as ‘other’ or out-with the 
usual clinical genetics service provision. One referred to the tests “we want to 
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do”, inferring that DTCGT is outside the remit of clinical genetics, framing it in 
paternalistic terms. Another with departmental managerial responsibilities 
outlined her concerns along similar lines, though she also describes being at a 
loss for solutions to this challenge, exemplifying the on-going dispute about 
DTCGT in the context of the NHS. 
 
If people … want to get their 23andMe, I‘m not bothered. I 
am bothered if they then use up healthcare resources to 
interpret findings that are meaningless for a test that wouldn’t 
be offered on the healthcare system. And you know I don’t 
know how we deal with that. I mean I don’t think this just 
applies to genetic tests. It applies to body scanning, it applies 
to lots of things. (Nurse CP5) 
 
She uses the word “bothered” to stress her understanding of the conflict being 
presented by personalised medicine to NHS resources, rather than the 
challenge it may present to individuals who avail themselves of direct-to-
consumer health information services. This understanding would appear to 
encompass the idea that her genetic counselling service would refuse to see 
people to discuss DTCGT alone. However, beyond understanding the conflict 
of rationing services in her own department, she suggests that the conflict 
remains so far unresolved providing evidence of lack of closure of the debates 
about DTCGT in the UK. 
 
This doctor demonstrates a tension between using expensive resources for 
unplanned consultations and the moral imperative of providing succour to 
those in need of healthcare services, although her department was alone in 
providing counselling to anyone who requested it. The explanation for this 
department’s approach appears to excuse their lack of rationing and possibly 
their lack of engagement with a need to ration services by falling back on the 
NHS principle of free health care to all at the point of access. 
 
Well one of the things I find difficult is that we get, when 
these things come up the people are very, very upset and 
they want to be dealt with on an urgent basis and so that’s 
really expensive time, that kind of emergency time. And I find 
it really hard to justify taking up emergency time but I don’t 
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want to see the patient suffering either; if they are very upset 
about it I really struggle with abandoning them. And they are 
all patients of the NHS so we end up doing it. (Doctor CP2)  
 
An experienced doctor with academic and commercial responsibilities in 
addition to his clinical role expressed a more democratic view, in the sense 
that he presented arguments for both personalised and collective medicine 
perspectives. 
 
It comes down to whether you want to take a public health 
approach or an individual healthcare view of it and we all 
oscillate between those positions. There’s clearly a danger 
that unregulated, genetic testing causes a lot of people a lot 
of distress, exposes unrecognised non-paternities, makes 
people anxious who are already anxious which is why they 
did the test, doesn’t resolve their anxiety, it just makes them 
go to the doctor and pester him who then has an 
opportunistic cost because he’s so busy seeing that person 
that he doesn’t see the next one and you can portray a very 
negative perspective. On the other hand you can also say 
that if you empower the individuals to care for themselves 
and make those tests available in a controlled way, quality 
control them well, we could massively expand genetic testing 
and people’s appreciation and understanding of it because 
it’ll touch more and more of their lives and you’ll just make it 
more and more part of routine health care which is where it’s 
now capable of moving. So I kind of sit in the optimistic let’s 
have a go camp. (Doctor CP10) 
 
This extract demonstrates the participant’s overarching view of the debate 
between personalised and collective medicine, no doubt informed by his more 
strategic and wide-ranging role as a Consultant. Whilst he outlines the issues 
that are used in arguments against DTCGT, he then goes on to propose how 
increasing use of genetic testing could be taken up as part of “routine health 
care”. This is interesting because this doctor uses the terms that are 
characteristic of both perspectives, such as anxiety on the one hand and 
empowerment on the other. Rather than presenting similar views to the other 
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clinicians by defending the NHS and protecting the public from harm, he 
appears to be supportive of widening access to genetic information and uses 
the tropes of personalisation by suggesting this could “empower the individuals 
to care for themselves”. This is more congruent with the views of the users 
who talked about the potential for personal genomics to facilitate increased 
individual responsibility for health. It also suggests that genomics may indeed 
become integral to health care in the UK. However, this may not be in the 
individualised way that some users envisage, given the contingent and 
complex nature of genomic information that is based on population studies and 
appears currently to simply reinforce established public health advice or stratify 
people into treatment groups, rather than provide truly individually tailored 
health care (Hedgecoe and Martin 2003, Kraft and Hunter 2009).  
 
Empowering individuals suggests equipping people with the authority and 
confidence to manage their lives. This requires knowledge and understanding 
of their genomic information. As has been demonstrated in Chapters Four and 
Five, this study’s users of DTCGT have developed knowledge and 
understanding of genetics and genomics by virtue of their prior knowledge and 
experience of DTCGT, giving them a level of expertise in personalised 
genomics. The issue of how this equates to expertise commensurate with that 
of genetics clinicians presents challenges for the NHS and clinical genetics 
services in particular, as I shall explore in the next section. 
 
Empowerment or expertise 
The concept of patient empowerment has been adopted in Western society as 
an approach to engage citizens in health promotion and preceded genomics 
by several decades in healthcare policy in the UK (Petersen and Lupton 1996). 
This has partly contributed to the shift in the relationships between the public 
and healthcare professionals, along with challenges to medical authority from 
a more informed and critical public as well as alterations to funding streams 
and management structures in the NHS (Freidson 1988, Bury 1997, Elston 
2002). Because NHS policy has highlighted the importance of patient 
engagement and neoliberal policies have promoted a focus on individual 
autonomy and empowerment, the pursuit of DTCGT to gain health information 
is arguably unsurprising. Some of those who have bought DTCGT join the 
informed public who can be critical of healthcare professionals. About half of 
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the users in this study fall into this category and voiced strong opinions about 
what they perceived to be the deficits in NHS staff knowledge and service 
provision. Clinicians were more united in their views; they have different ideas 
about the value of SNP genotyping, as shown in Chapter Four, and a wider 
perspective of what NHS genetic service should prioritise. In this section I shall 
explore how the concept of empowerment and users’ and clinicians’ 
knowledge of SNP genotyping relate to expertise and how these different 
interpretations result in conflict. Empowerment is specifically relevant here 
because it is, as the word suggests, the concept of power that is central to this 
aspect of the dispute about DTCGT. The credentialed expertise of clinicians 
who are employed by the NHS, the authority at the centre of the wider social 
context of the dispute about DTCGT technology, provides a cohesive and 
influential position from which they can contest the claims of those who 
advocate for DTCGT. Correspondingly empowered users of DTCGT, who are 
also increasingly empowered NHS patients, have a different experiential view 
of the technology and use their informed position to contest clinicians’ (and 
others’) claims against DTCGT. 
 
It is no surprise that some of the users of DTCGT in this study appeared to 
equate their ability to gain health-related information with a sense of autonomy 
and empowerment, given the emphasis on personalisation used by 
commercial genomics companies. In doing so they compare their knowledge 
to that of the healthcare professionals they come into contact with, finding the 
latter to be wanting. Whilst very few participants stated that they knew more 
about genomics than healthcare professionals, several were critical of either 
GPs or the NHS because of their perceived lack of engagement with, or 
ignorance about, genomics. Being in a position to critique healthcare 
professionals would indicate that these people feel they are knowledgeable 
about genomics and health and feel empowered to challenge NHS staff who 
do not place the same emphasis on personal genomics as they do. I feel it is 
important to examine how this relates to expertise, as both groups of 
participants imply that they have knowledge and understanding that could be 
equated with different understandings of expertise.  
 
Prior refers to experiential or partial knowledge as constituting lay-expertise in 
health care rather than the more broadly based knowledge and expertise of 
qualified experts (Prior 2003). In this study it would appear that users may 
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have expertise in DTCGT by virtue of their experience, while clinicians have 
skills and expertise in clinical genetics rather than SNP genotyping per se. 
However, as Collins and Evans assert the term “lay-expertise” is an oxymoron 
and would be more likely to support my suggestion that DTCGT users are 
experiential experts (Collins and Evans 2002). Evans and Plows pointed out 
that the use of the terms “scientist” and “public” in the debate about public 
engagement with science are too reductionist to be helpful, assuming the term 
“public” equates to the lay-person (Evans and Plows 2007). Users of DTCGT, 
who are experiential experts in personal genomics, might be members of the 
public but, as I demonstrated in Table 3.1, most of this study’s users also have 
varied experience of genetics, genetic genealogy, public health, illness and 
personal genotyping. Thus, they cannot be considered to be in the same 
category as members of the public who have no understanding or experience 
of genetic or genomic testing, with the exception of Jane and Ian. So to equate 
DTCGT users with the public, whom Evans and Plows describe as those with 
“no particular expertise in the topic other than that acquired in everyday life”, 
appears to be an incongruous association (Evans and Plows 2007:828). 
 
Using focus groups, Kerr et al explored the public’s understanding and lay 
expertise about the new genetics. Whilst none of the participants in my study 
explicitly claimed expertise in SNP genotyping and its application to health risk, 
I would suggest that the users are similar to participants described in Kerr et 
al’s study, by virtue of being experts in their own lives with a good grasp of 
ethical and social issues related to genetics. This level of knowledge was 
relevant and applicable for them and their kin, if not detailed in relation to the 
technical aspects of testing and interpretation of results (Kerr et al 1998). 
Whether due to their experiential expertise of SNP genotyping and their self-
knowledge, or because of earlier difficulties with healthcare services, it is clear 
that several of the users expressed concerns about NHS doctors’ ignorance of 
or lack of interest in genomics. For some this was related to personal 
experiences of health care unrelated to genomics. Helen, Laura and Nicola all 
expressed criticism of NHS doctors, which was informed by their negative 
experiences of trying to get help for illnesses that conventional NHS and 
private healthcare providers had been unable to diagnose or treat satisfactorily. 
They felt disempowered as individuals in the NHS and felt that there was often 
little, if any, appreciation of their own knowledge or views in their interactions 
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with healthcare professionals. Laura describes her difficulties in the extract 
below and has similar suggestions to Barbara in relation to prevention. 
 
The health service seems to work with doctors being in 
charge with the patient being a kind of vessel that they look 
at and treat and examine; I rather baulk at that, I like to be 
involved in it and I do meet doctors who are like that, it’s a 
kind of partnership as to how you deal with the various 
problems, but I have also met other people who tell you what 
to do. I find it really frustrating and difficult to deal with, so I 
like having control over it and I’d rather skip the doctors 
giving me a pile of information I already know and sometimes 
don’t agree with and I like to have the information there and 
be able to mull it over in my own time. I do find doctors’ 
appointments are really pressured as well, you get 10 
minutes to talk to a Consultant sometimes and you have to 
say everything in that 10 minutes, coherently; and you don’t 
get another appointment for months for instance and it’s just 
a horrible, horrible experience … I think the medical 
profession ought to get with it, make use of it [genomics]. I 
think they are pretty stuck in the past. I think it’s appalling the 
lack of uptake of new technologies in the NHS. It’s just a 
huge big sluggish monster and they are barely doing any 
sequencing of people as far as I can tell. I don’t think they are 
any good at preventative or diagnostic medicine, it’s all 
reactive what the NHS does and I wish they’d get more 
proactive and do things ahead of time rather than letting 
people get ill and then put a sticking plaster over the top of it. 
(Laura UP15)  
  
Laura describes finding short, time-pressured NHS appointments unhelpful for 
her condition, particularly as she feels she seldom has any control or any 
contributory role in the management of her problem. The implication is that 
SNP genotyping has given her personal health information at her own 
instigation and which she can access at any time, resulting in a new sense of 
autonomy and empowerment. This is an example of Juengst et al’s suggestion 
that empowerment could be used to reverse the control of medical paternalism, 
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as people like Laura (and Helen and Nicola) gain knowledge that is no longer 
privileged and confined to medical professionals (Juengst et al 2012). She 
appears to contrast this more positive experience with her experiences in the 
NHS and associate her negative impressions with a perception that the NHS is 
failing in relation to new genomic technologies and preventative medicine. 
 
Others were sceptical about doctors’ knowledge of genomics, although most 
did not refer to specific incidents. However, Ann, the DNA enthusiast with an 
encyclopaedic knowledge of genetic genealogy, was explicitly critical about 
healthcare professionals’ knowledge of genomics. The collective “we” in this 
extract refers to genetic genealogists who are members of ISOGG. 
 
The amateurs seem to know more than the experts and 
certainly for these tests we’ve found that to be the case. I 
mean things like doctors don’t get training in genomics. I 
can’t imagine there are many people in the health service 
who know the first thing about how genomics works, so if I 
wanted to know, if there was anything of concern in my 
results I would go to the people within ISOGG. We’ve got 
people who actually are doctors as well and they’re the ones 
who really, their opinion I would trust more than anyone else 
because they’ve got the medical background but they’ve got 
expertise from using all the different tests [themselves]. In 
fact a lot, I mean even the Human Genetics Commission, 
they’ve put some misleading stuff out on their website about 
genetics tests and I wrote to them about it and they never 
changed it. (Ann UP2) 
 
It was not clear to me on what basis Ann made her assertions about NHS 
doctors’ lack of training or knowledge of genomics. However, she clearly feels 
that her knowledge of genomics and that of fellow enthusiasts in her biosocial 
community is greater than that of qualified healthcare professionals and this 
gives her a platform from which to dismiss them. Her assertion that she would 
refer to a doctor in her genetic genealogy organisation if she had any 
questions suggests that, although she uses a deficit model to view NHS staff in 
relation to personal genomics, she may be more comfortable discussing 
genomic information in a community she identifies with, rather than with 
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outsiders whose views of personal genomics do not support her own. This is 
indicated by her criticism of the Human Genetics Commission information. 
 
Maria, the young genetics researcher, felt that some doctors were unlikely to 
know much about genomics. 
 
I don’t know how up to date they are kept with all these 
things. I can imagine some GPs in some parts of the country 
if you turn up with a 23andMe result, they wouldn’t know 
what to do with it. (Maria UP15) 
 
Her assumption appears to be that, as a researcher, she is working at the 
forefront of genetics and genomics. Having bought a DTCGT, she has 
additional personal experience that could be interpreted as expertise, which 
she imagines places her in a more knowledgeable position than that of many 
GPs. The tentative nature of her remark, as expressed in her use of the phrase 
“I imagine”, could indicate she lacks experience on which to base it. 
 
Two of the clinicians, an experienced nurse and the oncologist, both felt that 
GPs were ideally placed to handle and interpret enquiries about DTCGT 
results because of their experience of risk assessment in very short time 
frames. It is not clear if this perception was based on their experience or was a 
plausible suggestion given their knowledge of the nature of consultations in 
general practice. However, it was not confirmed by either the users’ 
experiences or other clinicians’ views. 
 
Almost half of the clinicians expressed similar doubts about GPs’ knowledge 
and understanding about genetics or SNP genotyping, as Maria and the other 
users referred to above. Some suggested that they need to have topical 
updates to familiarise them with developments in the field or that they had too 
little time to deal with genetic issues in 10-minute appointment slots and 
should refer patients on. 
 
In general practice they are more likely to refer. I think that’s 
partly because GPs just don’t have time and partly because 
they accept that they send a lot of patients on to specialist 
services for whatever reason and a lot of clinicians don’t 
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understand a lot about genetics anyway. Probably less than 
you’d expect actually. (Doctor CP15) 
 
This doctor, a trainee in clinical genetics, assumes that specialist expertise is 
the preserve of hospital-based clinical specialists rather than GPs. He 
describes their reliance on referring patients to geneticists, as do other 
specialists in hospitals. His comment about lack of understanding about 
genetics by non-specialist colleagues suggests that he is surprised by how 
little genetics knowledge his colleagues have retained or developed, not being 
involved in the subject on a daily basis as he is. This view is more aligned with 
those of the users, who use a counter-deficit model in their views about GPs’ 
understanding and engagement.  
 
Users’ views about doctors’ ignorance of, or lack of engagement with 
genomics cannot necessarily be attributed to their relative expertise in the field, 
as respective understandings about the meaning of genomic data can be 
divergent. Whilst the users described above can be seen to be adopting the 
utopian vision of personalised medicine and criticising the NHS for not 
endorsing this view, the clinicians, in supporting the collective public health 
service, have a different perspective of the utility of genomics. As I have 
already described in Chapters Three and Four, the data show that many of the 
clinicians’ technological frame supports the notion that the contingent nature of 
SNP genotyping data rendered its application to relevant health information 
useless and were concerned that the public might not interpret the risk data 
appropriately. These differences are supported by Parsons’s and Atkinson’s 
description of the fundamental differences between professional and lay 
interpretation of risk in a study of women with first-degree relatives affected by 
Duchenne muscular dystrophy (Parsons and Atkinson1992). Joanna Latimer’s 
analysis of medical dominance in the genetics clinic also suggests why these 
two perspectives are in conflict. Whilst she suggests that, on the one hand new 
genomic technologies can be seen as empowering and enabling, on the other 
they are also problematic. This is because their contingent nature undermines 
the prestige that medical knowledge derives from being associated with 
science and truth (Latimer 2013). 
 
Medical expertise, which is often described as being based on privileged 
knowledge, endows practitioners with power and authority over those who are 
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not part of the profession (Freidson 1988, Elston 2002). Thus, it is exclusive 
and arguably undemocratic. Experiential expertise in new technologies is 
similarly undemocratic, excluding those who are not part of that group of early 
adopters. This results in experiential experts in the public speaking to those 
who have no experience rather than for them, despite their thoughts to the 
contrary, as Epstein emphasised in his work with HIV/AIDS activists (Epstein 
1995). Personalised genomics, in common with other new medical 
technologies, is specifically undemocratic because it excludes those who 
cannot afford it or who are otherwise vulnerable, as well as challenging expert 
authority (despite the democratising arguments for personal genomics). This 
disparity is at the heart of the conflict between this study’s participants’ 
opposing views and between personalised versus collective medicine. The 
NHS and the clinicians who work in it are essentially providing a public health 
service for the collective good, which inevitably requires rationing, and many of 
them imply that this includes protection from unanticipated demands such as 
those that result from privately generated, uncertain health information 
(Juengst et al 2012). 
 
In exploring how new medical technologies are experienced, negotiated and 
challenged in the clinic, Brown and Webster noted the impact of these actions 
on the trust relationship between patients and healthcare professionals (Brown 
and Webster 2004). They suggest that healthcare practice is unfeasible when 
trust fails; whilst it would be an exaggeration to claim a breakdown of trust 
between users and healthcare professionals, these data suggest a shift in the 
nature of some of the users’ relationships with the doctors they encounter that 
may be partly informed by their engagement with personal genomics. The 
threat to the relationship between practitioner and patient has been partly 
responsible for many calls for regulation of personalised genomics, the topic I 
shall go on to next to complete this analysis of the data.  
 
Regulation 
This section builds on the detailed discussion about Regulation of genetic 
testing in Chapter Two, which I will not repeat here. This landscape has 
changed somewhat during the course of this study, owing to the changes in 
the market of DTCGT described in Chapter Two. However, these changes 
post-dated the interviews. Discussions I had with participants in the interviews 
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elicited strong views about regulation that shed further light on participants’ 
thinking about personalised medicine and the NHS and I will go on to examine 
these next. 
 
As I argued in Chapter Two, moral order in society relies on people sharing 
understanding of matters important to that community; the absence of 
consensus about DTCGT leaves room for uncertainty. This ambiguity may 
partially explain why many clinicians, ethicists and lawyers interested in the 
debate about the availability of health information technologies direct-to-
consumer call for regulation. Motivations for doing so differ whether they are 
driven by hopes for public protection, paternalism, boundary work in protecting 
different groups’ identity and practice, or similar, it appears to be the fall-back 
position for these concerned professionals and academics. Others disagree 
with regulation; this may be because they are enactors of this emerging 
technology seeking to recruit selectors to invest in or make use of DTCGT as 
described in the section on Expectations in Chapter Three. Alternatively, they 
may be selectors (here I equate this to early adopters) whose expectations 
have been built up by the enactors and who do not wish to consider the 
potential uncertainties or difficulties that the new technology is associated with 
(Groves and Tutton 2013). Finally, there are those who are more familiar with 
the scientific aspects of DTCGT and its uncertainties, those who arguably have 
more expertise in the field and who feel that onerous regulation would be 
unwieldy and excessive given the nascent and non-deterministic nature of 
SNP genotyping information (Hennen et al 2008). All these groups’ agendas 
contribute to the contestations about DTCGT and the lack of stability of the 
technology. 
 
I asked participants about their views on regulation of DTCGT and their 
reactions to suggestions that DTCGT should not be allowed. Users’ were 
mostly strongly in favour of maintenance of the status quo in terms of 
availability of DTCGT, though for various reasons. These included it being too 
early in the developments to regulate it, it being too late as it is already freely 
available, and the more popular argument about autonomy and the rights to 
one’s own genetic information. Clinicians were generally in favour of some kind 
of regulation to ensure transparency in marketing materials and quality 
assurance which could be interpreted as an extension of the professional 
protocols that give their group its influence in censuring DTCGT. 
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The users who championed personalised medicine and SNP genotyping were 
likely to comment on the relationship of regulation to medical hegemony. The 
geneticist Fiona observes that 
 
The rhetoric that’s coming out at the moment from the 
medical profession over direct-to-consumer testing does 
sound a bit like ‘but we’ve always done this bit, we want to 
carry on doing this bit’ rather than actual real genuine 
concern. (Fiona UP8) 
 
Fiona conveys the perception that the medical profession wish to maintain 
professional authority over genetic testing. The phrase “we’ve always done this 
bit, we want to carry on doing this bit” suggests that she interprets this as 
related to medical professional authority and boundary work. She appears to 
think that, like her, the medical profession does not necessarily view DTCGT 
as harmful, but rather that the prospect of individuals autonomously obtaining 
their own health information pushes the boundaries between professional 
authority and informed patients too far. 
 
Some users qualified their views about regulation in relation to the lack of utility 
or harm from DTCGT, suggesting that there was no point in regulating 
something that simply provided personal information. Whilst she supported this 
view, the genetics statistician Kirsten acknowledges a different perspective in 
the debate over who should have access to genomic information. 
 
Yeah, it seems really odd to me that you want to regulate a 
test that has so little utility. It just seems a complete waste of 
time and using a sledgehammer to crack a nut sort of thing, 
so I’m aware of some of this and have been on the websites 
like some of the genetics associations in the States who say 
“You should not do a direct-to-consumer genetic test – that’s 
it”. And it’s like “What? Hang on, no conflict of interest here of 
course!” But I think the level of regulation should reflect the 
value of the information that they are providing. So I would 
expect a much higher level of vigilance for, you know, 
sequencing for BRCA1 variants for example which could 
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have huge downstream implications for mammography and 
oophorectomy or whatever, than compared to a company 
that’s telling me that my type 2 diabetes risk genetically is 
slightly above average. So yeah, it’s not something that 
concerns me. And I think that there’s the whole other side of 
this isn’t it, where genomesunzipped is coming from, that this 
is our DNA that we have a right to find out what is in that and 
the medical community should not stand between us and our 
DNA, empowerment rather than endangerment and I think 
that’s slightly disingenuous. (Kirsten UP14) 
 
Kirsten expresses her view about the pointlessness of regulation for relatively 
non-deterministic information by using the metaphor “using a sledgehammer to 
crack a nut”. She emphasises this by critiquing medical professionals’ 
boundary work, which is implicit in the policy documents that she has found 
online. She uses the example of BRCA1 sequencing as a contrast, by way of 
emphasising the non-deterministic nature of SNP genotyping. Her views seem 
to be pragmatic and balanced and similar to those expressed by Hennen et al 
who proposed that regulation need only be proportional to risk (Hennen et al 
2008). She also directly criticises those who subscribe to the democratisation 
of genomic data for reasons of empowerment, implying that this view is no 
more appropriate than a paternalistic one.  
 
Few of the users appeared to have considered either the problematic nature of 
interpreting SNP genotyping data or the confidentiality of their data or samples 
in the present or future, should the genomics companies cease trading in their 
present form. As a result, discussions with users about regulation seldom 
encompassed issues related to quality assurance or requirements for sample 
and data storage or destruction. The same cannot be said of the clinicians’ 
views, which were more focused on these issues. 
 
The majority of clinicians thought that DTCGT should be regulated. This 
advocacy for regulatory control could be interpreted as being aligned with this 
relevant social group’s professional power and the reassertion of boundaries 
between medicine and the public. However, nationally (or internationally) 
applied regulation would require the engagement of, and negotiation between, 
different groups of actors, which appears to have been avoided in relation to 
  190 
DTCGT, resulting in its lack of stabilisation as a new technology. Suggestions 
about regulation were mostly grounded in participants’ direct experience of 
their professional working directives, including stringent quality standards for 
genetic testing laboratories, as in the NHS and professional requirements for 
Genetic Counsellor registration that are required for NHS clinical genetics 
services. Some participants expressed their suggestions from a moral 
standpoint, suggesting that NHS Clinical Genetics services provide the 
normative framework on which other provisions should be based, as this 
participant suggests. 
 
They should just provide the correct service. If you could 
guarantee that any company out there was going to make 
sure that people were given a good service and had all the 
relevant information in an appropriate way to start with so 
they weren’t going into something with their eyes shut then 
no but I don’t know how so I have to say yeah, I think they 
should be regulated. Just to guarantee that people are going 
to get the right service. (Nurse CP9) 
 
What is the “right service”? (Teresa) 
 
The “right service” is preparation and understanding and an 
education about what they’re going in for. I suppose for me 
it’s proper informed consent to do the test. And proper 
informed consent is understanding what the consequences 
are of this test so you can make up your mind if it’s 
something you want to go ahead with. If you have had that 
and after you had that information you still think that is the 
right test for you then that is the right test for you and that’s 
absolutely fine. But it’s having that information and at the 
right level for that person. (Nurse CP9) 
 
This nurse supports the need for regulation and emphasises this in relation to 
informed consent. She uses the words “correct” and “right”, giving emphasis to 
her support for regulation in relation to the principles that genetic counselling is 
based on. She does not appear to consider the different types of information 
that genetic testing and genotyping generate or the respective implications for 
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the consultand; she appears to assume that any kind of genetic information 
should be accessed through the genetic counselling framework. 
 
This nurse was not alone in suggesting that regulation was required for public 
protection. Like these other participants, she appears to be basing her 
suggestions on the ethical principles underpinning genetic counselling which 
have been developed with monogenic disorders inherited in a Mendelian 
pattern. As other clinicians pointed out, applying the frameworks for regulation 
that apply to inheritance patterns and implications of monogenic disorders is 
not appropriate for genomic data based on GWAS (Arribas-Ayllon 2011). 
Those participants who suggested this were very experienced in their field, 
with wider responsibilities than the clinicians who supported regulation for the 
purposes of public protection. The experienced doctor with a broad portfolio of 
responsibilities expressed it thus. 
 
But in a sense this conversation is slightly being distracted, 
as is always the case because really when we think about 
over-the-counter-testing we always get hung up on the really 
high penetrance conditions. But there’s a whole other 
massive market that’s not high penetrance disease and I’m 
weary about talking about HD because it always comes up 
you know “What about HD?” HD is an annoyance in a way 
because we crack the exception before we go to the rules. 
The vast majority of genetic testing is done to benefit the 
health care of the individual and the family and does so in a 
much more direct way than simply predicting they’ve got an 
incurable disease. So, for the high-penetrance autosomal 
dominant conditions for which we have a treatment it really is 
a no-brainer that we should be doing more of it. And if you 
look at conditions like FH which is the one I always throw 
back at the HD model, [it’s] about 20 times more common 
and causes vast numbers of young people to drop down 
dead avoidably. The thing is that when we do cholesterol 
measurement we’re doing a genetic test, we’re just 
measuring the gene product rather than the gene itself. It is 
outrageous to be honest that we are still not routinely testing 
everybody for FH. Vastly common, totally treatable, people 
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dying in their 40s and 50s that could have been prevented if 
they’d been picked up and put on statins. But you know the 
NHS can’t afford to roll it out and they don’t like putting it out 
over-the-counter because it’s genetics. (Doctor CP10) 
 
The interesting point in this extract is that this doctor dismisses HD as the 
basis for regulation that should be applied to generating and communicating 
any genetic information. He illustrates this by contrasting HD with familial 
hypercholesterolaemia (FH), a very common genetic disorder. Although it is 
inherited in the same pattern as HD and has potentially lethal consequences, it 
is easily treatable. Despite these similarities, marketing a genetic test for FH 
over-the-counter has failed to be approved, owing to concerns about DTC 
access to genetic testing in the UK, because it is a genetic test rather than 
because of any potential harm. The doctor is clearly frustrated by this barrier to 
helping people potentially at risk of avoidable disease because of funding 
constraints. These blocks to selling testing DTC could be interpreted as 
representing a reluctance of the collective provision of health care in the NHS 
to move beyond the deterministic model of genetic testing and acknowledge 
the different types of genetic information and testing that new medical 
technologies are producing. Equally it could be interpreted as representing as 
their adherence to a particular technological frame for genetic testing in 
general, rather than one specific to DTCGT owing to the challenges that 
institutional and professional opposition present for new medical technologies 
(Green 1991). 
 
Other suggestions for regulation included adherence to advertising standards 
for which requirements are already in place and enforcement of legal 
requirements in international law to control the global reach of online marketing. 
A few clinicians and one of the users referred to the concept of self-regulation 
as being an appropriate mechanism by which to achieve acceptable test 
quality and ethical standards without any impact on public services or costs. It 
appeared that the foundation for all these suggestions was based in the 
boundary work discussed in Chapter Four and was simultaneously aimed to 
protect the NHS from opportunistic demands on resources from early adopters. 
 
Several authors have noted that grounds for regulation rely on perceptions of 
boundaries that no longer exist, such as those between authoritarian 
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healthcare professionals and ignorant patients or between expert scientists or 
researchers and the uninformed public. The undermining of these boundaries 
indicates that, even if regulation in personalised medicine is attempted beyond 
that of the FDA’s Cease and Desist notices, it is unlikely to be effective and 
may not be an appropriate response (Boddington 2009, Juengst et al 2012, 
Prainsack et al 2008). 
 
Common ground 
If SNP genotyping for common complex diseases has the potential to disrupt 
the trust on which patient-practitioner relationships have historically been 
based, the data in this study suggest that one aspect of genomics on which 
members of both the study’s relevant social groups concur is 
pharmacogenomics. This is perhaps fortunate, given that one of the areas of 
health care in which patients (in the UK) continue to be dependent on qualified 
healthcare professionals is in the prescribing of medicines. However, the 
scientific uncertainties that apply to disease-risk testing are equally applicable 
in pharmacogenomics but arguably have more serious implications. 
Establishing someone’s genotype for drug metabolism will lead to prescription 
of drug treatment along with others of similar genotype, there being no 
individually designed medicines or market for their development (Prainsack 
and Wollinsky 2010). In addition, pharmacogenomics can also marginalise 
those who cannot access testing or exclude from treatment those whose 
genotype is not catered for (Juengst et al 2012). Despite these concerns, the 
majority of participants in both users’ and clinicians’ groups spoke positively 
about the potential of pharmacogenomics to improve health care. For users, 
this was typically couched in discourse related to empowerment, whilst 
clinicians referred to SNP genotyping for drug prescribing in favourable terms, 
unlike their views on testing for disease risk. The following two extracts 
demonstrate examples of this. 
 
Carol anticipated a future in which she would negotiate her drug regimen with 
her GP. 
 
On my genetic thing it says there’s a sensitivity to Metformin. 
I obviously get it from my mother and Metformin is such a 
typical drug for giving to Type II diabetic patients so it’s going 
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to be interesting if I ever get to the point of having a GP say 
he’s going to put me on Metformin, [I wonder] how much 
notice he’s going to take when I say “I don’t think so”. (Carol 
UP4) 
 
Carol’s description of how she will handle communicating her 
pharmacogenomics data in future is arguably presented in rather 
confrontational terms. She envisages the GP will prescribe the drug in 
question without any discussion and that she will refuse to have it, thus 
anticipating on-going challenges by informed patients to authoritarian doctors 
in an effort to personalised medical treatment. 
 
The doctor who led a regional genetics department and who referred to 
DTCGT as “snake oil” has a different view in relation to pharmacogenomics as 
this extract illustrates. 
 
I can see the value in these types of things; you know 
Warfarin, Warfarin’s a black art. When I worked on the wards 
as a junior doctor, I was on a cardiology ward right. I was told, 
“Start this guy on Warfarin.” “Right, how do you do that?” 
“Prescribe him 10 [mg] today, 10 tomorrow and 5 the day 
after that and test his INR.” With the wee old women you’d 
maybe go 10, 5, 5 or something like that but it was a bit of a 
guess. And you’d test their INR and some guys INR hadn’t 
shifted from baseline so you’d whack them another 10 [mg] 
and some little old woman who was ready to bleed out all 
over the ward because her blood was so thin, it was like 
dilute orangeade! So it was, it was a guess, but now we’re 
getting a handle on that. A little bedside SNP [would do it]. 
They come in and get full Us and Es, you’d type the SNP so 
we’d know how to prescribe and then start them on Warfarin. 
Patients with rheumatoid [arthritis] or Methotrexate, type 
them so we know [how much to give them]. It just seems to 
me sensible to get that kind of information. But that’s not 
predicting a genetic disease; we need this information to look 
at how to dose you. (Doctor CP13) 
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The doctor’s vivid narrative explains his positive view about SNP genotyping 
for pharmacogenomics, as being related to better prescribing (and thus 
reduced side-effects), as an encouraging prospect. He explores the positive 
potential of SNP genotyping amidst medical jargon related to prescribing 
anticoagulants, which requires titration to the patient’s coagulation time12. His 
exploration of this possibility suggests that he envisages possible applications 
for SNP genotyping in the NHS in future. However, studies have not 
demonstrated that genotyping patients for Warfarin metabolism and dosing 
them accordingly makes any significant difference to the efficacy or safety of 
this difficult and potentially dangerous treatment. Neither the efficacy of 
patients’ anticoagulant therapy, in terms of the time that their clotting is within 
the target range during treatment, nor the side-effects of inappropriate dosing, 
including haemorrhage or thromboembolism, are significantly different in those 
whose dosing is guided by genotype data rather than by clinical variables 
alone (Kimmel et al 2013, Stergiopoulos and Brown 2014). This casts doubt on 
the possible advantages of point-of-care genotyping in Warfarin dosing; in 
addition there are difficulties with the adoption of other pharmacogenetic tests, 
related to lack of evidence of efficacy or clinical validity, cost considerations, 
lack of clinicians’ knowledge and inconsistent regulation in the EU (UK 
Pharmacogenetics Study Group 2006). 
 
The participants’ support for pharmacogenomics could represent a space in 
which to negotiate the socially acceptable aspects of genomic technology in 
the NHS in future, an opportunity for stabilisation of the technology as 
Hedgecoe and Martin argued in relation to pharmacogenomics over a decade 
ago (Hedgecoe and Martin 2003). 
 
The challenges in reconciling personalised and collective medicine within a 
public health service are significant and may be impossible to overcome, 
                                                
12 Warfarin dosing is titrated according to the patient’s clotting times as measured by 
their Prothrombin Time (PT) and aims to achieve a time within the International 
Normalised Ratio (INR). Warfarin has a narrow therapeutic index (established by an 
INR of between 2.0-3.0 or 3.5 depending on the indication for anticoagulation); its 
metabolism varies considerably between individuals, and is affected by diet and other 
medications as well as individual (genetic) differences in metabolism. Side effects of 
haemorrhage or thromboembolism are not uncommon and can be fatal which is why 
titration of dose to INR is important (Keeling et al 2011). The genetic basis for 
individual differences in Warfarin metabolism includes variants in the gene CYP2C9. 
This encodes the enzyme Cytochrome P450 2C9 that plays a major role in oxidation of 
various compounds (including Warfarin) in the liver, but it is not the only genetic 
influence on drug metabolism (Kniffin 2010). 
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particularly as the future of the NHS is increasingly the topic of much public, 
media and political wrangling. However, having discussed their views about 
DTCGT and the challenges it represents for health care, some of the 
participants (users and clinicians) were keen to highlight the importance of the 
NHS for the country and the public, as I did at the beginning of this chapter. 
They referred to examples from their practice or research, or the media 
references to the NHS as a national emblem, which were ubiquitous at the 
time some of the interviews were conducted, to illustrate the UK public’s 
attachment to the NHS and the preference for its services over seeking 
healthcare information independently. This excerpt represents the overall 
sentiment about the public and the NHS. 
 
They are actually preferring to go for the tried and tested 
NHS, because people know what they’re doing so let’s trust 
them [NHS staff] and maybe that is the motivation for people 
going through that somewhat tortuous route [genetic 
counselling], maybe people are kind of seeing the benefits of 
that. It is an issue of trust that they’re not clicking in droves 
and sending their 99 pounds, or dollars even. (Scientist CP7) 
 
This scientist, having earlier reflected on why people might choose DTCGT, 
concluded that the relationship of trust between the NHS and its patients is 
intact. Her use of the phrase “tried and tested” suggests that this might be 
related to their familiarity with this model, rather than pursuing the personalised 
medicine options for obtaining genetic information, despite the cumbersome 
nature of clinical genetics. 
 
Maria, the genetics researcher who tested because of her “narcissistic” 
curiosity, saw distinct differences between the NHS responsibilities and her 
interest in DTCGT. 
 
The NHS doesn’t have the resources to do these things for 
people who are just interested or curious, here people really 
generally trust the NHS and I think most British people have 
huge affection for the NHS and there’s a lot of respect for it. 
It’s something we are really proud of and so we tend to trust 
the NHS, even though it’s not perfect. (Maria UP16) 
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Again, the importance of trust is evident here as in previous extracts and Maria 
uses it repeatedly. She describes the public’s view (which is presumably 
founded on her own), using emotive words such as “trust”, “affection” and 
“respect”, suggesting that the model of collective medicine on which the NHS 
stands is positive and beneficial overall. 
Conclusion 
I would argue that the data analysed in this chapter are representative of the 
prevailing tension between personalised and collective medicine in the UK. 
Whilst DTCGT is the point of focus for the conflict between the two positions, I 
would argue that it is not the cause; rather, it is a vehicle that this study’s 
participants have used to express their views in relation to this emerging 
challenge. It is important to re-iterate that, whilst support for personalised 
medicine was voiced by quite a few of the users, it was not a position 
universally held by that group, although all the clinicians supported the NHS 
collective model of health care, as one would anticipate. 
 
As the data have demonstrated, expectations that healthcare services could 
be overwhelmed by demands for consultations from people worried about 
DTCGT results have not yet materialised. The NHS is not being tested in that 
sense – in clinical genetics departments at least. However, the NHS is being 
tested by the concepts of personalisation and consumerism and the 
associated challenges of public responsibility and expertise, which are related 
consequences of personalisation and an increasingly informed public. 
Arguably, this should come as no surprise, particularly to the NHS and its staff. 
Healthcare policy in the UK has been increasingly orientated towards 
individual choice and health promotion since Thatcher’s first radical changes 
and shift from the paternalistic, universal model towards a more consumer, 
choice-focused one, in rhetoric at least (Klein 2010). In light of these changes, 
the uptake of opportunities to avail oneself of health information is not 
unreasonable. The reportedly dismissive response by healthcare professionals 
could be interpreted as understandably frustrating and is the basis for the 
Nuffield Council on Bioethics recommendation that healthcare professionals be 
trained in genomic technologies (Nuffield Council on Bioethics 2010). 
Conversely, professional frustrations are equally understandable, given the 
lack of transparency in commercial health information marketing materials and 
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the unremitting and significant restraints within which clinicians are expected to 
provide services to patients who have increasingly high expectations of the 
NHS. In addition, the apparent lack of any changes to users’ lifestyles in the 
light of their test results perhaps indicates a lack of genuine engagement with 
responsibility for their health and negates the argument for empowerment. 
 
When examining the concept of “personalisation”, the Nuffield Council on 
Bioethics suggested it encompassed four aspects, including individualised 
care, holistic care, commodification of care and responsibility and autonomy in 
managing one’s own care (Nuffield Council on Bioethics 2010). With the 
exception of commodification, these aspects are not new to the fundamental 
basis of professional health care (theoretically at least) and I would argue that 
health care has always been personalised to some extent. A recent medical 
paper even cunningly invented the term “personomics” to revisit the 
importance of individualised care within increasingly ‘omic’-focused medicine 
(Ziegelstien 2015). The shift to personalised health care is thus not the point 
here, an argument lent weight in the case of DTCGT by the impersonal, 
population studies GWAS data are based on. The point is who should take 
responsibility for individuals’ health; the dissonance of views between the 
public (as represented by some of the users in this study) and the NHS 
(represented by the clinicians) demonstrates the ambiguous position health 
care in the UK currently finds itself in. We are between what Klein refers to as 
Church (paternalistic, collectivised medicine) and Garage (consumerist, 
individualised medicine) (Klein 2010:282). New health technologies do offer 
the potential for people to be more involved in their health management rather 
than simply being passive recipients of healthcare decisions. This could 
facilitate disease-risk management as a cooperative venture, although the 
caveats that marketing information should be more transparent and healthcare 
professionals should be trained in genomics both apply in order for a 
relationship of trust between professionals and the public to be maintained. 
 
In the next and final chapter of this thesis I shall pull together the three themes 
I have explored in Chapters Four, Five and Six. In doing so, I shall discuss the 
shaping of discourse about personal genomics technology in the UK in relation 
to biosociality, before concluding with suggestions for future study in this area. 
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Chapter 7 : An unresolved dispute and future 
possibilities  
 
It remains to draw conclusions about how users and genetics clinicians 
are shaping the technology of personal genomics in the UK and discuss 
the implications of the findings of this study. To do so, I will summarise the 
current state of the debate about DTCGT and then discuss the important 
aspects of SCOT in this study and the three principal data themes. Then I 
shall broadly relate theoretical work on biosociality to the empirical 
findings of this study. Finally, I shall complete the thesis with a discussion 
about the possibilities for future work in this area that could either follow 
the disputes over new genomic technologies into WGS (which is where I 
see this particular dispute shifting) or engage in theory development. 
 
Developments in the commercial sector following the FDA’s letter to 
23andMe in November 2013 show how this company, at least, is willing to 
both circumvent some of the obstacles to selling personal genotyping 
directly to the public and simultaneously work with regulators to address 
others, thus keeping their business active and their options open. In 2014 
23andMe launched SNP genotyping tests that include common complex 
disease risk testing in both Canada and the UK, as neither country has 
regulation in place to prevent them doing so (Gibbs 2014, Pickard 2014). 
More recently the company received authorisation from the FDA to market 
a test for Bloom’s syndrome carrier status. But as Cecile Janssens points 
out, this is for a specific carrier test and not for 23andMe’s more broad 
SNP genotype service including common complex disease susceptibility 
testing (Janssens 2015). Obtaining approval to market testing for Bloom’s 
syndrome is an interesting move on both the company’s and the FDA’s 
parts. This test is relatively harmless and uncontentious; using it as a 
foundation from which to negotiate with regulators for future approvals 
could be interpreted as symbolic of future potential for widening public 
discussion and knowledge about commercial genomics. 
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Whilst the academic ELSI community is arguably less focused on the 
disputes about DTCGT now than in the latter half of the last decade, there 
is no indication from the literature or this research that this is due to any 
settlement or closure of the points of debate. I would suggest that this is 
due to two other factors. First, as several researchers and the data from 
this study suggest, there is little evidence of users of DTCGT coming to 
any harm (Heschka et al 2008, McGowan et al 2010, Kaphingst et al 
2012). Second, focus has shifted to WGS, as exemplified by the 
announcements from David Cameron and Barack Obama about the UK’s 
and the US’s respective national initiatives to complete WGS projects in 
healthcare research and their attendant promissory expectations 
(Genomics England n.d., Brice 2015, Collins and Varmus 2015). However, 
whilst the focus of media and scholarly attention may have moved on to a 
new problem, the points of contention about DTCGT in the UK remain 
unresolved and this concluding chapter will summarise these outstanding 
issues next. 
 
The findings 
Claims and counter-claims about selling SNP genotyping based on 
contingent science directly to the public have resulted in the disputes 
around DTCGT that this study has sought to illuminate. Whilst purchasing 
health-related tests in the context of insurance-based private health care 
such as the US model may not seem controversial, in the UK’s publicly 
funded NHS system it was not clear how users or clinicians would be 
affected by this commercially-offered genomic technology or influence its 
development. Interviews with early adopters of personal genomic testing 
and genetics clinicians who may have a role in supporting users, or at 
least a professional interest in the debate about DTCGT, have shed light 
on both groups’ views and experiences. In this section I shall discuss the 
use of SCOT for this study and each of the three data themes as they 
relate to my conclusions about this research. 
 
Social construction of technology 
The use of the SCOT framework for this study has demonstrated its value 
in illuminating the black box of DTCGT. Here I will summarise the factors 
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in each of the components of SCOT that are noteworthy for their specific 
bearing on this study. 
 
Relevant Social Groups 
Paying attention to the relevant social groups’ understandings about 
DTCGT, and to the groups within those groups, has shed light on 
contrasting experiences, groups’ influence and power, their different 
technological frames and the subsequent impact on people’s 
understanding of DTCGT. Genetic genealogists encountering DTCGT 
with health data for the first time appear to maintain their enthusiasm for 
personal genomics. This is demonstrated through their strong networks 
and their eagerness to share their experiences and support for the 
technology with me. Those who work in genetics research directly or in 
similar areas conveyed curiosity about the technology and that they were 
sharing this with colleagues in professional networks; those with health 
concerns seemed to view it as a means to gain personal information that 
they had agency over and share with family. The couple who were outliers 
appeared to have a different experience; this could be seen as 
contributing an experience more representative of the wider population 
without the other users’ arguably activist attributes. However, whether 
they are more widely representative or not, collectively the users in this 
study are arguably illustrative of a diverse group. The challenge of having 
diverse relevant social groups in analysing SCOT is that some powerful 
voices may maintain that they speak for the whole group when in fact sub-
group’s experiences and technological frames may differ (Russell 1986), 
and that may well be the explanation for the outliers’ different experiences. 
 
The genetics clinicians’ influence is aligned to their professional duty to 
individuals and the NHS. The moral boundary work they engage in 
informs much of their understanding and discourse about DTCGT though 
the professional sub-groups of doctors, scientist counsellors and nurse 
counsellors demonstrate variations in the emphasis they place on this in 
relation to DTCGT. This groups’ collective professional power and their 
generally sceptical views of DTCGT based on its lack of clinical utility, 
present a strong counter influence to the users’ enthusiasm for DTCGT. 
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Wider social context  
The context of the NHS in this study is key to understanding how the 
relevant social groups both conceptualise DTCGT in relation to 
responsibility for health and the influence of these views on DTCGT. The 
NHS represents a powerful construct in that it is widely supported by 
citizens and its employees in the UK (Klein 2010), and participants from 
both groups in this study had positive views of it. However their different 
expectations of its provision, is one of the principal points of conflict in 
relation to DTCGT. Users suggest that a more individualised 
consideration of people’s health needs through genomics is important, in 
line with commercial rhetoric in personal genomics. But this is in 
opposition to the conservative approach clinicians represent. They defend 
the collective model of health care that they envisage may be threatened 
by those needing help with interpreting privately acquired screening 
information, although this eventuality has not so far materialised.   
 
Interpretative flexibility 
The different meanings and interpretations of DTCGT by users and 
genetics clinicians in the UK essentially align to one of two positions. 
Users appear to support its personal utility and relevance for its 
individually orientated information although there was very little evidence 
of this influencing people’s behaviour. Its direct availability is key to their 
view and they would not countenance regulation. They view this as 
unnecessary and paternalistic. Genetics clinicians are mainly sceptical of 
the value of SNP genotyping, owing to the flawed science it is based on, 
its misleading marketing and concerns about potential harm to individuals 
who are receiving genetic information without conventional support.  
 
The participants also demonstrated their interpretative flexibility within 
their individual accounts of what they understand DTCGT to represent. 
This illustrates the relevance of Potter’s and Mulkay’s experience of 
scientists’ interpretative flexibility in understanding the variation in their 
views and how their understandings are re-worked according to the 
specific context under consideration (Potter and Mulkay 1985). A scientist 
recognised that disease-risk results should not lead her to make 
unhealthy lifestyle choices, but pharmacogenomics results meant she 
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would not agree to being prescribed certain oral hypoglycaemics in the 
future. A doctor thought DTCGT was akin to snake oil but that SNP 
genotyping for warfarin metabolism could be a boon for both patients 
requiring anticoagulation therapy and the junior doctors who need to 
prescribe for them. Participants seeking genomic information to shed light 
on chronic ill health shifted their hope on to the future promise of their 
genomic data when the tests failed to fulfil their expectations.  
 
Stability and closure 
These changes and swings in understanding DTCGT illustrate and 
support the lack of stability of this technology in the context of the UK and 
the NHS, despite pharmacogenomics providing a focal point for 
converging views between some users and some clinicians. Stabilisation 
is described as being relative for different groups and needs to be 
achieved in the eyes of each of the relevant social groups (Pinch and 
Bijker 1984). Whether DTCGT will ever achieve closure or not is currently 
moot, but I suspect that it is unlikely given the irreducible nature of the 
differences between the two groups in this study. I suggest that it will be 
stabilised by virtue of being superseded by new problems, as I shall 
consider in the final section of this chapter. Having established the 
significance of interpretative flexibility in terms of participants’ accounts, I 
shall go on to summarise the three main themes from the study. 
 
Networks and expectations 
Perhaps surprisingly, given the personalised basis for marketing DTCGT 
and its association with the increasingly neoliberal culture that the 
participants in this study live in, social networking and sharing with others 
who have common interests were principal features of the participants’ 
accounts. Both groups’ networks and their attendant social practices were 
in existence before the emergence of personal genomics. As 
demonstrated in Chapter Four, participants found out about DTCGT 
through their social networks, whether recreational, family, or professional. 
Networks and membership of them are crucial because enrolment to and 
socialising within them informs and reinforces the participants’ values in 
respect of DNA. This is achieved by shaping expectations in relation to 
new technology, as Brown and Michael suggest, or bolstering professional 
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authority by alignments within professional networks through what Callon 
might refer to as networks of associations (Callon 1986, Brown and 
Michael 2003). As a result, norms can be adopted that provide principles 
for behaviour within the actors’ respective networks. This is supported by 
the distinctly different experience of the two users who were not directly 
involved in these networks but were bought DTCGT by a relative who was. 
 
In trying to establish users’ motivations for testing, it appears that most 
people’s expectations and engagement were not about clinical utility. 
They were more aligned to the concept of personal utility, as 
demonstrated by references to their interest and curiosity and their 
extension of their personal identities through this newly acquired genomic 
information. This supports the observation that personal utility is important 
to DTCGT users, whether as a moral justification for engaging with it or as 
an alternative criterion for judging its utility (Khoury et al 2009, Vayena et 
al 2012, Bunnik et al 2014). For the three participants specifically 
interested in health-related data their expectations for useful data from 
their DTCGT were not reified. None seemed particularly disappointed by 
the characteristically unfulfilled promise of personal genomics to date 
(Brown 2003), but translated utility of their data into future hope, in a 
fashion similar to Brown’s “regime of hope” (Brown 2005:333).  
 
Clinicians were orientated to the importance of clinical utility and their 
professional network appears to be important in facilitating their shared 
moral stance against DTCGT on the basis of its lack of clinical utility and 
companies’ misleading marketing. Their networks also circulated the 
expectation that their services would be inundated with requests for 
consultations to explain DTCGT results. This has not been reified, any 
more than have those users’ hopes for clinically useful information about 
their health, as I established through the difficulties recruiting clinicians to 
the study and from the accounts of their experiences from those who did 
volunteer. So the impact of DTCGT on NHS genetics services has proved 
to be negligible. This last point is also related to the issue of expertise, in 
that it would appear to indicate that credentialed expertise in clinical 
genetics is not required for DTCGT interpretation, despite the early 
concerns about genetic tests being sold directly to the public without 
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involvement of clinicians (Wolfberg 2006, Matloff and Caplan 2008, 
Marietta and McGuire 2009).  
 
Participants’ expectations of the NHS represent a point of tension around 
responsibility and the groups’ different understandings of it as I will 
discuss shortly in the section on Individualised or collective medicine 
 
Individuals and identity work 
Participants’ expectations about DNA on a personal level constituted their 
thinking about DNA and the information they gleaned about it, 
incorporating this into their self-knowledge or aligning it into their genetic 
counselling practice. This personal and internal reflection relies on pre-
existing knowledge and, for users, facilitates the extension of individuals’ 
identities in many facets of their life, including their health and families. 
For clinicians, it facilitates imagining what users’ motivations and 
experiences of genetic testing might be and how this might extend the 
possibilities for public engagement with genetics or conflict with their 
genetic counselling approach and lead to anxiety and a possible drain on 
precious NHS resources. 
 
The user participants in this study appear to be building on their pre-
existing knowledge of genetics in deciding to acquire additional 
information about themselves with their DTCGT,13 in keeping with many 
early adopters of new technologies (McGowan et al 2010, Vayena et al 
2012). Users incorporated this new information into their personal 
identities, as O’Riordan suggests, forming new personal and social 
identities (Atkinson and Glasner 2007, Kelly 2007, O’Riordan 2010, 
Prainsack 2014a). Arguably, this knowledge also provides a foundation for 
imagining their future health care on a more individual plane. This could 
be described as extending their own self-knowledge as well as their 
knowledge of genomics, particularly given that all the users claimed to 
understand their DTCGT results. Apparently negative responses from 
GPs with whom some users shared their test results appear to have 
bolstered users’ views that the NHS is out-dated in terms of its care 
                                                
13  This is with the exception of Jane, one of the two exceptional cases whose 
knowledge of genetics was minimal. 
  206 
provision. This aligns to Novas’s and Rose’s “somatic individual”, for 
whom the outcomes of extending one’s identity into the genetic, 
influences relationships with others including clinicians (Novas and Rose 
2000:487). 
 
Clinicians’ individual thoughts about the possible impact of commercial 
genotyping varies from being actively encouraging to expressing concerns 
about possible harm to individuals and their kin through rehearsal of the 
discourse of genetic counselling. Clinicians’ cautious attitude to DTCGT 
appears to be based on the post-eugenics anxiety that the informed 
consent, non-directive counselling model of clinical genetics has been 
built on (Fox Keller 1992). But their moral boundary work here is based on 
the model of single-gene mutation or chromosomal abnormality that 
clinical genetics services commonly deal with, rather than imprecise SNP 
genotyping for common complex disease susceptibility. However, their 
concerns are arguably unfounded, given that the anticipated onslaught of 
requests for consultation from the worried-well, with their electronic 
device-access to their SNP genotype results, does not appear to have 
materialised, leaving clinicians concerns largely imaginary so far. 
 
These individual expectations, which are in a dynamic relationship with 
the socially shared aspects of personal genotyping, both influence and 
converge in the final theme in the data, the NHS, which I shall complete 
this section by summarising. 
 
Individualised or collective medicine 
The central focus of the dispute about DTCGT in the UK context is 
between the models of personalised versus collective medicine. As I 
outlined in Chapters One and Two, an increasingly neoliberal emphasis 
on globalisation has supported the commercialisation of health care and 
the impetus for individuals to take responsibility for their health. This has 
been capitalised on by personal genomics companies and those who 
campaign for democratisation of health information; many companies 
have deliberately marketed their products by emphasising the personal or 
individual in their choice of company name (23andMe) and their marketing 
focuses on providing information to facilitate autonomy and empowerment 
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in relation to lifestyle choices for health. Marketed largely on the Internet, 
which is awash with the use of similar rhetorical devices, personal 
genomics purports to empower responsible individuals with access to their 
valuable personal genomics information via their iPhones, iPads, iMacs or 
similar devices (Dickenson 2013). 
 
In parallel with the published debates about DTCGT, this specific issue 
figures as a central point of tension for participants in this study, with 
responsibility being the feature on which the tension between users and 
clinicians turns. Users’ adoption of new genomic technology represents a 
more responsible approach to their view of themselves or their life 
strategies, particularly in relation to health. Genetics clinicians’ counselling 
work is centred on helping consultands to develop responsibility in terms 
of health behaviours and relationships with family, whether actual or 
potential. So whilst both seek to achieve the same end, their concerns 
about how it will be achieved are at odds. 
 
Users appear to have aligned themselves with the tropes of 
personalisation that commercial genomics companies use to market their 
products, regardless of their original motivation for engaging with SNP 
genotyping. Clinicians, on the other hand, express concerns about the 
scientific basis for SNP genotyping in order to illustrate its irrelevance in 
terms of the provision of clinical genetics services in the NHS. Whilst 
nurses and some doctors also rehearse the moral arguments for 
maintaining genetic testing within their professional service, several 
clinicians show a more balanced view, acknowledging some of the 
possible advantages to obtaining genomic information without having to 
endure the rigours of navigating the NHS to do so. However, the point 
clinicians seem agreed on is their protection of the collective NHS model 
of health care; their dismissal of DTCGT appears to be as much about 
their concern to protect the NHS from being drained of its resources by 
the worried well pursuing genomic tests privately (or indeed other 
screening options) (Henrikson et al 2009, Nuffield Council on Bioethics 
2010). 
 
As Richard Tutton shows, personalised medicine is not an entirely novel 
concept. Individualised medicine has figured in health care for centuries, 
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with a focus on the individual featuring in medical practice before the 
development of hospitals in the 19th century (Foucault 1994) and being 
increasingly central to healthcare practice and policy since the latter half 
of the 20th century (Klein 2010, Tutton 2012). The alignment of 
personalised medicine to the HGP enabled researchers and scientists to 
raise expectations and funding for their pharmacogenomics research 
(Hedgecoe 2003). This useful rhetorical tool, which is in keeping with the 
neoliberal agenda of the times, disguises the fact that pharmaceutical 
developments are not being individualised in a literal sense. Rather, 
populations are being categorised into groups who respond differently 
physiologically to particular drugs (Hedgecoe and Martin 2003, Tutton and 
Jamie 2013). Individualised drug treatment is highly unlikely to be reified, 
given the lack of financial incentive to pharmaceutical companies to invest 
in what could be termed niche products.  
 
It is ironic to note that whilst the tropes of personalisation, individual 
autonomy and democracy are used to market DTCGT and are being 
subscribed to by users of personal genomics, the data that customers’ 
SNPs are analysed against are large-scale data used for GWAS (Khoury 
et al 2010, Prainsack et al 2014). What is more, the basis on which 
personal genomics companies’ business plans are developed, that is, to 
sell their customers’ health and genomic data on to biotechnology and 
pharmaceutical companies, is anything but personal. This aspect of 
commercial biotechnology was alluded to by one of this study’s clinician 
participants, along with others with an interest in the field and 
subsequently announced by 23andMe early in 2015 (Hamilton 2008, 
Herper 2015). 
 
The two moral standpoints, of personal autonomy and responsibility on 
the one hand and informed consent and protection from harm on the other, 
align themselves to the two opposing models of health care, personalised 
and collective medicine respectively, while both illustrate different aspects 
of responsibility. The data show how users’ and clinicians’ views, being 
linked to personalised health care in the case of the users and collective 
health care in the case of the clinicians, may thus seem diametrically 
opposed in their interpretation of the relevance of genomics to the NHS. 
The shared views about pharmacogenomics, rather than being a basis for 
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resolution of the debates about DTCGT, are instead of concern. This hope 
for the future promise of genomics on the part of some clinicians and 
many users indicates a lack of understanding of the capabilities of 
pharmacogenomics, which has so far been unable either to show better 
routes to effective prescribing of many common drugs (including 
anticoagulant therapy14 ) or to be translated effectively into the clinic 
(Voora 2011). 
 
Participants’ interpretative flexibility and the tensions and agreements 
between users and clinicians in relation to the three main themes 
emerging from the data demonstrate the on-going and complex nature of 
the debate about personalised medicine, particularly in the UK’s context of 
collective health provision in the NHS. This is further complicated by the 
apparent lack of categorical alignments of this study’s users and clinicians 
into groups that support or oppose personal genomics or behave in 
particular ways depending on their experience of it. However, from the 
indeterminate positions of the participants’ views, empirical evidence has 
emerged related to previous theoretical work on biosociality. I shall 
discuss this in the following section before concluding with suggestions for 
future work on the basis of this study and the ensuing discussion. 
 
Biosociality 
The debates around personalised genomics have not only so far failed to 
resolve but now appear more opaque than originally envisaged at the start 
of this study. Whilst it is neither possible nor necessarily appropriate to 
resolve that opacity here, it warrants discussion in relation to the 
implications of the findings for current theory.  
 
The central tension between personal and collective medicine revealed in 
this study is a focal point for exploring the relationship between genomics 
and biosociality. The concept of biosociality in this study is in contrast to 
Rabinow’s original use of the term that he suggested related to groups 
formed by those with common genetic anomalies after testing (Rabinow 
                                                
14 The drug most participants referred to in discussing pharmacogenomics was 
Warfarin, a commonly prescribed but potentially dangerous anticoagulant. See 
Common ground in Chapter Six for detail.  
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1996). However, my study demonstrates the importance of sociality in 
genomics, whether pre- or post-testing, supporting Gibbon’s and Novas’s 
suggestion that biosociality is useful for thinking about emergent identity 
practices associated with changing understanding of disease and 
diagnosis (Gibbon and Novas 2008). Following on from Rabinow’s work 
on biosociality, Nikolas Rose has suggested that people’s social 
groupings and the formation of new associations and communities around 
genetic conditions are part of the identity work that results from their 
genetic testing15 (Rose 2007). Subsequent to developing these social 
groups and networks, sustained as they are by the expectations they 
circulate (Brown 2005), members develop their individual knowledge and 
build on this to develop a level of expertise, in this case about genetics 
and, for users, genotyping technologies and commercial testing. Indeed 
this could be equated to Brekke and Sirnes examination of biosociality in 
which users are seen as actively engaged in using and analysing 
biomedical developments (Brekke and Sirnes 2011:349). For both users 
and clinicians this knowledge, or what Jenny Reardon refers to as 
“learnedness”, appears to emerge as a result of their membership of 
networks (whether recreational, occupational or professional) and informs 
their identity, both individual and social (Reardon 2011:97). Importantly in 
this study, networks also inform participants’ decisions either to test or to 
be wary of commercial testing, although the clinicians were not unified in 
condemning DTCGT. 
 
The problem of the clash between individual and collective medicine 
highlighted by the data is bound up with tensions. Rose’s work on 
biomedical politics and genomics points to individual responsibility, 
showing how people are encouraged to optimise their future health by 
undertaking self-management of their somatic existence. This carries an 
ethical dimension by placing value on bodily health, which could be seen 
to influence people’s decision to engage with genomics for susceptibility 
testing to avoid future disease. Furthermore, public health initiatives seek 
to provide biological education of citizens in order for them to take 
responsibility for and improve their health (Hood and Friend 2011). On this 
                                                
15 It is important to note that Rose sets this in the context of individuals having complex 
fields of identity practices of which their genetic identity is part, rather than individual 
identity being a singular notion. 
  211 
basis it is then arguably unsurprising that, when an opportunity to engage 
with health information at a molecular genomic level is available, 
interested people avail themselves of it. In this context, biological citizens 
can be conflated with highly discriminating consumers, who are often 
seen as a powerful resource for informing and driving others’ decisions 
through shared networks, including the Internet. Consumers of DTCGT 
are thus likely to consider their test results in the context of the health and 
illness discourse that they have been exposed to and urged to engage 
with as responsible citizens, particularly as this discourse is reinforced by 
the rhetorical style of personal genomics companies’ information (Rose 
2007). Motivations for testing by the users in this study were not 
intrinsically related to the concerns for their future health16. However, 
having tested, they did appear to engage with the health-related test 
results in a manner informed by both the commercial genomics market’s 
rhetoric of personalisation and public health discourses around 
responsibility for health. 
 
In light of this it is understandable that people might feel that it would be 
appropriate to share this information with healthcare professionals they 
consult with, usually GPs. Indeed, Rose suggests that, in developing a 
molecular genetic aspect to their identity and behaving as responsible 
citizens in respect of their health, people are able to become more active 
participants in their health and can work in alliance with, rather than as 
subservient to, healthcare professionals (Rose 2007). Discussing the 
incorporation of genomics into identity practices, O’Riordan similarly 
suggests that medical issues (as exemplified by genomics) are no longer 
confined to the boundaries of professional medicine (O’Riordan 2013). It 
is therefore predictable that the users’ reported experiences of either 
dismissal or disinterest (or in one case referral of their concern to a 
hospital consultant) seemed to cause or reinforce feelings of frustration 
and dissonance between the public and professional interest in genomics. 
It is possibly emblematic of the inequalities that Plows and Boddington 
                                                
16 Three users were motivated to test by current health problems. Two other users 
tested with family health problems in mind. Barbara was interested in her family history 
of cancer, which had informed her initial engagement with genealogy that led into 
genetic genealogy, but her motivation for testing was not solely related to her concerns 
about developing cancer in the future. Christine’s parents were both affected by cancer 
but she also had a wider interest in testing informed by her work as a public health 
scientist. 
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argue persist, but are underplayed by Rose and Novas’ work on 
biocitizenship, here in respect of professional and institutional power over 
individual citizens or patients (Plows and Boddington 2006). This would 
explain users’ calls for the NHS to adopt a more contemporary, 
collaborative approach to health care generally and to the inclusion of 
genomics in particular. 
 
The relationship of biosociality to either engagement with emerging 
genomic technologies or moral boundary work associated with distancing 
them is clearly important, as shown by this study and its substantiation of 
earlier theoretical work in this area. Having developed learnedness 
through biosociality, claims are made for what might be termed expertise 
about personal genomics by both early adopters and healthcare 
professionals, but this aspect of the findings is complex and thus difficult 
to evaluate satisfactorily here. 
 
Expectations and future directions 
From the data collected and my analysis of them, I do not think that 
rhetorical closure of the debate around DTCGT has been, or will be, 
achieved (Pinch and Bijker 1987). Despite regulatory changes such as the 
FDA’s letter to 23andMe and regulatory suggestions from the joint 
European Academies of Science Advisory Council and the Federation of 
European Academies of Medicine report, companies are working round 
these challenges to renew their commercial ventures; personal genomics 
appears to present a moving target rather than a point for resolution of the 
technology (EASAC FEAM 2012, Brice 2013, Cohn and Surofchy 2014, 
Prainsack 2014b). 
 
What is more likely is that the expectations of WGS being circulated and 
invested in at government level in the UK and the USA will shift both 
public attention and the definition of the problem on which the disputes 
about genomics are focused. Both of these large projects have, like the 
HGP and subsequent commercial DTCGT, been initially funded by public 
investment on the basis of their promissory potential for personalised 
diagnosis and treatment of disease in the future, with private commercial 
investment being incorporated for their future sustainability (Genomics 
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England n.d., Brice 2015). The irony of the use of public money to fund 
projects that are then capitalised on for profit by private commerce in true 
neoliberal fashion is notable. But funding issues aside, the debates about 
genomic technology such as the accuracy of sequencing data, disclosure 
of incidental findings, who gets WGS, how their data are used and by 
whom, are likely to distract from and collapse the current disputes around 
DTCGT (Caulfield et al 2008, Allyse and Michie 2013). 
 
Genetic testing in general and consumer genomics, in particular, 
continues to provide cases for study that are troubling and complex. I 
have shown through the data chapters and the discussion in this chapter 
that the concept of biosociality is fundamental in developing an 
understanding of people’s engagement with emerging genomic 
technologies and of the disputes that result, particularly in the UK context. 
This indicates the potential for further work in this area from two 
perspectives. First, it will be important to examine people’s relationships to 
genomic technology as it develops and is more widely adopted. Second, 
there is a need for further theory development in respect of biosociality in 
genomics, but particularly in the concept of citizenship and its relationship 
to people’s engagement with genomics. 
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Appendices 
Appendix  1: School of Social Sciences REC Application 
 
Cardiff School of Social Sciences 
Ethical Approval Papers 
MPhil/PhD Doctorate Research Projects 
SREC/826 
Principal Investigator (PI): 
Teresa M. D. Finlay, ESRC +3 PhD Student, Socsi/Cesagen, 
finlaytm@cardiff.ac.uk 
3 Alexandra Road, Oxford, OX2 0DD 
The research:  
 “Direct-to-consumer genetic testing: users’ experiences of testing for disease 
risk and genetics clinicians’ perceptions of its impact on NHS genetics 
services.” 
Direct-to-consumer genetic testing (DTCGT) for disease risk is now widely 
available to purchase online. Those in favour of DTCGT champion the rights of 
individuals to access their genetic information, while many medical 
professionals think a vulnerable public needs to be protected by regulation. 
Neither of these views is evidence-based, but they reflect changes in society 
that the growth in personalised medicine is driving. The paucity of published 
research data indicates that little is known about DTCGT generally and its 
uptake in the UK in particular. This PhD research project thus aims to:- 
 
i. explore UK users’ motivations and expectations of DTCGT for disease 
risk and its impact on them 
ii. establish how people make sense of complex disease risk information 
iii. explore clinical genetics professionals’ perceptions of DTCGT’s impact 
on users, and their involvement with helping users of DTCGT 
iv. draw out the implications of DTCGT for users, professionals and the 
NHS.  
The research will answer the following questions: 
i. What do people know about DTCGT and what are their sources of 
information?  
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ii. What are people’s experiences of DTCGT and to whom do they turn for 
further help?  
iii. What are clinical genetics professionals’ views of DTCGT?  
iv. What are clinical genetics professionals’ experiences of supporting 
users of DTCGT?  
v. What are the likely implications of DTCGT for users and professionals 
in the NHS? 
 
Funding: 
The PI has an ESRC funded Social Science PhD studentship with support 
from Cesagen. 
 
Participant details: 
1) Up to 20 DTCGT users will be purposively recruited online, the medium 
in which  
DTCGT is traded. Advertisements will be placed on Internet search 
engine pages linked to searches for DTCGT companies, related 
weblogs and User Group websites inviting people who have had a test 
to visit the research project website for information and then to email 
the PI to express interest in being interviewed about their experiences. 
Participants (Users) will be UK residents, able to read and converse 
fluently in English, 18 years or older, who have had a DTCGT and are 
competent to give consent.  
 
• People who are not UK residents will not be eligible as they will 
not have automatic access to the NHS. 
 
• People who are not able to read or converse fluently in English 
will not be recruited as it will undermine the quality of the 
interview data and participants’ confidentiality to use translators 
for interviews, as well as being beyond the scope of this project. 
 
• People must be 18 years or older to buy a DTCGT and thus to 
participate in this research.  
On receipt of emails from interested Users the PI will reply attaching a 
copy of the Participant Information sheet (Users) (Appendix 6) and 
Consent Form (Appendix 8) and request a telephone contact number to 
screen the person for suitability to participate and arrange an interview. 
Understanding of the project and competence to consent will be 
assessed in the screening call prior to interview.  
2) Up to 20 registered clinical genetics professionals will be purposively 
recruited using snowball sampling, starting with clinical geneticists 
known to the PI and supervisors. An email (Appendix 5) will be sent to 
known clinicians inviting expressions of interest from those who have 
been consulted by users about their DTCGT results (not necessarily 
the Users recruited to participate in this study). These clinicians will be 
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asked to forward the invitation to colleagues elsewhere in the UK who 
have similar clinical expertise. Participants (Clinicians) will be UK 
residents, registered and practising as clinical geneticists or genetics 
counsellors in the NHS. These participants will be participating in their 
professional capacity and as such it is assumed they will be fluent in 
English and competent to consent by virtue of their professional 
registration and practice in the UK. 
 
Methodology and data handling: 
Methods: Participants will agree to an interview, preferably conducted in 
person but possibly on the telephone if a meeting is difficult to arrange. 
Interviews with Users and Clinicians will last no longer than 1.5 hours and will 
be audio-recorded. The PI will record participants’ consent at the beginning of 
the interview either in writing or on the telephone, depending on the mode of 
the interview. Interviews will be semi-structured and will aim to cover the topics 
required to answer the research questions and meet the research aims and 
objectives. The PI will keep a diary recording non-verbal communication and 
other related observations during the interviews. Interview recordings will 
subsequently be transcribed by the PI. Interview data will be analysed using a 
theme-orientated approach.  
Storage: The PI will be responsible for the research data, all of which will be 
stored in the form of electronic files including participants identifying 
information, voice recordings, interview transcripts and written analysis and 
discussion of the findings. These will be stored in password-protected files on 
encrypted devices. Any paper copies of data will be stored in a locked filing 
cabinet on University premises. Raw data pertaining to the project will be 
viewed by the PI (and possibly supervisors) only; no other independent 
contractors (e.g. research assistants or transcribers) will be involved. 
Electronic data will be stored for 10 years following completion of the project 
after which time it will be destroyed. Data will be by deletion from electronic 
devices or shredding. 
Anonymity: Participants will each be assigned a code and their data 
subsequently handled using their individual code. Participants could be 
identified by their code should there be a need to contact them for further 
information following initial data analysis. Participants’ information and codes 
will be stored separately from their data. While all possible steps will be taken 
to anonymise data in the written report and publications, it may not be possible 
to completely anonymise participants’ contributions due to the relatively small 
numbers of people involved. Participants will be made aware of this in the 
Participant Information Sheets (Appendices 6 and 7). 
Dissemination: Findings from the study will be shared with participants, 
colleagues and peers at local, national and international specialist meetings 
and published in the professional literature. Copies of the completed PhD 
thesis will be stored in academic libraries. 
 
Shaded box (ethical) considerations: 
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Possible Harm: At the beginning of interviews when consent is obtained, the PI 
will re-iterate that all interviews are in confidence and that participants can 
withdraw at any time without penalty, should they feel unable to continue. 
Should they choose to do this all data pertaining to that interview will be 
destroyed and will not be included in the research. 
Some participants may experience strong emotions when discussing issues 
related to disease risk and/or the perceived impact of genetic information on 
family members. The interviews will be conducted sensitively by the PI who is 
a registered nurse and lecturer with considerable experience of facilitating 
challenging, emotional discussions. Should a participant become distressed, 
the interview will be suspended and they will be reminded that they may 
withdraw from the study if they wish. Should emotional support be required 
over and above that which can be immediately provided, the PI will 
recommend that the participant seek help from an appropriate external source 
such as their General Practitioner surgery or similar agency. 
 
Information and consent: 
In the recruitment advertisements prospective participants (Users) will be 
directed to the study website for information about the study including the 
Participant Information Sheet (Users) (Appendix 6) and Consent Form 
(Appendix 8). The website will ask potential participants to email the PI within 
one week with their expression of interest in participating in an interview. A 
reply will be sent requesting a telephone contact number with a copy of the 
Participant Information Sheet (Users) and Consent Form attached in case 
these have not been accessed on the website already. If a reply with the 
contact telephone number is not received within one week, one email reminder 
will be sent. 
 
Prospective participants (Clinicians) will be sent a Participant Information 
Sheet (Appendix 7) and Consent Form (Appendix 9) with the email inviting 
expressions of interest in participating in the research by clinicians. On 
receiving an email expressing interest, a reply will be sent requesting a 
telephone contact number with a copy of the Participant Information Sheet 
(Clinicians) and Consent Form attached in case these have not been accessed 
from the previous email. If a reply with the contact telephone number is not 
received within one week, one email reminder will be sent.  
The time and venue for interviews will be arranged by phone call at the 
participants’ convenience, taking precautions to minimise risks to the PI as per 
the Code of Practice for the Safety of Social Researchers. 
Consent to be interviewed will be obtained from participants by the PI prior to 
the interview either in writing on the form or verbally on the telephone with the 
researcher completing the form depending on the mode of the interview 
(Appendices 8 and 9). 
It is unlikely that any of the participants will be known to the PI or in a 
dependent relationship with her. No payments or incentives will be offered for 
participation and participants will be reminded that their contribution to the 
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research is based on altruism rather than any personal benefit; consent should 
therefore be given without any pressure (real or implied) to do so.  
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Appendix  2: School of Social Sciences REC Approval  
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Appendix  3: Cardiff and Vale University Health Board, R & D 
Committee Governance Review Approval 
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Appendix  4: Email to Recruit Clinicians 
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Appendix  5: Information Sheet for Users 
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Appendix  6: Information Sheet for Clinicians 
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Appendix  7: Consent Form for Users  
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Appendix  8: Consent form for Clinicians 
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Appendix  9: Interview Schedule for Users 
 
  256 
 
  257 
 
  258 
Appendix 10: Interview Schedule for Clinicians 
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